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Abstract 
In the last four years, seven new drugs have been FDA approved for the 
treatment of late stage melanoma, for the field of melanoma, this marks an incredibly 
exciting. Three of these new therapies, vemurafenib, dabrafenib and trametinib are 
small molecule kinase inhibitors that target the MAPK pathway and as such have been 
approved for the treatment of BRAFV600 mutant melanomas. Yet despite recent 
advances, mechanisms of intrinsic and acquired BRAF inhibitor resistance continue to 
undermine uniform and long-lasting therapeutic responses. Several studies have shown 
that the reactivation of MAPK signaling is a critical event leading to BRAF inhibitor 
resistance. These studies lead to the evaluation and subsequent FDA approval of 
frontline BRAF (dabrafenib) plus MEK (trametinib) inhibitors to delay drug resistance.!
Though this approach has meaningful clinical benefit, there are still a number of patients 
who do not respond to therapy or who, through unknown mechanisms, succumb to 
refractory disease. In an effort to identify drivers of MAPK inhibitor resistance, several 
studies have relied on traditional genomics methods. While gene-based approaches 
have guided precision medicine, they do not address the dynamics of the global 
signaling changes that occur following acquired resistance.  
The dissertation herein will describe our efforts to fill these gaps of knowledge 
and will expand upon the evolution and development of our understanding of intrinsic 
and acquired MAPK pathway inhibitor resistance. This work will elaborate on our early 
understanding of single agent BRAF inhibitor resistance, the use of genomic and 
proteomic approaches to further elucidate these mechanisms, and evidence based 
! xii 
approaches to delay and overcome single agent BRAF inhibitor resistance. This work 
will describe global phosphoproteomic and bioinformatics methodologies to elucidate 
the underlying processes of both single (BRAF) and dual agent (BRAF plus MEK) 
inhibitor resistance as well as strategies to constrain dual agent BRAF plus MEK 
inhibitor resistance.  
 
 
 
 
 
 
 
 
 
 
! 1 
 
 
Chapter 1 
Introduction 
Note to Reader 
Portions of this chapter have been previously published in Skin Cancer and Melanoma, 
Biotargets of Cancer in Current Clinical Practice, M. Bologna Editor, Springer/Humana 
Press, New York, April 2012 1 and have been reproduced with permission from Humana 
Press Publishing. Author contributions: Paraiso KH (writing and figures), John J 
(writing), Smalley KS (writing, concept and design). Portions of this chapter have also 
been previously published in Fibroblast-mediated drug resistance in cancer. Biochem 
Pharmacol. 2013 Apr 15;85(8):1033-41 1,2 and have been reproduced with permission 
from Elsevier Publishing. Author contributions:  Paraiso KH (writing, figures, concept 
and design), Smalley KS (writing, concept and design).  
Melanoma: Incidence, Epidemiology, and Risk Factors 
Skin cancer is the most common type of cancer whose major risk factor is 
ultraviolet (UV) radiation 3. Non-melanocytic and melanocytic skin cancers follow distinct 
biological behaviors and clinical courses. For example, while basal cell carcinomas 
(BCC) are the most common form of skin cancer, accounting for approximately 56% of 
skin cancers, they rarely metastasize and are infrequently fatal. In contrast, melanomas 
account for less than 2% of all skin cancers yet are frequently aggressive, therapy 
resistant, and responsible for the majority of skin cancer related deaths 3,4.  
! 2 
In 2014, it was estimated that 76,100 new cases of melanoma would be 
diagnosed in the US, with 63,770 of these cases being melanoma in situ.  In addition, it 
was predicted that approximately 9,710 deaths would occur due to melanoma 4,5. While 
overall rates of cancer deaths continue to decrease, the risk of death from melanoma, 
particularly in male patients, continues to rise with a 7% increase in male deaths from 
1990–2006 6.  The incidence of melanoma is both gender and age related with 
frequencies being higher in women than men who are less than 40 years of age and 
then significantly higher in men than women who are 40 years of age or older 7,8. The 
incidence of melanoma has been steadily increasing over the last 30 years with 
frequencies in younger adults (age 20-39) rising at alarming rates 9, 10. Among teens 
aged 15-19, melanoma accounts for 6% of all cancer cases compared to 4.6% for 
patients of all age groups 11.  
The two main risk factors for developing melanoma are UV exposure (e.g., 
sunlight and the use of tanning beds) and a family history of melanoma, with skin type, 
number of nevi, age and ethnicity also playing a role in melanoma development 7,10. 
Ultraviolet radiation is known to damage genomic DNA leading to mutations, and as 
such, significant correlations have been found between average annual UV exposure 
and melanoma risk 12. Similar melanoma risk correlations are also related to latitude 
(with UV radiation being most intense at the equator) and altitude (where UV exposures 
are greater at higher elevations) 12. The causative role of UV exposure in melanoma 
development is supported further by the findings that individuals with poor tanning 
responses (such as those with fair skin and a tendency to freckle), and a presumably 
higher rate of UV-induced DNA damage, have the highest risk of melanoma 
! 3 
development 7. Support for these epidemiological studies also comes from whole 
genome-sequencing studies where multiple UV-signature mutations were detected in 
human melanoma cell lines 13. Additionally, the reduction of UV exposure through the 
regular use of sunscreens has been shown to significantly reduce melanoma 
development by ~50% 14. 
The second largest risk factor for developing melanoma is family history, with 
approximately 10% of all melanomas occurring in familial clusters 7. High-penetrance 
genes, encoding for the cyclin-dependent kinase inhibitor 2A (CDKN2A: p16) and 
cyclin-dependent kinase 4 (CDK4), respectively, have been associated with the 
development of hereditary melanoma 15,16. Of these, the incidence of CDKN2A mutation 
is more prevalent and thought to account for 20-40% of all familial melanomas 15. In 
comparison, CDK4 mutations have only been identified in 15 families worldwide, making 
them relatively rare 16.  
Another predictive factor for melanoma development is the presence of large 
numbers of nevi 17. Commonly acquired nevi are melanocytic proliferations that 
generally develop on areas of sun-exposed skin 18. Although most nevi are benign, they 
can, in rare cases, develop into melanoma. There is a good correlation between nevus 
number and melanoma development, with a 20-fold increased risk of developing 
melanoma in individuals who have >120 nevi 18,19. 
Melanoma Diagnosis and Prognosis 
Currently accepted prognostic markers for melanoma are vertical tumor 
thickness (Breslow thickness), mitotic rate (measured as the number of mitoses per 
mm2), presence of ulceration, degree of lymph node involvement, invasion level (Clark 
! 4 
level), the absence or presence of vertical growth phase and regression 20-22. Breslow 
thickness is measured in millimeters from the granular layer of the epidermis down to 
the deepest point of invasion (Fig. 1.1) while Clark level describes the level of 
anatomical invasion of the melanoma in the skin (epidermis, papillary dermis, reticular 
dermis, subcutis) 12,23,24. The current version of the AJCC melanoma staging and 
classification defines tumor thickness, mitotic rate and ulceration as the most powerful 
predictors of survival in patients with localized melanomas (stages I and II) 20,25. For 
patients with nodal metastases (stage III), the number of regional lymph nodes 
harboring metastatic disease, regional node tumor burden, and ulceration of the primary 
tumor are the most powerful independent predictors of survival. Among patients with 
stage IV disease, the anatomic site of distant metastases was the most significant 
predictor of survival. In those with distant skin, subcutaneous tissues, and/or lymph 
node basin metastasis 62% had a one-year survival rate. Pulmonary metastasis was 
associated with a one-year survival rate of 53% while non-pulmonary visceral 
metastases and/or an elevated serum lactate dehydrogenase (LDH) have the worst 
one-year survival of 33% 20. 
 The risk of metastasis to lymph nodes is directly related to Breslow thickness, 
mitotic rate and ulceration of the primary melanoma 26,27. Metastases are rare for thin 
melanomas (<1 mm) while the risk for tumors 1-4 mm thick is about 5%. Melanomas 
with an intermediate thickness (1-4 mm) have a risk that starts at about 8% for 1.0-mm 
tumors, this risk increases steadily to 30% with increasing depth. In addition to a high 
risk of systemic spread, melanomas >4.0 mm have a risk of approximately 40% nodal 
involvement. Though the survival benefit of sentinel lymph node dissection is highly 
! 5 
debated, the status of the sentinel lymph nodes (which receive direct lymphatic 
drainage from the primary tumor site) does provide accurate prognostic information for 
overall and disease-free survival for melanomas stage T1b or greater 20,28-30.  
 
Fig. 1.1. Schematic showing the progression of melanoma by Clark level Breslow thickness and mitotic 
rate. Diagram shows the layers of the skin and its constituent cells. 
 
Although most melanomas can be adequately diagnosed through histological 
criteria, there are subsets of melanoma that are difficult to distinguish from benign 
melanocytic nevi. Specific examples include certain types of nevi, such as dysplastic 
nevi and Spitz nevi, as these share overlapping histopathological features with 
melanomas. Diagnosis of these cases is especially difficult as none of the histochemical 
or immunohistochemical markers used in routine diagnosis can sufficiently differentiate 
between nevi and melanoma 31-33. The one exception to this is the marker HMB45, 
which, in benign and dysplastic nevi, shows a gradient of strong staining in the 
superficial cells and weak-to-negative staining in the deeper tumor cells. In melanoma, 
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The majority of  thin melanomas (95% with Breslow 
<0.75mm) do not metastasize after resection; 
however, biomarkers would be invaluable for the 
detection of  the remaining 5% of  high risk, thin 
melanomas. 
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HMB45 shows strong staining in the deep tumor cells. Since misdiagnosis can have 
potentially serious consequences, there have been a number of attempts to develop 
diagnostic markers that allow for the differentiation of benign and malignant melanocytic 
lesions. A study by Kashani-Sabet et al. defined a panel of five molecular markers that 
included developmental WNT pathway member-2 (WNT-2), fibronectin (FN1), actin-
related protein 2/3 complex subunit 2 (ARPC2), secreted phosphoprotein-1 (SPP1), and 
regulator of G-protein signaling 1 (RGS1) 34. Using a sample set of 693 melanocytic 
lesions (composed of Spitz nevi, melanomas, nevi, and misdiagnosed melanomas), the 
authors successfully used their marker panel to differentiate benign melanocytic lesions 
from melanoma with a specificity of 95% and a sensitivity of 91% 34. 
The diagnosis of amelanotic melanomas can also be difficult. In these cases, the 
approach of choice is the immunohistochemical staining of lesions for components of 
the pigmentation machinery including the S100 protein, gp100 (HMB-45 antigen), and 
melanoma antigen recognized by T-cell one (MART-1; Melan-A protein). MART-
1/Melan-A, S100, and gp100/HMB-45 show high sensitivity for melanoma (75-92%, 97-
100%, 69-93%). However, since all of these markers are also found in melanocytic nevi, 
their specificity to distinguishing melanoma from nevi is low 31-33. MART-1/Melan-A and 
S100 strongly stain both benign and malignant melanocytic neoplasms.  
Melanomas frequently metastasize to distant sites (Table 1.1 35-37), therefore it is 
critical to identify patients who are at risk for relapse and dissemination. Although 
biomarker strategies have been used successfully for prognostic and diagnostic 
purposes in other tumor types, no reliable biomarkers have yet been identified that are 
both highly sensitive and melanoma specific 38,39. A recent meta-analysis of the 
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literature identified over 515 publications 40 that described novel melanoma biomarkers. 
As yet, none of these have found their way into routine clinical practice for either 
diagnostic or prognostic purposes. The reasons for this lack of translation were manifold 
and included the lack of statistical power in the sample size and inadequate validation 
techniques. Of the initial 515 studies under consideration, only 37 of these were judged 
to be worth analyzing. The molecules identified in this subset of publications included 
melanoma cell adhesion molecule (Mel-CAM), matrix metalloproteinase-2 (MMP-2), the 
proliferation markers Ki67 and proliferating cell nuclear antigen (PCNA), and the tumor 
suppressor locus p16 INK4A 40.  
Table 1.1. Sites and frequencies of melanoma metastases. Several factors such as integrins, 
chemokines/chemokine receptors and growth factor/growth factor receptors have been associated with 
homing of disseminated melanoma cells to specific tissues. 
 
The Ki-67 protein is expressed at all stages of the cell cycle except for the G0 
quiescent phase and is considered to be a sensitive marker of cell proliferation. 
Expression of dermal Ki-67 is related to the development of melanoma metastases, with 
high dermal expression of Ki-67 of >20% being demonstrated to be an independent 
prognostic factor 41. A 10-year retrospective study of 396 patients with thin melanomas 
stained for Ki-67 identified two groups with high risks of metastasis: the first consisted of 
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men and women with a dermal mitotic rate of >0 and a dermal Ki-67 positivity of >20% 
and the second group consisted of men with a mitotic rate of >0 and a dermal Ki-67 of 
<20%, with 10-year metastasis rate of 39% and 20%, respectively 41.  
The increased invasive potential of melanoma cells compared to melanocytes is 
due in part to altered expression of cell–cell and cell–matrix proteins, and a number of 
these molecules have been investigated as potential prognostic biomarkers for 
melanoma. Melanoma cells are known to express increased levels of receptors of the 
immunoglobulin gene superfamily of cell adhesion molecules (CAMs), such as 
melanoma cell adhesion molecule (MCAM, Mel-CAM, MUC18, CD146), L1 cell 
adhesion molecule (L1-CAM, CD171), activated leukocyte cell adhesion molecule 
(ALCAM, CD166), vascular cell adhesion molecule 1 (VCAM-1, CD106), intercellular 
cell adhesion molecule 1 (ICAM-1, CD54), and carcinoembryonic antigen-related cell 
adhesion molecule 1 (CEACAM1, CD66a) 42. Of these, Mel-CAM is required for 
homologous melanoma/melanoma and heterologous melanoma/endothelial cell/cell 
interactions 43,44. In melanocytic cells, expression of Mel-CAM is initially found in nevi, 
when the cells have separated from the epidermal keratinocytes and have migrated into 
the dermis 44,45. As the tumor progresses, Mel-CAM expression gradually increases and 
is at its highest in melanoma metastases 43,44,46-48. Two recent studies (n  = 76 and n = 
170, respectively) have shown Mel-CAM expression to independently predict for 
development of lymph node metastases and worse overall survival (after adjustment for 
age, Breslow index, and Clark level) 49,50. It was noted that Mel-CAM-negative patients 
had a 5-year survival of 92% compared to 40% for patients who were Mel-CAM positive 
49. One further study, on a larger cohort of patients (n = 340) showed Mel-CAM 
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expression to predict for disease-free and overall survival in a univariate analysis but 
not when a multivariate analysis was performed. The discrepancy between this and the 
two previous studies was suggested to be a consequence of differences in the 
antibodies used and the methods of sample preservation 51.  
L1-CAM is a neuronal cell adhesion molecule that is expressed in melanoma 
cells 51,52. It mediates adhesion through hemophilic (L1-CAM/L1-CAM) and heterophilic 
(L1-CAM-/!v"3 integrin) mechanisms and allows for melanoma/melanoma and 
melanoma/endothelial cell interactions through its binding to !v"3 integrin 53,54. The 
interaction of L1-CAM and !v"3 integrin plays an important role in transendothelial 
migration of melanoma cells, while overexpression of L1-CAM in the absence of 
upregulated !v"3 integrin expression, promotes the conversion of melanomas from 
radial to vertical growth phase 55,56. L1-CAM immunoreactivity is also increased in 
melanoma compared to nevi 57. A study that systematically identified novel melanoma-
specific genes confirmed that L1-CAM was not expressed in normal skin and 
melanocytic nevi but was highly and differentially expressed in primary melanoma 
tissues and melanoma lymph node metastases 58. A recent study, evaluating 12 nevi, 
67 primary melanomas, 40 sentinel lymph nodes and 35 distant metastases, showed 
L1-CAM to be a highly sensitive (90–93%) and specific (100%) diagnostic marker for 
melanoma 33. A 10-year retrospective biomarker study, evaluating 100 melanoma 
specimens, showed the expression of L1-CAM in human primary cutaneous melanoma 
to be associated with metastatic spread and an independent predictor for metastasis 52.  
Intercellular adhesion molecule (ICAM)-1 binds to integrin !L"2  (lymphocyte 
function associated antigen 1, LFA-1) and Mac1 on lymphocytes 59. Its expression is 
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known to correlate with melanoma progression and the increased risk of metastasis 60. 
Increases in ICAM-1 expression parallel the transition from nevi to melanoma 
metastasis and correlate with Breslow index in primary melanomas 61-64. The role of 
ICAM-1 in melanoma progression and metastasis was also supported by the fact that 
stage I patients with ICAM-1-positive melanomas had a significantly shorter disease 
free interval and overall survival than those with ICAM-1 negative tumors 62. Further, the 
suppression of ICAM-1 in an animal model study reduced the metastatic capacity 65. 
However, the exact role of ICAM-1 in melanoma progression remains obscure with 
contradictory reports showing that ICAM-1 promotes both the aggregation of melanoma 
cells with leukocytes, thereby enhancing survival of tumor cells in the vascular system, 
and that ICAM-1 is shed from melanoma cells, possibly in a form that inhibits 
lymphocyte–tumor cell interactions 66-68.  
CEACAM1, CD66a, is a member of the immunoglobin family of cellular adhesion 
molecules involved in intercellular adhesion. In epithelial cells, CEACAM1 acts as a 
growth suppressor with its expression being either lost or significantly down- or 
deregulated in carcinomas of liver, prostate, endometrium, breast, and colon 42. 
CEACAM1 interacts with the "3 integrin subunit via the CEACAM1 cytoplasmic domain 
colocalizing at the tumor–stroma interface, suggesting a role for the CEACAM1-integrin 
"3 interaction in melanoma cell migration and invasion and the development of 
metastases 69,70. Forced overexpression of CEACAM1 in CEACAM1-negative 
melanocytic cells and melanoma cell lines leads to increased migratory and invasive 
growth potentials in vitro, supporting the role of CEACAM1 in melanoma progression 
and metastasis 71. An evaluation of 12 nevi, 67 primary melanomas, 40 sentinel lymph 
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nodes, and 35 distant metastases showed CEACAM1 to be a highly sensitive (93-97%) 
and specific (63%) diagnostic marker for melanoma 33. 
E-cadherin is expressed on the cell surface of both keratinocytes and 
melanocytes and is the major adhesion molecule mediating the interaction between 
these two cell types in the epidermis 72 73. In culture, melanoma cells undergo a 
cadherin switch. This loss of E-cadherin and gain of N-cadherin expression allows 
melanoma cells to associate with fibroblasts and vascular endothelial cells 72. Although 
experimental studies confirm that E-cadherin loss is critical to melanoma progression, 
the clinical data are conflicting and show that E-cadherin expression is not decreased in 
many cases of advanced melanoma 74-76. A study evaluating 144 primary melanomas, 
53 metastases, and 8 nevi reported E-cadherin expression to be significantly correlated 
with primary tumor depth, but not predictive of patient outcome 77. However, when the 
E-cadherin expression data was combined with that of the calcium-binding protein 
S100A4 data, a significant positive correlation between S100A4 negative, E-cadherin 
high biopsies and disease-free survival was revealed 77. Another study evaluating 115 
melanoma samples (55% of which were acral lentiginous melanomas), with a range of 4 
to 85 months follow-up (median 69 months), reported that 91% of the tumors showed 
reduced E-cadherin expression; however, in this study there was no significant 
correlation between the level of E-cadherin expression and patient survival 78. 
Molecular Subtypes of Melanoma 
BRAF Mutant Melanoma 
A significant advance in our understanding of melanoma initiation and 
progression was the discovery of activating BRAF mutations that occur in over 50% of 
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melanomas 79,80. Rapidly growing fibrosarcoma (derived from Raf) proteins constitute a 
three member family of serine/threonine kinases (ARAF, BRAF, and CRAF) with closely 
overlapping functions 81. So far, over 50 distinct mutations in BRAF have been identified 
82. Of these, the BRAFV600E mutation, resulting from a valine to glutamic acid 
substitution, is the most common and accounts for over 80% of all reported BRAF 
mutations 79,83. Most of the tumor initiating activity of the BRAFV600E mutation is 
thought to result from the stimulation of the MAPK pathway (Fig. 1.2) 79. Constitutive 
activity in the RAS/RAF/MEK/ERK MAPK pathway contributes to the oncogenic 
phenotype of melanoma by increasing cell proliferation, invasion, and survival (Fig. 1.3) 
84.  
 
Fig. 1.2. Cell signaling scheme of pathways activated in melanoma cells through either receptor tyrosine 
kinases (RTKs), Ras, or BRAF. Irrespective of the activating oncogenic mutation, nearly all melanoma 
cells are known to have constitutive signaling in the BRAF/MEK/ERK and PI3K/AKT pathways. Together, 
these pathways drive the uncontrolled growth of melanoma cells and prevent the induction of apoptosis. 
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Regulation of cell growth, particularly at the G1 cell-cycle checkpoint is the most 
well characterized role for downstream MAPK signaling in melanoma. Progression 
through the G1 restriction point into S-phase is driven by cyclin-dependent kinases 
(CDK) 4 and 6 which interact with cyclin D1, as well as by CDK2 which interacts with 
cyclins A/E (Fig. 1.2) 85. Inhibition of either BRAF or MEK in melanoma cell lines using 
siRNA strategies and pharmacological inhibitors leads to a profound G1 phase cell-
cycle arrest. In melanoma, cell cycle progression is also associated with upregulated 
cyclin D1 and downregulated p27 expression 86.  
 
Fig. 1.3. Constitutive MAPK signaling plays a key role in the oncogenic behavior of melanoma cells. 
Increased activity in the MAPK pathway is known to decrease control by local skin keratinocytes by 
downregulating E-cadherin expression. Pathway activity also stimulates melanoma growth by increasing 
cyclin D1 expression and invasion through the modulation of integrin expression and increased matrix 
metalloproteinase (MMP) release. 
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In experimental systems, the role of mutated BRAF in melanoma is convincing. 
In vitro studies have shown that V600E mutant BRAF is an oncogene in immortalized 
mouse melanocytes and that selective downregulation of the V600E-mutated BRAF 
using RNAi leads to reversal of the melanoma phenotype 87,88. Increased BRAF activity 
also suppresses the activity of the melanocyte-specific transcription factor 
microphthalmia (MITF), diverting the melanoma cells from a differentiated state into one 
of rapid proliferation 89. There is also evidence implicating BRAF in the of anoikis, with 
siRNA studies showing a link between mutated BRAF down-regulation of the pro-
apoptotic BH3-family (Bcl-2 family) proteins BIM, BAD, and Mcl-1 90-92.  
Acquisition of the BRAFV600E mutation appears to be an early event in 
melanoma development with a high percentage of nevi found to be BRAFV600E 
mutation positive 93. In line with observations that nevi only rarely develop into 
melanoma, the presence of a BRAFV600E mutation alone is not sufficient to 
oncogenically transform primary human melanocytes into melanoma and instead leads 
to an irreversible growth arrest which is characteristic of senescence 94. Clinical studies 
have confirmed these findings and have shown that most nevi are growth-arrested and 
stain positively for the senescence marker "-galactosidase 94.  This phenomenon, which 
is termed “oncogene-induced senescence” is an important mechanism by which cells 
protect themselves from oncogenic transformation by activating pathways leading to 
irreversible cell cycle exit, such as the ARF/p53/p21 axis and the cyclin-dependent 
kinase inhibitor p16 INK4A 94. As both silencing and mutation of the p16 gene is a 
common event in some inherited forms of melanoma, BRAF mutations were initially 
thought to occur in tandem with p16 inactivation 95. Interestingly, this seems not to be 
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the case with the introduction of mutated BRAF leading to an irregular pattern of p16 
induction 94. Further in vitro studies confirmed the clinical findings and showed that 
siRNA knockdown of p16 in melanocytes did not lead to malignant transformation when 
combined with the BRAFV600E mutation 94. In addition introduction of BRAFV600E 
alone not found to activate the ARF/p53/p21 axis 94. 
A preponderance of evidence now supports the idea that multiple signaling 
pathways must be activated to drive melanoma development. The other major signal 
transduction cascade known to contribute to melanoma initiation and development is 
the PI3K/ AKT pathway. Activation of PI3K/AKT signaling occurs via multiple 
mechanisms, and in BRAFV600E-mutated melanocytes, melanoma arises through loss 
or inactivation of PTEN, and mutations in AKT3 (Fig. 1.2) 95-97. The strongest supporting 
evidence for the dual requirement of BRAF and PI3K/AKT signaling in melanoma 
initiation comes from mouse modeling studies showing that the mutant BRAF alone can 
only lead to the development of melanocytic hyperplasia while mutant BRAF paired with 
PTEN inactivation leads to melanoma development 98.  
Less frequently, BRAF mutations also occur in positions other than 600. In 
isolated kinase assays, many of non-V600 BRAF mutants tend to show impaired BRAF 
kinase activation and are dubbed “low-activity BRAF mutants”. Similar to NRAS 
mutants, low-activity BRAF mutants require the presence of CRAF to transactivate their 
MAPK signaling 83. Analysis of a large panel of melanoma cell lines and tissues 
revealed that ~1% of melanoma cell lines had either D594G or G469E mutation in 
BRAF, respectively, and that 1% of melanoma specimens harbored a G469A mutation 
in BRAF 99. These low-activity BRAF-mutated cell lines differed in their signaling from 
! 16 
BRAFV600E mutants and showed high levels of phospho-ERK, low levels of phospho-
MEK, and resistance to MEK inhibition 99.  
NRAS Mutant Melanoma  
The first activating oncogenic mutation to be reported in melanoma was in NRAS 
100,101. NRAS mutant melanomas constitute the most significant subgroup of BRAF wild-
type melanomas identified so far. RAS proteins are a large family of low molecular 
weight GTP-binding proteins (or GTPases). Three of the RAS family members, NRAS, 
HRAS, and KRAS, are often mutated in human cancers, and >20% of all lesions harbor 
an activating RAS mutation 102. Since their discovery in 1984, NRAS mutations have 
been identified in 15-20% of all melanomas and are typically the result of a point 
mutation leading to the substitution of leucine to glutamine at position 61 79,103. NRAS 
mutations have also been reported at positions 12 and 13 104. Mechanistically, the 
acquisition of point mutations in NRAS leads to impaired GTPase activity, leading to 
more abundant levels of GTP-bound NRAS than GDP-bound NRAS. This facilitates the 
recruitment of adapter proteins leading to an increase in intracellular signaling. In 
addition to NRAS, 1-2% of melanomas have KRAS mutations while 2% having HRAS 
mutations 79,103. The predominance of mutations in NRAS (compared to the other 
isoforms of RAS) may be due in part to the overexpression of NRAS in melanocytes 
relative to other RAS isoforms. It is also possible that NRAS possesses distinct 
signaling properties from the other RAS isoforms that favor melanocyte transformation 
105. In agreement with this, NRAS has a greater transforming activity than KRAS in 
mouse melanoma models even though both mutated GTPases stimulate RAF signaling 
in mouse melanocytes 105. In its GTP-bound state, RAS binds to and activates a number 
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of effector signaling pathways involved in proliferation. The most well characterized of 
these is the serine/threonine kinase RAF 106. Most of RAF’s oncogenic activity is 
mediated through activation of the mitogen activated protein kinase (MAPK) cascade, 
which regulates the cell-cycle entry through control of cyclin D1 expression (Fig. 1.2) 107. 
RAS is also known to activate the PI3K/AKT pathway which contributes to tumor 
progression via the modulation of growth and survival of transformed cells (Fig. 1.2) 107.  
Although BRAF and NRAS mutant melanomas tend to show constitutive 
activation of RAF/MEK/ERK and PI3K/AKT signaling, there are important differences in 
how these pathways are regulated. Melanomas harboring activating NRAS mutations 
are different from melanomas with BRAF mutations in that they rely upon CRAF to 
induce their MAPK pathway activity 107. In normal melanocytes, receptor tyrosine kinase 
(RTK)-induced activation of RAS leads to the stimulation of both BRAF and CRAF 107. 
Under these conditions, constitutive protein kinase A (PKA) activity leads to the 
phosphorylation and inactivation of CRAF and therefore, activation of the MAPK 
pathway proceeds through BRAF signaling. In melanomas with NRAS mutations, the 
cyclic AMP/PKA system is deregulated so that PKA no longer suppresses CRAF, 
thereby allowing CRAF-mediated MAPK activation to occur 107.  
c-KIT Mutant Melanoma 
The KIT gene was originally identified as the viral oncogene v-KIT, derived from 
the feline sarcoma virus HZ 4-FeSV, and then subsequently as the proto-oncogene 
form c-KIT.  c-KIT is an RTK member of the platelet-derived growth factor (PDGF) 
family. Structurally, it is composed of five immunoglobin-like motifs in the extracellular 
portion and a hydrophilic kinase insert domain that forms the intracellular portion (Fig. 
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1.4). Its ligand is the glycoprotein stem cell factor (SCF), which is also known under a 
variety of other names including mast cell growth factor and steel factor (SF). SCF 
activates c-KIT through binding and the induction of a process that leads to receptor 
dimerization and autophosphorylation. Sequencing of c-KIT exons 11, 13, 17, and 18 
revealed the most prevalent mutations in melanoma to be K642E, L576P, D816H, and 
V559A substitutions 107.  
 
Fig. 1.4. Structure of the c-KIT receptor and signaling pathways activated downstream of KIT. Upon 
phosphorylation, the KIT receptor stimulates the MAPK pathway (Ras/Raf/MEK/ERK) through recruitment 
of an adaptor complex consisting of Grb2/Sos/Shc. Other phosphorylation sites on the KIT receptor are 
also known to recruit Src family kinases and the p85 subunit of PI3K. Activation of all of these pathways 
leads to increased growth and survival of melanoma cells. 
 
It was also shown that the presence of a c-KIT mutation is typically accompanied 
by an increase in KIT gene copy number and genomic amplification as identified by 
array comparative genomic hybridization (a-CGH) 108. There were cases where c-KIT 
was amplified in the absence of a mutation, and therefore it was reported that a total 
number of c-KIT aberrations (either amplification and/or mutation), were 39% for 
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mucosal, 36% for acral, and 28% for melanomas arising from sun-damaged skin 108. 
Subsequent studies have shown that c-KIT is expressed in 88% of oral mucosal 
melanomas and that at least 22% of these harbor activating c-KIT mutations 109. 
Another study also reported the presence of the activating L576P mutation in c-KIT in 
15% of anal melanomas, a mutation that was shown to be imatinib sensitive in vitro 110. 
It should however be noted that acral lentiginous and mucosal melanomas are relatively 
rare and when combined account for only ~ 4% of all melanomas 111, therefore the total 
number of melanoma patients presenting with activating mutations in c-KIT are likely to 
be quite low. 
Another subset of BRAF WT melanomas that express high levels of c-KIT and 
CDK4 have also been reported 112. These melanoma cell lines lacked activating c-KIT 
mutations and showed no evidence of an SCF/c-KIT autocrine loop. They were 
however, found to have constitutive c-KIT receptor signaling as shown by the presence 
of high-levels of phospho-c-KIT expression suggesting that the signaling activity may 
have arisen as a consequence of very high receptor expression levels leading to 
spontaneous receptor dimerization. Similar findings have been reported in non-small 
cell lung cancer where very high epidermal growth factor (EGF) receptor expression 
levels lead to constitutive signaling activity 113.  
BRAF/NRAS Wild-type 
Melanomas that are genetically classified as BRAF/NRAS wild-type (WT) 
comprise a considerable proportion (13-26%) of all melanomas 114,115. Tumor-initiating 
events for this subgroup are largely unknown and as such efforts are currently 
underway to study this significant subpopulation of melanomas 114 115. However, a 
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recent examination of the whole exomes of 34 patient-derived fresh-frozen primary 
cutaneous melanomas revealed that the majority of BRAF/NRAS WT melanomas 
lacked single driver mutations and instead carried an overall higher mutational burden 
when compared to BRAF or NRAS mutated melanomas 115. These mutations were 
consistent with UV-induced damage with a higher proportion occurring as C>T 
transitions and CC>TT dinucleotide transitions 115. These mutations were reported to 
occur within “hotspots” of the NF1 and RAC1 genes 114,115.  
Recent studies utilizing patient-derived melanoma cell lines also support the 
hypothesis that NF1 mutations could contribute to tumorigenesis in cutaneous 
BRAF/NRAS WT melanoma 116. Loss of NF1 (a tumor suppressor gene that encodes a 
protein required for hydrolyzing GTP to GDP) was associated with RAS upregulation 
and downstream ERK activity. BRAF/NRAS WT, NF1 mutants were found to be 
resistance to RAF inhibition but maintained MEK dependency as seen by sensitivity to 
the MEK inhibitor, trametinib, wherein treatment with the MEK1/2 inhibitor lead to 
durable ERK downregulation and growth arrest 116,117. However, cell death was not 
induced in studies of single agent MEK inhibitors. Therefore it remains to be seen 
whether further genetic subgrouping of this heterogeneous population of melanomas 
will be able to guide prospective therapeutic interventions.  
Pathological and Prognostic Features of Melanomas with Different Activating 
Mutations 
Both NRAS and BRAF mutant melanomas are found on sun-exposed skin, 
whereas c-KIT mutant melanomas arise on sun-protected sites 118,119. Therefore, BRAF 
mutant melanomas rarely occur on the palms of the hands, the soles of the feet (or as 
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acral melanomas occurring on subungual sites), or on mucous membranes (mucosal 
melanomas)108. Evidence is emerging that the duration and frequency of sun exposure 
may determine the nature of initiating oncogenic event, with BRAF mutant melanomas 
tending to occur in younger patients who have had lower lifetime UV exposure and 
NRAS mutant melanomas more likely to develop in older patients who have had a 
longer history of sun exposure 120. Additionally, BRAF mutations are more frequently 
found on skin that has had intermittent sun exposure and is infrequently found on skin 
that exhibits signs of chronic sun damage (as shown by increased solar elastosis) 
121,122.  
Careful pathological examinations of large numbers of BRAF, NRAS, and c-KIT 
mutant melanoma specimens have revealed significantly different mutation-specific 
biological behaviors 123. It was found that BRAF mutated melanomas had an increased 
tendency to upward migration and nest formation and gave rise to larger, rounded, and 
more pigmented tumor cells 123. In contrast, NRAS mutated melanomas were not found 
to exhibit these morphological and phenotypic characteristics 123. With regard to the 
possible prognostic value of mutation status, there is some suggestion that NRAS 
mutant primary melanomas may pose a higher risk of metastasis as they tend to be 
more deeply invasive at the time of initial diagnosis than BRAF mutated melanomas and 
tend to have a higher mitotic rate. The effects of the different initiating mutations upon 
melanoma prognosis and biological behavior remain an area of intense study. As things 
stand, the available evidence suggests that both BRAF and NRAS mutant melanomas 
ultimately follow a similar clinical course, with little differences in overall survival noted 
124.  
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Personalized Therapy 
Currently, there are few effective treatments for disseminated melanoma and as 
such, patients with metastatic disease have a median survival ranging from only 6 to 10 
months. While primary melanoma is easily curable through surgery, treatment of 
advanced disease remains a challenge with therapeutic strategies employed over the 
past 30 years not significantly improving cure rates. Until very recently, all major 
chemotherapy drugs, immunotherapies, and radiotherapies failed to prolong survival 
when tested in large-scale phase III clinical trials 125.  
However, there are now encouraging signs that the impasse in the therapeutic 
management of disseminated melanoma may soon be broken. The past decade has 
seen breakthroughs in personalized cancer medicine, with new targeted therapies being 
developed that inhibit cellular proliferation and survival in tumors with specific oncogenic 
mutations. Targeted agents, such as crizotinib (Xalkori™) for the treatment of 
echinoderm microtubule associated protein like 4/anaplastic lymphoma kinase (EML4-
ALK) rearrangement positive non-small lung cancer (NSLC) and dabrafenib (Tafinlar™) 
in combination with trametinib (Mekinist™) for the treatment of BRAFV600 mutated 
melanomas mark a revolutionized era in precision medicine 126,127.  
It is evident that melanomas constitute a heterogeneous group of tumors, with 
different patterns of oncogenic mutation, overexpression, and genomic amplification 
108,114,118. However, in the next section I will focus my discussion on BRAFV600 mutated 
melanomas in the context of drug development and resistance. 
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Targeting BRAF Mutant Melanoma 
BRAF inhibitors 
The dependency of melanoma on MAPK signaling for survival and growth has 
made it an attractive candidate for targeted kinase therapy. Indeed the hallmark 
discovery, made 13 years ago, that the valine to glutamic acid substitution at codon 600 
in BRAF (BRAFV600E) is a melanoma driver mutation has led to the rapid development 
of numerous RAF inhibitors 79. The most thoroughly studied of these is the pan-kinase 
inhibitor, sorafenib (Nexxavar) 128. Originally developed as a CRAF inhibitor, sorafenib 
was also found to inhibit BRAF with moderate potency and was evaluated as a potential 
first proof-of-concept for BRAF inhibition in melanoma 128,129. Though sorafenib was 
found to have some activity in cell culture experiments and caused growth arrest in 
human melanoma xenograft models, it was eventually shown to have little activity in 
melanoma patients 129-131. Additional preclinical investigations showed sorafenib to be a 
relatively weak inhibitor of BRAF, with many off-target effects including inhibition of 
VEGFR, PDGFR, and p38 MAP kinase 128,131. 
In the wake of the clinical disappointment of sorafenib, a new wave of more 
promising BRAF inhibitors were developed which boast higher specificities for 
oncogenic BRAF and fewer off-target side effects. These potent and selective next 
generation BRAF inhibitors include vemurafenib, dabrafenib, XL281, ARQ-736, 
RO521254, RAF265, LGX818, SB590885 and AZ628 45,132-141. Among these, 
dabrafenib and vemurafenib are currently FDA approved as single-agents. LGX818 is 
currently being evaluated in various stages as a single agent (LGX818), while all three 
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inhibitors are in current clinical testing in various inhibitor combinations (Table 1.2) 45,132-
140. 
Table 1.2. BRAF inhibitor combinations in current clinical trial. 
 
Vemurafenib and dabrafenib are both adenosine triphosphate (ATP)-competitive 
RAF inhibitors (vemurafenib: mutant BRAF IC50 = 31 nM, CRAF IC50 = 48 nM, WT 
BRAF IC50 = 100 nM; dabrafenib: mutant BRAF IC50 = 0.8 nM, CRAF IC50 = 4.8 nM, WT 
BRAF IC50 = 3.2 nM) that selectively target BRAFV600E 142,143. In preclinical models, 
treatment of patient-derived BRAFV600E cell line xenografts with either vemurafenib or 
dabrafenib lead to highly specific and potent inhibitions of BRAF, downregulation of 
ERK activity and partial to complete responses in all tumors 143,144. Vemurafenib-
induced tumor regression was also associated with increased BIM expression and the 
induction of apoptosis "#$. In phase III clinical trials, both vemurafenib (BRIM-3) and 
dabrafenib (BREAK-3) showed significant improvements in objective response (OR) 
rate, progression free survival (PFS) and overall survival (OS) compared to the 
alkylating chemotherapeutic, dacarbazine (DTIC) (Table1.3); furthermore, objective 
clinical responses to vemurafenib were associated with >80% MAPK signaling blockade 
Trial ID BRAF inhibitor 2nd drug 3rd drug 2nd drug target 3rd drug target Phase
NCT01902173 Dabrafenib GSK2141795 AKT 1, 2
NCT01750918 Dabrafenib Trametinib Panitumumab MEK EGFR 2
NCT01726738 Dabrafenib Trametinib MEK 2
NCT01989585 Dabrafenib Trametinib navitoclax MEK  BCL-2 1, 2
NCT02097225 Dabrafenib Trametinib, AT13387 MEK HSP90 1
NCT01719379 LGX817 BYL719, Cetuximab PI3K EGFR 1, 2
NCT01777776 LGX818 LEE011 CDK4/6 1, 2
NCT01820364 LGX818 MEK162 MEK 2
NCT01909453 LGX818 MEK162 MEK 3
NCT01543698 LGX818 MEK162 LEE011 MEK, CDK4/6 1b, 2
NCT01495988 Vemurafenib Bevacizumab VEGFR 2
NCT01512251 Vemurafenib BMK120 PI3K 1, 2
NCT01596140 Vemurafenib Everolimus Temsirolimus mTOR mTOR 1
NCT01689519 Vemurafenib GDC-0973 MEK 3
NCT01841463 Vemurafenib P1446A-05 CDK4/6 1, 2
NCT01616199 Vemurafenib PX-866 PI3K 1, 2
NCT01673737 Vemurafenib SAR260301 PI3K 1
NCT01835184 Vemurafenib XL184 c-MET 1
NCT01657591 Vemurafenib XL888 HSP90 1
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145-147. In the phase III study, common side effects for vemurafenib included cutaneous 
events, photosensitivity skin reactions (grade 2 or 3), and arthralgia. Of 336 patients 
treated with vemurafenib, 61 (18%) developed either secondary cutaneous squamous-
cell carcinoma or keratoacanthoma 146. For dabrafenib, common adverse events 
included pyrexia, fatigue, nausea, headache, chills, diarrhea, arthralgia, rash, and 
hypertension 127. Overall, a higher percentage of patients, responded to dabrafenib 
(54%) versus vemurafenib (48%), perhaps due to the higher potency of dabrafenib. In 
addition, secondary skin lesions occurred less frequently in dabrafenib vs. vemurafenib 
treated patients (9% vs. 18%, respectively) 146,148. 
Table 1.3. Summary of clinical trial results for dabrafenib, vemurafenib and trametinib. 
 
Intriguingly, the clinical response rates correlated with cell line based studies 
showing that not all BRAF mutated melanomas are sensitive to BRAF inhibition, with a 
significant proportion of BRAF mutated melanomas having variable degrees of intrinsic 
resistance (Table1.3) 136,137,149. A recent genetic study, which looked for patterns of 
mutations and genomic amplifications between vemurafenib-sensitive and vemurafenib-
resistant cell lines was unable to identify any unifying differences between the two 
groups 137. However, phenotypic studies from our own group (discussed in Chapter 2) 
implicated the loss of the tumor suppressor PTEN as being a potential mechanism of 
intrinsic resistance 150. In these studies, loss of PTEN (which is observed in ~20% of 
melanomas) was associated with increased PI3K/AKT signaling following BRAF 
inhibition 150-152. Increased AKT activity lead to suppressed of BIM and BAD expression, 
impaired apoptosis and decreased sensitivity to BRAF inhibition 150. In addition to 
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PTEN, it is also known that BRAFV600E mutated melanomas show alterations in cyclin 
D1, CDK2, CDK4, MITF, and AKT3 153-155. Clinical trials are currently underway that will 
address some of the aforementioned mechanisms of intrinsic BRAF inhibitor resistance 
(Table 1.2) 139,140.  In addition, BRAF inhibitors are currently being combined with 
immunotherapeutics (Table 1.4). A previous trial combining vemurafenib with 
ipilimumab was terminated due to unpredicted high levels of hepatotoxicity that was 
associated with the concurrent dosing regimen 156. Many of the current clinical 
evaluations are still in early phases, therefore it will be of great interest to see how 
combinatorial strategies such as metronomic dosing will be tolerated 140,156,157.  
Table 1.4. BRAF inhibitor/immunotherapy combinations in current clinical trial. 
 
 
An unanticipated clinical observation was that BRAF inhibitors actually induced 
the activation of the MAPK signaling pathway in BRAF WT melanoma (Fig1.5) 134,158. In 
cell line models, the paradoxical activation of MAPK signaling arose in BRAF WT 
melanoma cell lines that harbored either an oncogenic Ras mutation or had upstream 
constitutive RTK activity (events that can occur due to selection pressures brought on 
by BRAF inhibition)! 134,158,159. In these studies, BRAF inhibition lead to the formation of 
BRAF/CRAF dimers that cooperated with oncogenic RAS to activate MAPK signaling 
(Fig1.5). Activation of RAF following BRAF inhibition resulted in enhanced proliferation 
Trial ID BRAF inhibitor 2nd drug Immunotherapy 2nd immunotherapy Phase
!"#$%&'&()( *+,-+./01, #-+2/3101, 45161272+,89+031:"#;<(8= %
!"#$>$>&?'% *+,-+./01, #-+2/3101, @A*4(&B'89+031:C*;%8= %D8>
!"#$>%B$('' *+,-+./01, #-+2/3101, C/2,-E61F72+,89+031:C*%= %D8>
!"#$%)G)(%) H/27-+./01, <IE531J/8K/6683L/-+5M %
!"#$%')''(> H/27-+./01, @C*;B>G$<89+031:C*;%= %
!"#$%?(B(>> H/27-+./01, N1OL:IEP/8103/-./-E08+6.+:>, %D8>
!"#$%?)?'BB H/27-+./01, CAQ:103/-./-E0 %D8>
!"#$%'$B>%> H/27-+./01, 403/-6/7R108> 403/-./-E08+6.+:>, %D8>
!"#$%')?%)% H/27-+./01, <IE531J/8K/6683-+0P./- N1OL:IEP/8103/-6/7R108> >
!"#$%&)(B&' H/27-+./01, 403/-6/7R108> >
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(increased MAPK signal), survival (increased anti-apoptotic Mcl-1 expression), and 
invasion (increased FAK activity) of RAS mutated cells 159. !
 
Fig. 1.5. BRAF inhibition causes paradoxical MAPK activation in BRAF WT cells. In the absence of BRAF 
inhibition, WT RAF signal output is normal (left). WT BRAF inhibition drives BRAF/CRAF dimerization and 
cooperates with RAS or RTK activation leading to increased MAPK pathway signaling (middle). Paradox 
breakers inhibit MAPK signal output by inhibiting mutant and WT BRAF, CRAF and SFK kinase activity 
(right). 
 
There is increasing clinical evidence that squamous cell carcinomas (SCC), 
keratoacanthoma (KA), new nevi and secondary (BRAF wild-type) melanomas may 
arise as a result of the paradoxical activation of MAPK signaling. Indeed almost all of 
the clinically evaluated BRAF inhibitors, including sorafenib, vemurafenib, dabrafenib 
and XL281, have been associated with the development of these proliferative skin 
lesions 127,138,148. Sequencing of spontaneous KA’s from RAF inhibitor treated patients 
revealed that these patients had a greater likelihood of developing KA’s with RAS 
mutations than non-RAF inhibitor treated patients (21.1% RAFi vs. 3.2% non-RAFi, 
p<0.01) 160. Interestingly, compared to vemurafenib treated patients, fewer patients 
developed secondary SCC or KA’s when treated with dabrafenib, perhaps owing to the 
higher potency of dabrafenib for non-mutated BRAF (vemurafenib: CRAF IC50 = 48 nM, 
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WT BRAF IC50 = 100 nM; dabrafenib: CRAF IC50 = 4.8 nM, WT BRAF IC50 = 3.2 nM) 
142,143.!
Paradox Breakers!
To address the issue of paradoxical activation, a new class of non-agonistic 
BRAF inhibitors, known as paradox breakers or pan-RAF inhibitors (CCT196969, 
CCT241161, PLX7904 and PLX8394) have been developed 161-163. Recent preclinical 
studies have shown that treatment with PLX7904, PLX8394, CCT196969 or 
CCT241161 could effectively inhibit MAPK signaling in BRAFV600E melanomas without 
agonistic effects on WT RAF signaling (Figure 1.5) 161-163. Studies conducted with 
PLX7904 demonstrated that paradox breaker mediated inhibition leads to G1/S cell 
cycle arrest and growth inhibition in melanoma cell lines with acquired vemurafenib 
resistance (secondary NRAS mutation) 161,162. Additionally, treatment with PLX8394 
lead to growth arrest and cell death in melanoma cell lines harboring vemurafenib 
resistant, BRAF splice variants 161,162. !
The pan-RAF inhibitors, CCT196969 and CCT241161 have also shown 
impressive preclinical efficacy in both in vitro and in vivo models 163. To evaluate BRAF 
inhibitor resistance, these studies utilized xenografts derived from BRAFV600 tumors of 
stage IV melanoma patients with either acquired (partial or complete responses) or 
intrinsic resistance (no therapeutic response) to vemurafenib. In addition, patient-
derived xenografts (PDX) were also established from a patient who had a partial 
response to combined dabrafenib plus trametinib followed by relapse. In these mouse 
models, CCT196969 and CCT241161 were well tolerated at their effective dose of 
20mg/kg with no evidence of weight loss, clinical signs of adverse effect during 
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treatment or post-mortem microscopic tissue changes. Importantly, in all PDX models, 
treatment with CCT196969 and CCT241161 lead to significant tumor growth inhibition 
(compared to vemurafenib or dabrafenib plus trametinib) which was associated with 
inhibition of MAPK and src family kinase (SFK) activity 163. The studies conducted with 
the CCT196969 and CCT241161 inhibitors have garnered much excitement and it is 
hoped that their improved inhibitory profile may translate into first line therapies for 
treatment of naïve melanomas or second line therapies for treatment refractory lesions. !
MEK inhibitors  
The first MEK inhibitor studies preceded the discovery of BRAF activating 
mutations in melanoma and emphasized the role of MAPK in suppressing differentiation 
164-166 Many of these studies, which utilized inhibitors such as PD98059, PD0325901, 
CI-1040, UO126 and AZD6244 (selumetinib), found that inhibition of MEK in melanoma 
cells resulted in G1 phase cell cycle arrest correlating to MAPK inhibition, cyclin D1 
downregulation, p27 upregulation and hypophosphorylation retinoblastoma (Rb) protein 
"%&'"%() Although PD0325901 and selumetinib are highly potent MEK1 inhibitors (MEK1 
IC50=0.33nM and 14nM, respectively), clinical testing of early MEK inhibitors were met 
with poor clinical efficacy and further clinical evaluations were abandoned 169-171. In fact, 
prior to the development of trametinib, MEK inhibitors were generally found to induce 
only modest levels of apoptosis in the most sensitive of BRAF mutated melanoma cell 
lines 172-175. However, the understanding that near complete MAPK blockade is required 
for tumor regression, that reactivation of MAPK signaling is critical to BRAF inhibitor 
resistance, and a dire need for therapies to manage NRAS mutated melanomas has 
prompted renewed interest in the further development of MEK inhibitors 133,176-179.  
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To date, the FDA approved highly selective allosteric MEK1/2 inhibitor (IC50: 
MEK1 = 0.92 nM, MEK2 = 1.8 nM), trametinib, is the most potent and well-studied 
inhibitor in its class 180,181. In the phase III trial of 322 BRAFV600E/K melanoma 
patients, trametinib was shown to have the best single agent activity of any MEK 
inhibitor evaluated so far (trametinib vs. DTIC: PFS = 4.8 months vs. to 1.5 months; OS 
= 81% vs. 67%; OR = 22% vs. 8%) (Table 1.3) 180. The most common toxic effects 
observed in trametinib treated patients were rash, diarrhea, and peripheral edema. 
Importantly, secondary skin neoplasms were not observed 180. Trametinib in 
combination with dabrafenib as a first-line therapy for treatment naïve BRAFV600 
mutant melanomas has also been recently FDA approved 127,148,182. Clinical 
comparisons of dabrafenib plus trametinib vs. dabrafenib monotherapy indicated that 
the addition of a second MAPK pathway inhibitor could improve PFS by 3.6 months and 
improve response rates by 22% (Table 1.3) 127. Notably, although there was still some 
evidence of paradoxical activation of MAPK signaling, as seen by the development of 
secondary cutaneous SCC’s in patients receiving combinatorial drugs, the addition of a 
MEK inhibitor was able to significantly lessen development of secondary tumors 
(patients with SCC or KA: dabrafenib plus trametinib = 2 %; dabrafenib = 9%; trametinib 
= no secondary skin lesions reported) 127. Similar clinical outcomes have also been 
reported for the combination of vemurafenib plus the MEK inhibitor, cobimetinib 
(Genetech: GDC-0973, Exelixis: XL518) 183,184. 
ERK inhibitors  
Another class of drugs targeting the MAPK pathway are the ERK inhibitors which 
include SCH772984 (IC50: ERK1 = 4 nM, ERK2 = 1nM) and VX-11e (IC50: ERK2 = 
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48nM) 185,186. Studies evaluating ERK inhibitors as a monotherapy have primarily 
focused on the ATP-competitive compound, SCH772984. Recent in vitro studies have 
indicated that sensitive and resistant (BRAF amplification, MEK1 mutation, RAS 
mutation) V600E melanomas may be amenable to ERK inhibition 186,187. In these 
studies, treatment of melanoma cell lines with SCH772984 lead to cell cycle arrest and 
apoptosis 186,187.  
Similar to previous findings utilizing SCH772984, recent data from our own group 
(188 and data not shown) have demonstrated that VX-11e may be combined with a MEK 
inhibitor such as trametinib or selumetinib in NRAS mutant melanomas to induce growth 
arrest and apoptosis. Similar effects were also seen when VX-11e was combined with a 
BRAF and MEK inhibitor (vemurafenib and selumetinib) in treatment sensitive V600E, 
BRAF inhibitor resistant V600E (data not shown) and NRAS mutant melanomas. In all 
studies of the SCH772984 and VX-11e ERK inhibitors, cytostatic and cytotoxic effects 
were associated with decreased MAPK activity and downregulated cyclin D1 expression 
(188 186,187 and data not shown). The evaluation of ERK inhibitors is still in its relative 
infancy therefore it will be of interest to see if these compounds can be utilized clinically 
as frontline monotherapies for BRAF and NRAS melanomas or in combinations with 
MEK and/or BRAF inhibitors to increase MAPK blockade.   
HSP90 inhibitors 
In cancer, HSP90 stabilizes a multitude of client proteins known to be essential 
for cellular signaling pathways such as growth, survival, differentiation and DNA 
damage response making HSP90 an attractive therapeutic target. In addition, several 
proteins known to be important for melanoma signaling, including BRAFV600E, have 
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been identified as HSP90 clients 189. In oncogenic cells, HSP90 client-chaperone 
complexes are enriched, are functionally distinct, and have greater binding affinities for 
HSP90 inhibitors (Figure 1.6) 190.  
 
Fig. 1.6. In stress environments, HSP90 exists in an activated state allowing for increased binding and 
stabilization of oncogenic proteins.  
 
Under homeostatic conditions, HSP90 proteins exists in a latent state, interacting 
with client proteins in a low-affinity, ATP-dependent manner 191-193. However, under 
stress conditions (typified by the hypoxic and nutrient deprived cancer milieus), HSP90 
interactions become deregulated. In this environment, HSP90 proteins have a higher 
affinity for client and co-chaperone proteins (HSP70, HSP40, cdc37) leading to 
aberrantly elevated and stable formations of HSP90/onco-client/co-chaperone 
complexes 191-193. Additionally, HSP90 inhibitors have been shown to preferentially bind 
to oncogenic clients (e.g. BRAFV600E and Bcr-Abl) with greater affinity and are 
therefore selectively retained in tumorigenic tissues 190. Currently, this observation is 
being explored to improve drug delivery methods 190,194. 
Historically, attempts to utilize HSP90 inhibitors to treat melanoma were marred 
with difficulties in achieving effective tolerable doses; however, 2nd generation HSP90 
inhibitors have now been developed which exhibit greater bioavailability, higher potency 
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and lower toxicity profiles resulting in greater efficacy (Table 1.5) 195,196. Work by our 
group and others have shown that HSP90 inhibitors can induce cell death in melanoma 
through simultaneous degradation or inhibition of several key client proteins that are 
necessary for cancer survival, proliferation and metastasis 197-199. Recent clinical 
evaluations of the HSP90 inhibitors have also demonstrated that HSP90 inhibition could 
overcome multiple mechanisms of resistance across multiple cancer types e.g., 
trastuzamib resistance in HER-2 positive breast cancer and bortezomib resistance in 
multiple myeloma 196,200.   
Table 1.5. Second-generation HSP90 inhibitors in development. 
 
Our own data, (discussed in Chapters 4 and 5) demonstrated that treatment of 
single and dual agent MAPK inhibitor resistant melanoma cells with HSP90 inhibitors 
leads to the rapid degradation or inhibition of key HSP90 client proteins and results in 
marked inductions of apoptosis 197,198. These findings support our hypothesis that 
resistance proteins are critically dependent upon HSP90 for stabilization and that the 
HSP90 machinery is indispensible for the mechanisms that promote oncogenesis. 
Moreover, our studies demonstrate that combined BRAF and HSP90 inhibition may 
dramatically delay the onset of BRAF inhibitor resistance 193,197,198.  
HSP90 inhibitor Class Company
Retaspimycin hydrochloride (IPI-504) Hydroquinone derivative Infinity
SNX-5422 Indazol-4-one Seranex
XL888 Other chemotype Exelixis
DS2248 Other chemotype Daiichi Sankyo 
Debio 0932 Purine-Scaffold Debiopharm
MPC-0767 Purine-Scaffold Myrexis
MPC-3100 Purine-Scaffold Myrexis
PU-H71 Purine-Scaffold Samus
AUY922 Resorcinol-Isoxazole Novaris
Ganetespib (STA9090) Resorcinol-Triazole Synta
AT13387 Resorsinol containing synthetic agent Astex
HSP990 Resorsinol containing synthetic agent Novartis
KW2478 Resorsinol containing synthetic agent Kyowa Hakko Kirin
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Mechanisms of BRAF inhibitor Resistance 
Tumor Intrinsic Mechanisms 
The clinically approved BRAF inhibitors, vemurafenib and dabrafenib, are the 
most well studied with phase III reports indicating that these highly potent and selective 
compounds can significantly delay the time to relapse and improve therapeutic 
responses (Table 1.3). Although the results have been encouraging and provide strong 
evidence that melanoma is amenable to targeted therapy, response rates are still well 
below 100% (dabrafenib 51%, vemurafenib 48%). Median progression-free survival was 
also reported as 6.9 months for dacarbazine and 5.3 months for vemurafenib, with 
refractory disease being the eventual outcome for the majority of patients 127,146. 
Therefore, the two major hurdles to effective therapeutic intervention are intrinsic and 
acquired vemurafenib resistance. These observations mirror the pattern of response 
seen to targeted therapy in NSCLC, chronic myelogenous leukemia (CML) and 
gastrointestinal stromal tumors (GIST), where an initial period of tumor regression is 
later followed by relapse 201-203. Imatinib resistance in CML and GIST and erlotinib 
resistance in NSCLC generally emerges following the acquisition of secondary 
mutations “gatekeeper” sites. Mutations of these target kinase ATP binding residues 
prevent the binding of drug to the hydrophobic pocket 201,203,204. Though BRAF 
gatekeeper mutations have been predicted in silico and generated drug resistance in 
vitro, similar drug-insensitive BRAF mutations have not yet been detected in melanoma 
patients 205-208.  .  
Melanoma is a notoriously heterogeneous disease with diverse and complex 
adaptive mechanisms. As such, resistance is often regulated by multiple factors 
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occurring both upstream and downstream of mutated BRAF 134,206,209-215. In cancer cell 
lines, adaptive growth factor signaling can be activated through signal transduction 
inhibition (such as inhibition of mTOR, MEK or BRAF). In some cases, pathway 
inhibition leads to the de-repression of negative feedback signaling and reciprocal RTK 
signaling (Fig. 1.7) 216-218.  
 
Fig. 1.7. Derepression of negative feedback signaling. Following BRAF inhibition, one mechanism for 
tumor adaptation is through the relief of negative feedback signaling (inhibition of ERK) which in turn 
allows for reciprocal RTK activation.  
 
Studies from several independent groups have shown that BRAF inhibitor 
resistance is mediated through increased RTK signaling (e.g. HER3, PDGFR", IGF1R, 
c-MET, EGFR and EphA2) *"*'*"+,**$. In the case of IGFR1, downstream MAPK signaling 
was reactivated following the rerouting of signaling from mutated BRAF to ARAF and 
CRAF 212. However, cell line studies from our own group (data not shown) indicate that 
upregulated expression of PDGFR", IGF1R, EGFR or EphA2 does not confer 
resistance to BRAF inhibitors in the canonical sense. Though inhibition of RTK’s lead to 
decreased kinase activity (as measured by receptor tyrosine dephosporylation), siRNA 
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knock-down of RTK’s (PDGFR" or EphA2), or treatment with small molecule inhibitors 
(IGF1R: NVP-ADW-742 150; EGFR: lapatinib or erlotinib) in respective RTK 
overexpressing resistant cell lines did not lead to significant levels of cell cycle arrest or 
apoptosis. Further data from our group (Chapter 5) have also shown that receptor 
tyrosine kinases are not singly overexpressed following acquired resistance, with 
several cell lines observed to have increased activity in more than one RTK 197,198. 
Together, these observations indicate that targeting individual RTK’s may not be a 
viable treatment option for overcoming dynamic BRAF inhibitor resistance mechanisms.  
 
Fig. 1.8. Overview of tumor intrinsic mechanisms of BRAF inhibitor resistance. Reported tumor-mediated 
mechanisms of resistance are shown in yellow.  
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Rather than having canonical effects upon cellular growth and survival, recent 
data from the Marais lab and our own group have shown that RTK upregulation (EGFR 
and EphA2) leads to an adaptive switch whereby resistant cells adopt a more 
aggressive invasive and migratory phenotype 221,224. Unlike HER3, IGF1R and EGFR 
upregulation (which is likely due to the relief of feedback suppression) the processes 
underlying increased EphA2 overexpression are still unclear with evidence from our 
group (discussed in greater detail in Chapter 6), and others, which indicate that EphA2 
expression may be epigenetically controlled and is reliant upon histone deacetylase 
(HDAC) and DNA methyltransferase activity 224,225.  
Melanoma cells can also circumvent BRAF inhibition through downstream MAPK 
pathway signaling (Figure 1.8). A recent study demonstrated that increased COT 
(MAP3K8) expression drives BRAF inhibitor resistance through the RAF-independent 
activation of ERK 211. The clinical relevance of increased COT expression in the 
resistance phenotype was confirmed in a limited number of melanoma samples from 
patients failing BRAF and MEK inhibitor treatment 211. A number of other vemurafenib 
resistance mechanisms have also been reported for melanoma including upregulated 
receptor tyrosine kinase signaling secondary mutations (NRAS-Q61K and MEK1-
C121S), amplifications (BRAF and cyclin D1), loss of tumor suppressors (PTEN: 
discussed in Chapter 3 and NF1) and truncated BRAF (p61) expression 134,176,210,223,226. 
Tumor Extrinsic Mechanisms  
Recent studies have also implicated the role the tumor microenvironment in 
mediating BRAF inhibitor resistance. While resident fibroblasts actively suppress tumor 
initiation through the maintenance of tissue homeostasis, their function can switch 
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dramatically upon oncogenic transformation 227,228. The central role of cancer associated 
fibroblasts (CAFs) in tumor development and progression is suggested by their 
contribution to each of Hanahan and Weinberg's original hallmarks of cancer; sustaining 
proliferative signaling, evading growth suppressors, avoiding immune destruction, 
activating invasion and metastasis, inducing angiogenesis and resisting cell death 229 
(Fig. 1.8).  
 
 
 
 
Fig. 1.9. Carcinoma-associated fibroblasts in the tumor microenvironment. Activated tissue associated 
fibroblasts and myofibroblasts are recognized sources of carcinoma associated fibroblasts (CAFs). 
However, CAFs may also arise from diverse lineages including endothelial cells, mesenchymal stem cells 
(MSC) and epithelial cells. In addition to mitogenic factors and proteases, CAFs promote cancer 
progression through the secretion of various structural extracellular matrix (ECM) components such as 
fibronectin, collagen, laminin, proteoglycans, tenascin and osteopontin. In this manner, signal transduced, 
direct cell–cell and ECM mediated communication can occur between tumor cells and their associated 
fibroblasts leading to enhanced tumor survival, proliferation and metastasis. 
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Melanomas exhibit varying degrees of stromal infiltration with tumors having 
either the absence or presence of fibroblasts 230. Stromal patterns seen in melanoma 
specimens can also vary and are characterized as desmoplastic (fibroblasts with 
strands of ECM) or mixoid (stellate fibroblasts with the deposition of proteoglycans). 
Generally, the earliest stages of melanoma (RGP phase) show much less fibroplasia 
than intermediate (VGP phase) lesions (which often exhibit a pattern of concentric 
fibroplasia around nests of melanoma cells) 230.  
Numerous studies have now reported that the host microenvironment provides a 
protective niche allowing minor populations of cancer cells to evade therapy. The most 
thoroughly studied aspect of environmentally mediated drug resistance has been 
therapeutic escape via the adhesion of cancer cells to the extracellular matrix (ECM). 
This phenomenon, also known as cell adhesion mediated drug resistance (CAM-DR), 
was first seen in multiple myeloma, where it was observed that adhesion of myeloma 
cells to the ECM protein fibronectin decreased sensitivity to the chemotherapy drug 
melphalan 231. Mechanistically, the protection conferred by fibronectin resulted from the 
!-integrin-mediated amplification of IL-6 signaling leading in turn to increased cell 
survival mediated through increased anti-apoptotic Bcl-XL and decreased pro-apoptotic 
BIM expression 232. CAM-DR has also been observed in many other tumor types, with 
similar protective effects noted when NSCLC, uveal melanoma, ovarian and cutaneous 
melanoma cell lines were adhered onto ECM proteins such as lamin, collagen IV, 
fibronectin and Tenascin-C233-236.  
Recent studies from our own lab have also demonstrated that the adhesion of 
melanoma cells to fibroblast monolayers significantly reduces the cytotoxic effects of the 
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chemotherapy drug cisplatin 237. Although the mechanism underlying this protection is 
not yet known, there is evidence that melanoma cells and fibroblasts directly adhere to 
each other through N-cadherin, and that homotypic cadherin binding increases 
melanoma survival through increased AKT and BAD signaling 238. In addition to 
fibroblasts, other host cells are also known to be involved in microenvironment-
mediated drug resistance. Astrocytes can also reduce the efficacy of targeted therapy 
agents through direct cell adhesion and secretion of paracrine survival factors. A recent 
series of intriguing experiments showed that conditioned media derived from primary 
human astrocytes was more effective at stimulating pro-survival signals in melanoma 
cells than conditioned media from normal skin fibroblasts 239. It was further shown that 
astrocyte-conditioned media could increase melanoma invasion in comparison to 
fibroblast- conditioned media 239.  
The release of pro-survival growth factors, can arise from tumor or stromal cells 
240. In addition, growth factors can be also be released from “depots” in the ECM 
through the activity of enzymes such as heparanase 241,242. Host fibroblasts constitute 
an important source of growth factors that is permissive for therapeutic escape (Fig. 
1.10) 223. Recent cell proliferation based studies, using a high throughput screen of 
multiple cancer cell lines paired with multiple stromal cell types identified a number of 
pairings in which the host cells conferred drug resistance 223. It was generally observed 
that the stromal cells conferred the most resistance to targeted therapy agents (such as 
kinase inhibitors) as opposed to chemotherapies. For melanoma cells treated with 
vemurafenib, fibroblasts were the major host cell type implicated in transmitting BRAF 
inhibitor resistance, with 6 different fibroblast cell lines conferring resistance to 7 
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different BRAF V600E mutant melanoma cell lines 223. Of the many growth factors 
evaluated, HGF was identified as the key factor mediating resistance to BRAF inhibitor 
therapy. In total, 20 different BRAF melanoma cell lines were rescued from BRAF 
inhibition following co-treatment with exogenous HGF 223. Further analysis of melanoma 
patients receiving BRAF inhibitor therapy showed that individuals with increased stromal 
HGF secretion responded most poorly to the drug 223,240. These data fit with earlier 
preclinical studies showing that exogenous growth factors and cytokines could 
reactivate MAPK signaling and rescue melanoma cells from BRAF siRNA silencing-
induced cell death 243,244. However, a recent study of 41 melanoma patient specimens 
(which did find evidence of elevated HGF expression at disease progression), was not 
able to correlate HGF levels with clinical outcome 245. These results could be due in part 
to the small cohort of patient samples evaluated, therefore larger scale biomarker 
studies are needed. 
In another large-scale study, RNAi screen was utilized to understand the role of 
stromal-derived growth factors in driving therapeutic escape. In these studies, the TGF-
! signaling regulator MED12 was identified a potential mediator of resistance to multiple 
kinase inhibitors, including vemurafenib 246. Functionally, MED12 was found to suppress 
T!RII expression, where loss of MED12 was associated with increased TGF-! 
signaling, and conferred resistance to BRAF inhibitors through increased MAPK 
activation and the induction of an endothelial to mesenchymal transition (EMT) 246. 
Exogenous TGF-! alone was growth inhibitory on the A375 melanoma cell line, 
however, in the presence of targeted kinase inhibition, TGF-! activation conferred 
resistance to BRAF (vemurafenib) or MEK (AZD6244) inhibitors in the same cell line 246. 
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The authors concluded that although TGF-! signaling was growth suppressive for a 
subset of cancers, its effects were reversed in the context of targeted therapy. 
 
 
  
Fig. 1.10. Reciprocal relationship of CAFs and their associated cancer cells. The multipotency of CAFs to 
enable tumorigenesis is inherent to their production of numerous anti-apoptotic, inflammatory, mitogenic, 
angiogenic and ECM modulating tumor-promoting factors. The secretion of CAF proteins transforms 
malignant cells into highly aggressive cancers that in turn produce factors that enable the transformation 
of host stroma into activated tumor associated fibroblasts. This highly dynamic CAF–stroma interaction is 
a result of their co-evolution and results in highly aggressive, treatment refractory cancers. 
 
Taken together, it is expected that combinatorial strategies that incorporate the 
tumor autonomous and microenvironment-mediated drug resistance into their design 
will prove successful at significantly delaying or preventing the onset of resistance. In 
the next chapters I will discuss our early understanding of single agent BRAF inhibitor 
resistance, the use of proteomic approaches to elucidate mechanisms of single-agent 
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resistance, and evidence based approaches to delay and overcome BRAF inhibitor 
resistance. I will then go on to describe global phosphoproteomic and bioinformatics 
methodologies, use of these methodologies to elucidate the underlying processes of 
refractory disease (for both single agent BRAF and dual agent BRAF plus MEK inhibitor 
resistance) as well as strategies to constrain dual agent BRAF plus MEK inhibitor 
resistance.  
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Chapter 2 
Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF 
inhibitor therapy 
Note to Reader 
Portions of this chapter have been previously published in Br J Cancer. 2010 Jun 
8;102(12):1724-30 133 and have been reproduced with permission from Nature 
Publishing Group. Author contributions: Paraiso KH (designed/performed experiments, 
interpreted data, writing, figures); Fedorenko IV, Cantini LP, Munko AC, and Hall M 
(performed experiments); Sondak VK, Messina JL  (data interpretation, wording); 
Smalley KS (study concept, designed/performed experiments, interpreted data, writing, 
figures).  
Introduction 
Mutated BRAF exerts most of its oncogenic effects through the activation of the 
RAF/MEK/ERK MAPK pathway 247,248. Constitutive activation of BRAF drives the 
uncontrolled growth of melanoma cells via upregulated cyclin D1 expression and 
suppression of the cyclin-dependent kinase inhibitor p27KIP1 86,249. In vitro and in vivo 
studies from our group and others have shown vemurafenib, a BRAF inhibitor, to have 
excellent anti-tumor activity 90,132. In clinical vemurafenib studies, mutated BRAF was 
validated as a therapeutic target in melanoma, where initial phase I responses were 
observed in an unprecedented 70% of patients 146. However, the current post clinical 
trial data indicate that only 48% of patients with V600E-BRAF mutant melanomas will 
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likely respond to vemurafenib monotherapy 146. For patients who do respond, tumor 
regression is typically quite rapid. But unfortunately initial levels of dramatic tumor 
regression do not typically persist with most patients eventually succumbing to 
progressive disease after 10 months 146,250. In this study, we have identified the rebound 
activation of phospho-ERK (pERK) as being a mechanism of early therapy escape and 
show that combined BRAF/MEK inhibition can increase rates of response, enhance 
levels of apoptosis and delay the onset of resistance. 
Results 
PLX4720 has selective effects on BRAF-V600E-mutated melanoma cell lines 
Treatment of melanoma cells with increasing concentrations of the BRAF 
inhibitor PLX4720 led to a dose-dependent reduction in the growth of BRAF-V600E-
mutated melanoma cell lines (WM35, WM164 and 1205Lu) (Fig. 2.1A). In contrast, cell 
lines that harbored an NRAS mutation (WM1346, WM1361A and WM1366) were more 
resistant (Fig. 2.1A). Lower doses of PLX4720 (0.3 and 3"µM) led to a profound G1-
phase cell-cycle arrest and a reduction of 1205Lu cells entering into S-phase (Fig. 
2.1B). Increasing concentrations of PLX4720 (1"h) inhibited pERK signaling in three 
BRAF-mutated melanoma cell lines (WM35, WM164 and 1205Lu), but not an NRAS-
mutated cell line (WM1346) (Fig. 2.1C). It was noted that PLX4720 also reduced pRB 
protein phosphorylation, increased p27 expression, suppressed cyclin D1 expression 
and induced cleavage of PARP only in melanoma cell lines harboring the BRAF-V600E 
mutation (Fig 2.1D). Treatment of melanoma cells with increasing concentrations of the 
BRAF inhibitor PLX4720 led to a dose-dependent reduction in the growth of BRAF-
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V600E-mutated melanoma cell lines (WM35, WM164 and 1205Lu) (Fig 2.1A).   
 
Fig. 2.1. PLX4720 inhibits the growth of melanoma cells harboring the BRAF-V600E mutation. (A). Increasing concentrations of 
PLX4720 reduced the growth of melanoma cell lines harboring the BRAF-V600E mutation (WM35, 1205Lu and WM164), whereas 
melanoma cell lines that were BRAF wild type were relatively resistant (WM1346, WM1361A and WM1366). Cells were treated with 
drug (3"nM–30"µ M) for 72"h, and cell numbers were quantified using the MTT assay. Bars show s.e. mean. (B) Low doses of 
PLX4720 are cytostatic in melanoma cells harboring the BRAF-V600E mutation. 1205Lu cells were treated were either 0.3 or 3"µ M 
PLX4720 for 24"h before being fixed, stained with propidium iodide and analysed by flow cytometry. (C) PLX4720 inhibits MAPK 
signaling in BRAF-V600E-mutated melanoma cells. Cells were treated with increasing concentrations of PLX4720 (0.03–30"µ M, 
1"h); proteins were extracted and probed for expression of phospho-ERK (pERK). Blots were stripped once and reprobed for total-
ERK to show even protein loading. (D) PLX4720 induces a concentration-dependent reduction in the phosphorylation of the 
retinoblastoma protein (phospho-RB), induces the cleavage of PARP, stabilizes p27 and suppresses the expression of cyclin D1 in 
WM164 BRAF-V600E-mutated melanoma cells. Cells were treated with increasing concentrations of PLX4720 (3"nM–30"µ M) for 
24"h, after which time, protein was extracted and resolved by western blotting (C=vehicle control). Blots were stripped once and 
probed for actin to show equal protein loading. 
 
In contrast, cell lines that harbored an NRAS mutation (WM1346, WM1361A and 
WM1366) were more resistant (Fig 2.1A). Lower doses of PLX4720 (0.3 and 3"µM) led 
to a profound G1-phase cell-cycle arrest and a reduction of 1205Lu cells entering into 
S-phase (Fig. 2.1B). Increasing concentrations of PLX4720 (1"h) inhibited pERK 
signaling in three BRAF-mutated melanoma cell lines (WM35, WM164 and 1205Lu), but 
! 47 
not an NRAS-mutated cell line (WM1346) (Fig 2.1C). It was noted that PLX4720 also 
reduced pRB protein phosphorylation, increased p27 expression, suppressed cyclin D1 
expression and induced cleavage of PARP only in melanoma cell lines harboring the 
BRAF-V600E mutation (Fig 2.1D). 
PLX4720-mediated apoptosis induction is BRAF-V600E-mutation specific 
Concentrations of PLX4720 >3"µM were required for apoptosis induction across a 
panel of three BRAF-mutated melanoma cell lines (WM35, WM164 and 1205Lu) (Fig 
2.2A). The pro-apoptotic effects of PLX4720 were found to be BRAF specific, with high 
levels (>30%) of apoptosis only induced in the BRAF-V600E-mutated melanoma cell 
line panel (WM35, WM164 and 1205Lu), and not the NRAS-mutated melanoma cell 
lines (WM1346, WM1361A and WM1366) (Fig. 2.3). The induction of apoptosis was 
found to be time dependent with apoptosis observed only >24"h.  
 
 
Fig. 2.2. PLX4720 induces apoptosis in BRAF-V600E-mutated melanoma cell lines. (A) PLX4720 induces apoptosis in three BRAF-
mutated melanoma cell lines. Cultures were treated with increasing concentrations of PLX4720 (0.03–30"µ M, 48"h), before staining 
for FITC-annexin-V and flow cytometry. Data show mean of three experiments. (B) PLX4720 reduces viability and invasion of 
1205Lu cells grown as 3D collagen-implanted spheroids. Preformed 1205Lu spheroids were implanted into collagen and overlayed 
with media. Cells were treated with PLX4720 (0.3–30"µ M for 72"h) before being treated with calcein-AM and ethidium bromide. 
Green, viable cells; red, dead cells. Lack of green staining also indicates a loss of cell viability. Magnification # 10. * P<0.05, 
Significant difference from control. 
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Often, the pharmacological profile of drugs in 2D culture is not predictive of 
response in 3D culture. Here, it was found that the concentrations of PLX4720 required 
(>3"µM) to induce apoptosis in 2D cell culture (Fig. 2.2B) were equivalent to those 
necessary for loss of spheroid viability (as shown by the reduction of green staining and 
increased red staining) (Fig. 2.2B). Interestingly, some viable melanoma cells persisted 
even at the highest concentrations of drug. 
 
Fig. 2.3. PLX4720 selectively induces apoptosis in melanoma cell lines harboring a BRAF V600E 
mutation but not those harboring an NRAS mutation. Melanoma cell lines were treated with PLX4720 (30 
µM) for increasing periods of time (24-72 hrs), before being stained with FITC-annexin-V. 
 
Some cells escape from PLX4720 treatment and become resistant 
We next asked whether BRAF-V600E-mutated melanoma cells escaped from 
PLX4720 therapy and become drug resistant. Here, melanoma cell lines (WM164 and 
1205Lu) were treated with PLX4720 (either 2 or 3"µM) over a 2-month period with fresh 
drug added twice per week. It was noted that after an initial round of cell death, a limited 
number of viable cells remained and as treatment progressed, these clones began to 
regrow (>28 days) and eventually repopulated the whole culture (Fig. 2.4A).  
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Fig. 2.4. Melanoma cells escape PLX4720 and become resistant. (A) Photomicrograph of WM164 and 
1205Lu melanoma cells treated with PLX4720 (3"µ M). (B) Western blot of pERK in naive (N) and 
resistant (R) (8 weeks, 3"µ M) WM164 and 1205Lu cell lines. Resistant cells were maintained 
continuously in the presence of PLX4720 (3"µ M). (C) Resistant 1205Lu and WM164 cell lines continue to 
incorporate BrdU in the presence of PLX4720 (3"µ M). Treatment-naive or resistant WM164 and 1205Lu 
cell lines (control) treated with PLX4720 (3"µ M) or the MEK inhibitor U0126 (3 and 10"µ M). Cells were 
stained for BrdU (20"µ M, 1"h) uptake and the cell viability marker 7-AAD and analysed by flow cytometry. 
(D) Sequencing trace from Exon 3 of MEK1 of 1205Lu cells chronically treated with PLX4720 for 8 weeks, 
arrow indicates site of P124L mutation identified previously in Emery et al (2009). 
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The drug-resistant phenotype of the surviving cells was demonstrated by the 
ability of both cell lines to maintain their pERK signaling and incorporate BrdU in the 
continuous presence of PLX4720 (3"µM) (Fig 2.4B and C). In contrast, PLX4720 
treatment (3"µM) potently inhibited BrdU incorporation in the PLX4720-naive WM164 
and 1205Lu cell lines (Fig. 2.4C). It was further shown that the proliferation of the 
PLX4720-resistant WM164 and 1205Lu cell lines was dependent on MAPK signaling, 
with MEK inhibitor treatment (U0126; 3 and 10"µM) preventing the incorporation of BrdU 
(Fig 2.4C). 
Prolonged PLX4720 treatment leads to a recovery of pERK signaling 
Having shown the reliance of the PLX4720-resistant melanoma cell lines on 
MAPK signaling, we next investigated the time course of pERK signaling recovery. 
Treatment of drug-naive WM164 cells with PLX4720 (3"µM) showed the pathway to be 
rapidly inhibited, with some recovery of signaling >24"h (Fig. 2.5A and B). The recovery 
of pERK signaling observed was found to be insensitive to repeated PLX4720 
treatments (drug added every 24"h) (Fig. 2.5A). To explain the apparent anomaly 
between the recovery of pERK signaling >24"h and the profound growth 
arrest/apoptosis observed at 48 and 72"h (Fig 2.1 A and 2.2A), we next investigated the 
cell cycle and signaling profile of cells treated with PLX4720 over a 72-h period. These 
studies showed that even though pERK signaling recovered, the majority of the cells 
remained growth arrested (Fig 2.5C), and that this was associated with increased p27 
expression and hypophosphorylation of the pRB protein (Fig. 2.5D). Interestingly, a 
minor population of cells were identified that continued to proceed through S-phase (Fig 
2.5C). The existence of a minor proliferating subpopulation was also confirmed by BrdU 
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incorporation assays (1–4 weeks), with studies showing that 2–4% of WM164 and 
WM793 cells continued to incorporate BrdU in the continuous presence of PLX4720 
(3"µM) (Figure 2.6). Cell counting experiments were performed to better understand how 
PLX4720-induced apoptosis, cell-cycle arrest and therapy escape impacted on the 
population as a whole (Fig 2.5 E). It was observed that after an initial drop in cell 
numbers, the population remained relatively stable, suggesting that the recovery of 
pERK signaling attenuated the anti-melanoma activity of PLX4720. 
 
 
Fig. 2.5. pERK signaling recovers after PLX4720 treatment. (A) Naive WM164 melanoma cells were 
treated with PLX4720 (3"µ M, every 24"h) for increasing periods of time (0–48"h) and probed for pERK and 
total-ERK (tERK). (B) Recovery of pERK is observed in three naive BRAF-V600E-mutated melanoma cell 
lines. Cells were treated with PLX4720 for 0, 8, 24, 48"h (3"µ M) and analysed as in (A). (C) Most cells 
remain growth arrested even when pERK recovers. WM793 cells were treated with PLX4720 (3"µ M) for 
0–72"h. Cells were harvested, fixed and stained with propidium iodide before being analysed by flow 
cytometry. (D) p27 expression levels remain high even when pERK signaling recovers. WM793 cells were 
treated with PLX4720 as for (C); protein lysates were probed for expression of pERK, total-ERK (tERK), 
phospho-RB (p-pRB), total retinoblastoma protein (t-RB) and p27. Equal protein loading was confirmed 
by stripping the blot once and probing for GAPDH expression. (E) PLX4720 treatment leads to a drop in 
cell numbers followed by stabilization of the population. WM793, 1205Lu and WM164 melanoma cells 
were treated with PLX4720 (3"µ M) for 0–120"h. At each time point, the cells were removed from the plate 
and counted. Data show the mean±s.e.mean of three independent experiments. 
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Fig. 2.6. A minor population of cells continues to incorporate BrdU in the continual presence of PLX4720 
(3 µM). WM164 and 1205Lu cells were treated with PLX4720 over 1-4 weeks. At each time point, cells 
were pulsed with BrdU for 1 hr and then stained for anti-BrdU and 17-ADD. Numbers indicate the 
percentage of cells in S-phase. 
 
Rebound pERK treatment allows for escape from PLX4720-mediated apoptosis 
Having demonstrated that pERK signaling recovered after PLX4720 treatment, 
we next determined whether dual BRAF/MEK inhibition led to enhanced cytotoxicity. It 
was noted that although the recovery of pERK signaling was insensitive to repeated 
PLX4720 treatments (Fig. 2.5A), rebound pERK signaling was sensitive to the MEK 
inhibitor U0126 (3"µM) (Fig. 2.7 A and B). Combined treatment of drug-naive WM164 
cells with both PLX4720 and U0126 was found to decrease the expression of cyclin D1 
(Fig. 2.7C) and enhance the level of PLX4720-induced PARP and caspase-3 cleavage 
(Fig. 2.7C). In contrast, expression of p27, a protein relatively sensitive to BRAF/MEK 
inhibition, was little enhanced when PLX4720 and U0126 were combined. The western 
blotting results were also mirrored in apoptosis assays, with the addition of U0126 
(3"µM) significantly enhancing the pro-apoptotic activity of low-dose PLX4720 (3"µM) in 
drug-naive WM164 cells at both 24 and 48"h (Fig. 2.7D). 
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Fig. 2.7. The function of rebound pERK signaling in the escape from PLX4720 treatment. (A) U0126 
blocks the rebound increase in pERK after PLX4720 treatment. Melanoma cells were either treated with 
vehicle (0), PLX4720 (3"µ M) or PLX4720 + U0126 (both 3"µ M) for 48"h, protein was then probed for 
expression of pERK and tERK. (B) Melanoma cells were treated with increasing concentrations of U0126 
for 1"h before being probed for pERK and tERK expression. (C) Cells were treated with increasing 
concentrations of PLX4720 (30"nM–30"µ M) for 24"h in the absence or presence of U0126 (3"µ M), after 
which time, protein was extracted and resolved by western blotting and probed for either cleaved PARP 
(cl-PARP), phospho-ERK (pERK), cyclin D1 (Cyclin D1), p27 or cleaved caspase-3 (cl-casp-3). Blots 
were stripped once and probed for actin to show equal protein loading. (D) Combined BRAF and MEK 
inhibition leads to enhanced apoptosis. WM164 cells were treated with either vehicle, U0126 (3"µ M, 
3U0), PLX4720 (3PLX, 3"µ M) or the two inhibitors in combination for 48"h. Levels of apoptosis were 
measured by annexin-V staining and flow cytometry. Data show the mean of three experiments. * P<0.05. 
 
Combined BRAF/MEK inhibitor treatment prevents the acquisition of resistance 
In a final series of experiments, we explored whether dual BRAF/MEK inhibition 
blocked the MAPK-dependent escape from PLX4720 therapy and asked whether this 
prevented the onset of resistance. Here, WM164, WM793 and 1205Lu cells were 
treated with PLX4720 (3"µM), U0126 (3"µM) or the two inhibitors in combination for 4 
weeks. It was noted that although PLX4720 was more effective at reducing colony 
formation than U0126 (Fig 2.8A), a number of clones did remain. In contrast, treatment 
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with U0126 and PLX4720 in combination completely inhibited the formation of all 
colonies. A thorough microscopic examination of the plates revealed that no cells 
remained (Fig 2.8A, see inset). Examination of the vehicle control plates showed the 
cells to be highly confluent. It was further found that the combination of PLX4720 and 
U0126 (both 3"µM) also reduced the growth and survival of melanoma cell lines grown 
as 3D collagen-implanted spheroid cultures (Fig 2.8B). 
 
Fig. 2.8. Dual BRAF/MEK inhibition prevents escape from PLX4720 therapy. (A) WM164, WM793 and 
1205Lu melanoma cells were treated with vehicle (1 week), PLX4720 (3"µ M), U0126 (3"µ M) or the two 
inhibitors in combination (both 3"µ M) for 4 weeks. After this time, colonies were fixed and stained with 
crystal violet. Photographs are representative of three independent experiments. Photomicrographs show 
the detail of one colony each on the WM793 plate ( # 4). (B) Combined PLX4720 and U0126 treatment 
reduce growth of melanoma cells and enhance cell death in a 3D spheroid model. WM164 spheroids 
were implanted in collagen and treated with PLX4720 (3"µ M), U0126 (3"µ M) or the two drugs in 
combination for 72"h. After this time, plates were washed and cells were stained with a cell viability kit. 
Red=dead cells, green=live cells.  
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Discussion 
At the initiation of these studies in 2009 (and submission for publication in 2010), 
the structure of vemurafenib (PLX4032) had not yet been disclosed. Therefore most 
early evaluations of the Plexxikon BRAF inhibitor where conducted utilizing the less 
potent vemurafenib analog, PLX4720 (BRAF IC50 = 160 nM) 132. In this study, we 
focused on the earliest stages of BRAF inhibitor therapy. Through an initial series of 
experiments, we confirmed that PLX4720 had good selectivity for BRAF-mutated 
melanoma cell lines over those harboring NRAS mutations (BRAF WT) and also 
demonstrated that PLX4720 was able to induce significant levels of apoptosis. The 
induction of apoptosis induced had a slow onset (>24"h), but was very BRAF specific, 
with very little apoptosis observed in melanoma cell lines that were BRAF wild type. 
Relatively little was known about the mechanisms of therapy escape after BRAF 
inhibition at the time of this study. In non-melanoma systems, chronic treatment with the 
MEK inhibitor CI-1040 lead to resistance associated with increased KRAS and MEK 
expression 251. In melanoma patients, resistance to the MEK inhibitor AZD6244 is 
associated with C121S mutations in MEK1 209. Growth factors and cytokines had also 
been shown to rescue melanoma cells from apoptosis after siRNA-induced knockdown 
of BRAF 243,252. Other studies showed that acquired BRAF inhibitor resistance after 
long-term drug treatment is associated with pathway switching, where MAPK signaling 
is routed from BRAF to CRAF 135.  
This study made the unexpected observation that combined BRAF and MEK 
inhibitor treatment enhances the levels of apoptosis before resistance to BRAF 
inhibition is even acquired, suggesting that the recovery of melanoma signaling occurs 
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much earlier than previously suspected. The observation that dual MEK/BRAF inhibition 
blocks colony formation also argued that the rebound MAPK signaling observed has a 
key function in the escape from therapy. Although vertical targeting of the same 
pathway at two points seemed redundant, it is likely that this dual inhibition strategy 
counteracts feedback inhibition loops that are relieved after pathway blockade at a 
single point 253. Intriguingly, the possibility also exists that MEK and BRAF inhibitors 
may hit subtly different cellular targets.  
The finding that dual BRAF/MEK inhibition prevents the onset of resistance in our 
in vitro melanoma models suggested that MEK inhibitors might be of use in managing 
resistance to BRAF inhibitors, possibly delaying or even preventing the onset of 
resistance. These early findings provided a strong rationale for the clinical testing of 
combined BRAF and MEK inhibitors [dabrafenib + trametinib127 and vemurafenib + 
cobimetinib (Genetech: GDC-0973, Exelixis: XL518)183,184], evaluations that have now 
proven to significantly improve response rates, progression free and overall survival for 
patients whose melanomas harbor V600E/K BRAF mutations 148,254,255. 
Materials and Methods 
Cell culture and growth inhibition 
Melanoma cell lines were a gift from Dr Meenhard Herlyn (The Wistar Institute) and 
were genotyped as described in "&*. Cells were plated into a 96-well plate at a density of 
2.5 # 104 cells per ml and left to grow overnight before being treated with increasing 
concentrations of PLX4720 in triplicate; after 72"h, the levels of growth inhibition were 
examined using the MTT assay 168. Data show the mean of at least three independent 
experiments ± the s.e. mean. In all cases, *indicates statistical significance where 
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P<0.05. PLX4720 was dissolved in 100% DMSO and stored at $20°C as a 10"mM 
solution. U0126 was from EMD Biosciences (Carlsbad, CA, USA) and was prepared in 
a similar manner to PLX4720. 
Western blotting 
Proteins were extracted and blotted for as described in *-%. After analysis, western blots 
were stripped once and reprobed for !-actin or GAPDH to demonstrate even protein 
loading. The antibodies to pERK, cleaved caspase-3, phospho-RB protein, total-RB 
protein, PARP, CRAF, cyclin D1 and total-ERK were from Cell Signaling Technology 
(Beverly, MA, USA) and the antibody to p27 was from BD Biosciences (Franklin Lakes, 
NJ, USA). 
Flow cytometry 
Cells were plated into 10-cm dishes at 60% confluency and left to grow overnight before 
being treated with PLX4720 (0.3 and 3"µM) for 24"h. In other studies, cells were treated 
with PLX4720 (3"µM) in the absence or presence of U0126 (3"µM) and harvested after 
24 or 48"hours. Annexin-V labeling and propidium iodide staining were performed as 
described in *-&) 
BrdU incorporation 
Cells were seeded in 10"cm plates at a density of 100"000"cells"ml$1 and grown 
overnight before being treated with PLX4720 (3"µM) for 72"h or 1, 2, 3 and 4 weeks. For 
the 1-, 2-, 3- and 4-week treatments, PLX4720 (3"µM) was added twice per week. One 
hour before the end of the drug treatment, BrdU (Sigma-Aldrich, St Louis, MO, USA) 
was added to the cells to a final concentration of 20"µM for 1"h. Cells were fixed and 
permeabilised with eBioscience's fixation and permeabilisation buffers. The BrdU 
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epitopes were exposed by incubating with DNase (Sigma-Aldrich) before staining with 
anti-BrdU conjugated to FITC (eBioscience, San Diego, CA, USA). In all, 7-AAD (BD 
Bioscience) was added to stain for DNA before acquisition on a BD Facscalibur flow 
cytometer. 
MEK1 sequencing 
Sequencing of MEK1 Exons 3 and 6 was performed as described in *.+) 
3D spheroid assays 
Melanoma spheroids were prepared using the liquid overlay method 174. Spheroids were 
treated with 0.03–30"µM of PLX4720 or U0126, PLX4720 (both 3"µM) and both drugs in 
combination for 72"h before being washed (3 # in media) and treated with calcein-AM, 
ethidium bromide (Molecular Probes, Eugene, OR, USA) for 1"h at 37°C, according to 
the manufacturer's instructions. After this time, pictures of the invading spheroids were 
taken using a Nikon-300 inverted fluorescence microscope. 
Colony formation 
Cells (1 # 104 per ml) were seeded out into six-well plates and grown overnight before 
being treated with vehicle, PLX4720 (3"µM), U0126 (3"µM) or the two drugs in 
combination. Cells were left to grow for 4 weeks with new drug added twice per week. 
Media was aspirated, and plates were stained with crystal violet solution (50% methanol 
+ 50% H2O + 0.5% crystal violet). Control plates were grown for 1 week in the absence 
of any drug, until 100% confluency was reached. 
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Chapter 3 
PTEN loss confers BRAF inhibitor resistance to melanoma cells through the 
suppression of BIM expression. 
Note to Reader 
Portions of this chapter have been previously published in Cancer Res. 2011 Apr 
1;71(7):2750-60 150 and have been reproduced with permission from the American 
Association for Cancer Research Publishing. Contributions: Paraiso KH 
(designed/performed experiments, interpreted data, writing, figures); Xiang Y, Wood E, 
Abel EV, Koomen JM (designed/performed proteomic experiments); Chen YA (statistical 
analysis); Rebecca VW, Munko AC, Fedorenko IV (performed experiments); Anderson 
AR (data interpretion); Ribas A, Dalla Palma M (cell lines); Sondak VK, Nathanson KL 
(data interpretation, wording); Messina JL (pathology experiments, data interpretation, 
wording); Smalley KS (study concept, designed experiments, interpreted data, writing, 
figures).  
Introduction 
Clinical trial reports indicate that ~48% of patients with BRAF V600E mutated 
melanoma show some response to vemurafenib; however, this translates into >50% of 
patients being treated not meeting the Response Evaluation Criteria in Solid Tumors 
(RECIST) criteria threshold for a response 146. Mechanisms of intrinsic BRAF inhibitor 
resistance generally lead to increased cyclin D1 expression (in ~17% of BRAF mutated 
melanomas) thereby allowing for cell cycle entry when MAPK signaling is abrogated 
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153,258. However, constitutive activity in other pathways, such as phospho-inositide 3-
kinase (PI3K)/AKT/mTOR, also contribute to intrinsic resistance by limiting apoptotic 
responses 174,259.. One of the most critical negative regulators of AKT activity is the 
phosphatase and tensin homologue (PTEN), which hydrolyses PI-3,4,5-P3 to PI-4,5-P2, 
ultimately preventing the phosphorylation of AKT 260. In this study we identify loss of 
PTEN expression, observed in >10% of melanoma specimens, as being responsible for 
increased PI3K/AKT signaling when BRAF is inhibited. Utilizing a mass spectrometry 
based highly sensitive, precise and selective liquid chromatography multiple reaction 
monitoring (LC-MRM), we further show that PTEN loss contributes to the intrinsic 
resistance of BRAF V600E-mutated melanoma cell lines to PLX4720 by suppressing 
the expression of the pro-apoptotic protein BIM. 
Results 
The role of PTEN loss in the response to PLX4720 
Initial studies identified 6 BRAF mutated melanoma cell lines that retained PTEN 
expression (PTEN+; WM35, WM51, WM164, WM983A, 451Lu, SK-Mel-28) and 6 that 
lacked PTEN expression (PTEN$; WM239A, WM266-4, WM793, 1205Lu, WM9, M233) 
(Fig. 3.1A, Table 3.1). Genomic analysis showed the WM9 and M233 cell lines to be 
homozygously deleted for PTEN and the WM793 and 1205lu cell lines be hemizygously 
deleted for PTEN in conjunction with a PTEN mutation (Table 3.1). The PTEN+ cell 
lines had lower constitutive levels of pAKT (Ser473) compared to the PTEN$ (Fig. 
3.1A). Similar levels of pAKT (Thr308) were observed in the PTEN$ and PTEN+ cell 
lines. Analysis of the growth inhibitory effects of PLX4720 by the MTT and Alamar Blue 
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assays (Fig. 3.1B, Fig. 3.2) did not reveal any statistically significant differences in the 
GI50 values between the PTEN+ and PTEN$ cell lines (P=0.48, Fig. 3.3). 
 
Fig. 3.1. PTEN predicts for PLX4720-induced apoptosis. A, basal PTEN and phospho-AKT (pAKT; S473, T308) 
expression in PTEN+ (WM164, 451Lu, SK-mel-28, WM983A, WM35, WM51) and PTEN$ (WM239A, WM266-4, 
WM793, M233, WM9, 1205Lu) melanoma cell lines. B, MTT assay of PTEN+ (gray)-expressing versus PTEN$ 
(black) cell lines. C, PTEN+ cells are more sensitive than PTEN$ cells to PLX4720-mediated apoptosis. Cells treated 
for 48 hours with 3 or 10 µmol/L PLX4720 before being stained for TMRM and Annexin-V. Apoptosis was measured 
by flow cytometry. Data shows mean ± SE mean of 3 independent experiments. *, PTEN+ cohort significantly 
different from PTEN$ cohort (P < 0.05). 
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As increased PI3K/AKT signaling is known to limit apoptosis, we next measured 
PLX4720-induced apoptosis in our PTEN$/PTEN+ melanoma cell line panel (Fig. 3.1C). 
Here we observed that following PLX4720 treatment (3 and 10µM, 48 hrs), the PTEN$ 
melanoma cell lines showed significantly less apoptosis than the PTEN+ (*P<0.05: Fig. 
3.1C). PLX4720 mediated apoptosis was blocked by high doses (>75µM) of the capase 
inhibitor z-vad-fmak (Fig. 3.4). !  
Table 3.1: BRAF and PTEN mutation status of the cell line panel. Data shows PTEN status by MLPA, the 
location of PTEN mutations and PTEN protein expression status.  
 
 
Fig 3.2: Direct comparison of the MTT and Alamar Blue reagents shows similar results between the two 
assays. PTEN- (blue) and PTEN+ (red) cell lines were treated with 0.003-30µM PLX4720 for 72hrs prior 
to the addition of MTT (dashed lines) or Alamar Blue (solid lines) reagents. 
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Fig. 3.3. Analysis of GI50 values in the PTEN+ and PTEN- cell line panel shows no statistical significance difference 
between the two groups (P=0.48). 
 
 
Fig. 3.4. A reduction in apoptosis is only observed after administration of a high dose of the caspase inhibitor, z-vad-
fmk. Flow cytometric analysis following PI staining of WM164 (PTEN+) cells treated for 48hrs with DMSO (Control), 
10µM PLX4720 alone (PLX), 100µM z-vad-fmk alone or pretreated for 1 hr with 100µM z-vad fmk followed by 
treatment with 10uM PLX4720 (PLX+z-vad). Apoptosis is shown by the accumulation of the cells in sub-G1. 
 
Loss of PTEN expression is independent of melanoma stage 
We confirmed the incidence of PTEN loss in a tissue microarray containing a 
large sample of melanocytic neoplasms (n=192) drawn from all stages of tumor 
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progression (Fig. 3.5A-C). Results of immunohistochemical staining were graded from 
0-3+ based on strength of the staining. It was observed that while non-atypical nevi 
rarely demonstrated loss of PTEN, >10% of atypical nevi and every stage of melanoma 
demonstrated loss of PTEN expression (either 0 or +1). Significantly, primary 
melanoma, lymph node metastases and distant metastases melanoma demonstrated 
loss of PTEN in 12.5%, 27% and 14% of cases each (Fig. 3.5A and C). Staining of the 
same TMA for pAKT demonstrated an increase in AKT activation as the tumors 
progressed from primary melanoma to distant metastasis (Fig. 3.5B). The level of pAKT 
positivity only partially correlated with PTEN expression status (Fig. 3.5C). 
 
Fig. 3.5. PTEN expression is lost at all stages of melanoma progression. A, Images showing representative immunohistochemical 
staining of PTEN. B, pAKT expression in a tissue array of nevi, atypical nevi, primary, and metastatic melanoma patient tumor 
samples. 0 and 1 indicate no to low PTEN expression and +3 indicates the highest expression whereas +2 to 3 relate to high 
expression of pAKT. Magnification 200#. C, left panel shows percentage loss of PTEN expression in each subset of patient samples 
as indicated in first of three columns per grouping whereas the right panel shows AKT activity in matched samples.  
PTEN pAKT A B 
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PLX4720 and BRAF siRNA leads to AKT signaling in BRAF V600E-mutated/PTEN! 
melanoma cell lines  
Treatment of the PTEN+/$ cell line panels with PLX4720 increased pPDK1 and 
pAKT signaling only in the melanoma cell lines lacking PTEN expression (Fig. 3.6A). In 
contrast, PLX4720 inhibited BRAF activity in both PTEN$ and PTEN+ cell lines with a 
similar potency (Fig. 3.7) and prevented BrdU uptake in both PTEN+ and PTEN$ cell 
lines (Fig. 3.8).  
 
Fig. 3.6. Loss of PTEN is associated with PI3K/AKT signalling following BRAF inhibition. A, PTEN+ 
(WM35, WM164, WM983A) and PTEN$ (M233, WM9, WM793, 1205Lu) cells were treated with PLX4720 
(24 hours: 0.03–3 µmol/L) and probed for phospho-PDK1 (pPDK1), total PDK1, phospho-AKT (pAKT), 
total AKT (tAKT), phospho-S6 (pS6), and total S6. Numbers indicate relative intensity of pPDK1 
normalized to PDK1 and pAKT normalized to tAKT. B, PLX4720 increases pAKT following PTEN 
knockdown. WM35 cells were incubated with nontargeting siRNA (NT) or 2 different PTEN-specific 
siRNA's (PTEN) before treatment with either vehicle or PLX4720 (3 µmol/L). C, siRNA knockdown of 
BRAF increases pAKT in melanoma cell lines that are PTEN$. WM164 (PTEN+) and WM793 (PTEN$) 
cells were incubated with lipofectamine alone (L), nontargeting siRNA (NT), or BRAF-specific siRNA 
(BRAF). Protein was extracted, resolved, and probed for BRAF, pAKT, total AKT, and GAPDH. 
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Addition of PLX4720 also led to the inhibition of mTOR activity in the PTEN+ cell 
lines only (Fig. 3.6A) and was associated with stimulation of LKB1 and AMPK signaling 
(Fig. 3.9). The requirement for PTEN in the increased AKT signaling was confirmed by 
studies showing that PLX4720 stimulated pAKT in WM35 cells (PTEN+) when PTEN 
was knocked down by siRNA (Fig. 3.6B). The effects of PLX4720 upon pAKT signaling 
were BRAF specific, with BRAF siRNA knockdown found to increase pAKT in PTEN$ 
cells only (Fig. 3.6C). Mechanistically, PLX4720 increased IGF-I signaling in the PTEN$ 
cells, with the IGFR1 inhibitor NVP-ADW-742 being found to abrogate the PLX4720-
mediated increase in pAKT signaling (Fig. 3.10) 261.  
 
Fig. 3.7. The BRAF inhibitor, PLX4720 inhibits ERK activity in both BRAF V600E PTEN- and BRAF 
V600E PTEN+ cell lines. PTEN- (WM793, 1205Lu) and PTEN+ (WM35 and WM164) cells were treated 
for 1hr withPLX4720 (0.03-3µM) prior to probing for phospho-ERK1/2. Blots were stripped and reprobed 
for total ERK as a loading control. 
 
Fig. 3.8. PLX4720 causes S-phase arrest in both PTEN- (WM793) and PTEN+ (WM164) cell lines as 
seen by lack of BrdU incorporation. Cells were treated for 72hrs with PLX4720 (0.3 or 3µM) prior to 
pulsing with BrdU for 1hr. Cells were then stained with an anti-BrdU antibody and (y-axis) and 7-AAD (x-
axis) followed by flow cytometric analysis. Percentages in the upper right corner of each box correspond 
to the percentage of cells in S-phase. 
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Fig. 3.9. Following inhibition of BRAF, activation of LKB1 and AMPK corresponding to inactivation of 
RAPTOR is observed in PTEN+ (WM164) but not PTEN- (WM793). Cells were treated for 24 hrs with 
PLX4720 (0.03-3µM) prior to protein extraction and Western blotting. 
 
 
Fig. 3.10. Inhibition of IGFR1 prevents increased AKT activity following BRAF inhibition. WM793 (PTEN-) 
were serum starved overnight prior to 6 hrs treatment with 3uM PLX4720 alone, 1uM NVP-ADW-742 
alone or the two drugs in combination. Protein was extracted and probed for pAKT (S473) and total AKT 
or IGF-1 and GAPDH. Numbers below each band represent the relative intensity of each band 
normalized to the corresponding loading controls. 
 
PLX4720 treatment differentially regulates BIM in PTEN+ and PTEN! cells 
We next used LC-MRM to quantify the PLX4720-induced changes in the 
expression of 17 members of the Bcl-2 protein family (Fig. 3.11A, results for 9 proteins). 
BIM was the only proapoptotic protein to demonstrate significant differences between 
the  PTEN$  and  PTEN+  cell lines (14- and 4-fold increases, respectively) (Fig. 3.11A). 
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Fig. 3.11. LC-MRM identifies differential regulation of BIM in PTEN+ and PTEN$ cell lines following PLX4720 
treatment. A, LC-MRM data showing the fold changes in the expression of Bak, Bax, Bcl-2, Bcl-w, Bcl-xL, BID, BIM, 
Bok, and Mcl-1 over internal standard in the WM164 (PTEN+) and 1205Lu (PTEN$) cell lines following treatment with 
PLX4720 (10 µmol/L, 0–48 hours). Statistical analyses of BIM fold change in PTEN$ versus PTEN+. *, P < 0.05. B, 
Western blot of BIM expression following PLX4720 treatment (10 µmol/L, 0–48 hours) in PTEN$ (WM793, 1205Lu) 
and WM164 cell lines (PTEN+). C, immunofluorescence staining of BIM expression, DAPI staining of PTEN$ (M233, 
WM9, WM793, 1205Lu) and PTEN+ (WM35, WM164, WM983A) cells following PLX4720 treatment (3 µmol/L, 48 
hours). D, Western blot of BAD phosphorylation following treatment with PLX4720 (0–48 hours) in PTEN$ (WM793, 
1205Lu) and PTEN+ WM164. Annexin V binding following treatment with 3 or 10 µmol/L PLX4720 (48 hours) 
showing increased apoptosis in WM793 stably overexpressing WT BAD. *, P < 0.05.  
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 Western blots and immunofluorescence staining confirmed the LC-MRM data and 
showed a greater degree of PLX4720-induced (3 and 10 µmol/L) BIM expression in the 
PTEN+ cell lines compared to PTEN$ cell lines (Fig. 3.11B, C and Fig. 3.12). In parallel, 
we observed that PLX4720 also increased the inactivation of BAD (as shown by 
increased phospho-BAD) in the PTEN$ cells (Fig. 3.11D) and that overexpression of 
BAD in the PTEN$ cells enhanced PLX4720-mediated apoptosis (Fig. 3.11D). PLX4720 
treatment also increased total BAD expression in both the PTEN+ and PTEN$ cell lines. 
Little PLX4720-induced changes in Mcl-1 expression were observed in the PTEN+ and 
PTEN$ cell lines (Fig. 3.13).  
 
Fig. 3.12. BIM expression is higher in PTEN+ (WM164, WM983A) compared to PTEN- (M233, WM9, 
WM793) following treatment with PLX4720. Cells were treated for 0, 8, 24 or 48 hrs with 3µM PLX4720. 
 
 
 
Fig. 3.13. Following treatment with PLX4720, no significant change is seen within the PTEN+ and PTEN- 
cells in the expression of Bcl-2 and Mcl-1. PTEN+ (WM164) and PTEN- (WM793) were treated for 0, 8, 
24 and 48 hours with 10µM PLX4720 prior to protein extraction. 
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PTEN is required for efficient BIM upregulation following BRAF inhibition 
We next explored the link between PTEN expression status and PLX4720-
mediated induction of BIM. siRNA knockdown of PTEN using 2 siRNA sequences led to 
the inhibition of PLX4720-induced BIM expression in PTEN+ cells (Fig. 3.14A). We next 
determined whether reintroduction of wild-type PTEN (PTEN-wt) or lipid phosphatase 
mutated PTEN (PTEN-G129E) into a PTEN$ cell line enhanced BIM expression when 
BRAF was inhibited. In these studies, we used an isogenic pair of WM793 melanoma 
cell lines that expressed either doxycycline inducible PTEN-wt or PTEN-G129E mutant. 
Control studies showed that doxycyline (100 ng/mL, 48 hours) increased expression of 
PTEN in both cell lines (Fig. 3.14B). The impaired lipid phosphatase function of the 
G129E mutant was confirmed by the fact that only the induction of PTEN-wt suppressed 
pAKT activation (Fig. 3.14B). The role of PTEN in the PLX4720-mediated induction of 
BIM was confirmed by the enhanced expression of BIM seen when PTEN-wt was 
induced compared to when PTEN-G129E was induced (Fig. 3.14B) and was paralleled 
by a significant increase in PLX4720-mediated apoptosis (P < 0.05; not shown). 
Interestingly, the addition of PLX4720 decreased the expression of PTEN through 
mechanisms that are not currently clear. The effects of PI3K/AKT signaling upon the 
suppression of BIM were mostly mediated through AKT3, with siRNA knockdown of 
AKT3 found to increase BIM expression when BRAF was inhibited (Fig. 3.15). As a final 
test of the relevance of BIM induction in the PLX4720-induced apoptotic response, we 
showed that siRNA knockdown of BIM led to an impairment of PLX4720 (3 and 10 
µmol/L) induced apoptosis (Fig. 3.14C).  
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Fig. 3.14. PTEN is required for efficient upregulation of BIM following BRAF inhibition. A, WM164 cells (PTEN+) 
transfected with nontargeting siRNA (NT) or 2 PTEN-specific siRNAs (I and II) before treatment with PLX4720 (3 or 
10 µmol/L, 48 hours). Proteins were probed for expression of BIM, GAPDH, and PTEN. B, induction of PTEN-wt but 
not PTEN-G129E in WM793 (PTEN$) cells was sufficient to increase BIM expression when BRAF was inhibited. Left, 
Western blot shows induction of PTEN-wt and PTEN-G129E following doxycycline treatment. Right, induction of 
PTEN-wt + PLX4720 induces BIM more efficiently than PTEN-G129E + PLX4720. C, BIM is required for PLX4720-
induced apoptosis in PTEN+ cells. WM164 and WM983A cells were incubated with nontargeting siRNA (NT) or 
transfected with 2 BIM-specific siRNAs (BIM I and BIM II) before treatment with PLX4720 (3 or 10 µmol/L, 48 hours). 
Flow cytometry studies showed a significant reduction in TMRM loss and Annexin V binding when cells were 
transfected with BIM siRNA compared with nontargeting control siRNA (*P < 0.05).  
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Fig. 3.15. Dual inhibition of BRAF and AKT3 leads to a significant increase in BIM expression in PTEN- 
cells. 1205Lu cells were incubated with lipofectamine alone (L) or transfected with 25nM non-targeting 
siRNA (NT), 25nM AKT1 siRNA or 25nM AKT3 siRNA for 72 hrs prior to treatment with DMSO or 3µM 
PLX4720 for 24hrs. Numbers below each band of the PLX treated groups represent the relative intensity 
of BIM normalized to the corresponding controls. 
 
Dual BRAF/PI3K inhibition enhances BIM expression and apoptosis in PTEN! 
cells 
 One of the major effects of PTEN is to limit PIP3 levels through its lipid 
phosphatase activity. We next treated PTEN$ cell lines with a PI3K inhibitor (GDC-
0941, 3 µmol/L or LY294002 10 µmol/L), PLX4720 (3 and 10 µmol/L), or the 2 drugs in 
combination, and showed that combined PI3K and BRAF inhibition increased the level 
of BIM expression in both Western blot and immunofluorescence studies (Fig. 3.16A).  
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Fig. 3.16. Dual PI3K/BRAF inhibition upregulates BIM and enhances apoptosis in PTEN$ cells. A, left, Western blot 
of 1205Lu cells treated with PLX4720 (3 µmol/L, 48 hours), GDC-0941 (3 µmol/L, 48 hours), or both (P+G); right, 
immunofluorescence staining of BIM (green) and DAPI (blue) in PTEN$ cells after PLX4720 treatment (3 µmol/L, 48 
hours), LY294002 (10 µmol/L, 48 hours), or both (PLX+LY). B, left, immunofluorescence staining of PTEN$ 1205Lu 
following combined inhibition (3 µmol/L PLX4720 + 10 µmol/L LY294002, 48 hours) increases nuclear localization of 
FOXO3a (green). DAPI is shown in blue. 40x. Right, combined inhibition (3 µmol/L PLX4720 + 10 µmol/L LY294002, 
48 hours) increases PTEN$ WM793 BIM mRNA levels to those observed with single BRAF inhibition (3 µmol/L 
PLX4720, 48 hours) in PTEN+ WM35. C, PTEN$ cells were treated with PLX4720 (3 µmol/L, 48 hours), GDC-0941 
(3 µmol/L, 48 hours), or both (3P+3G). Annexin-V was analyzed by flow cytometry (*, P < 0.05 between combination 
and each inhibitor alone). D, BRAF/PI3K inhibitor treatment blocks the escape of 1205Lu cells (PTEN$) from therapy. 
1205Lu spheroids were treated with PLX4720 alone (3 and 10 µmol/L: data shows 3 µmol/L), LY294002 (10 µmol/L) 
or both drugs for 72 hours. In other studies, spheroids were treated with drugs for 72 hours and then allowed to 
recover for 120 hours. Micrograph shows viability staining (green = live cells, red = dead cells).10x. 
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Both the MAPK and PI3K/AKT pathways are known to regulate BIM RNA expression 
levels through the transcription factor FOXO3a 262-265. In agreement with this, PLX4720 
treatment increased the nuclear accumulation of FOXO3a in the PTEN+ but not PTEN$ 
melanoma cells (Fig. 3.16B; not shown). Consistent with a role for increased AKT 
signaling suppressing BIM expression in PTEN$ cells, dual BRAF and PI3K inhibition 
increased nuclear FOXO3a localization in the PTEN$ cell lines (Fig. 3.16B) and 
enhanced the level of BIM mRNA (Fig. 3.16B). siRNA knockdown of FOXO3a was 
further found to block PLX4720-mediated upregulation of BIM in PTEN+ cells (Fig. 
3.17). The observation that PLX4720 treatment led to increased PI3K/AKT signaling in 
PTEN$ melanoma cell lines suggested that dual BRAF/PI3K inhibition could be one 
strategy to overcome intrinsic resistance. In agreement with this, the combination of 
PLX4720 with the PI3K inhibitor GDC-0941 significantly enhanced the levels of 
apoptosis observed in PTEN$ melanoma cell lines compared to either the BRAF or 
PI3K inhibitor alone (Fig. 3.16C). Similar results were also observed in a 3D spheroid 
assay, where combined PLX4720 (3 µmol/L) and LY294002 (10 µmol/L) treatment 
prevented the recovery of cell growth observed when melanoma spheroids were treated 
with either drug alone (Fig. 3.16D). The proposed mechanism for BIM regulation is 
shown in Fig. 3.18.  
 
Fig. 3.17. FOXO3a silencing prior to BRAF inhibition leads to a decrease in BIM expression. WM164 
(PTEN+) cells were incubated with lipofectamine alone (L) or transfected with 25nM non-targeting siRNA 
(NT) or 25nM FoxO3a siRNA for 72 hrs prior to treatment with 3µM PLX4720 for 24hrs.  
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Fig. 3.18. Schema illustrating the differences signaling in PTEN+ and PTEN- cells following inhibition of BRAF. In 
both the PTEN+ and PTEN+ cells, inhibition of BRAF decreases the MEK/ERK mediated phosphorylation of BIM 
leading to its stabilization. In PTEN- cells, BRAF inhibition is associated with increased AKT signaling leading to the 
phosphorylation of FOXO3a, an increase in its nuclear exclusion and a decrease in BIM mRNA levels. Overall this 
leads to a decrease in BIM expression in the PTEN- cells when BRAF is inhibited and an impaired apoptotic 
response. 
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Discussion 
In this study we focused on the underlying mechanisms of intrinsic resistance 
observed that is observed in >50% of vemurafenib treated melanoma patients. 
Melanomas have constitutive activity in several oncogenic pathways to regulate cell 
cycle entry and survival. Of these, melanoma initiation and progression is known to be 
dependent on both the Ras/Raf/MEK/ERK and PI3K/AKT pathways 98,174,266,267. The 
processes underlying this signaling activity differ according to the initiating oncogenic 
event. As such, melanomas with activating NRAS mutations rarely harbor concurrent 
alterations in either BRAF or PTEN/AKT as Ras stimulates both the Raf/MEK/ERK and 
PI3K/AKT pathways 103,268. In contrast, melanomas with BRAF mutations require other 
mechanisms to activate their PI3K/AKT signaling and frequently show 
inactivation/deletion of PTEN or increased AKT3 expression 97,269-271. 
We began by investigating PTEN expression across a large sample (n=192) of 
melanocytic lesions and found that PTEN was lost in 10% to 27% of melanomas. 
Although PTEN loss overlapped with levels of pAKT staining, it was not always well 
correlated, agreeing with observations that other mechanisms may underlie the 
increased AKT activation associated with melanoma progression 272. Our results agree 
with other published studies on smaller numbers of melanoma samples (n = 16–39), 
and confirm that reduced PTEN expression is a significant oncogenic event for a 
restricted subgroup of melanomas 269,270,273. Although PTEN was retained in nonatypical 
nevi, a significant number (23%) of atypical nevi lacked expression, suggesting that this 
is an early event in melanoma development. This idea is supported by recent mouse 
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model studies showing that the conditional expression of the BRAF V600E mutation 
leads to melanoma development only when PTEN is suppressed 98.  
Though lack of PTEN expression did not predict for sensitivity of BRAF V600E-
mutated melanoma cell lines to the growth inhibitory effects of PLX4720, there were 
significant differences in PLX4720-mediated apoptosis between PTEN+ and PTEN$ 
melanoma cell lines. We hypothesized that PTEN$ melanoma cell lines would show 
higher levels of AKT activity and that this would mediate resistance to PLX4720. 
However, this was not the case. Instead we observed that increased AKT signaling only 
occurred in PTEN$ cell lines in the context of BRAF inhibition. The effects on AKT were 
recapitulated in PTEN+ melanoma cell lines when PTEN was knocked down, indicating 
that these effects were PTEN dependent. The increase in AKT signaling observed in the 
PTEN$ cell line panel was associated with PDK1 phosphorylation and increased 
expression of IGF-I. These effects were reversed following pretreatment with the IGF1R 
inhibitor NVD-ADW-742 261, suggesting a link between BRAF inhibition and enhanced 
IGF1R-mediated PI3K signaling. Similar findings, linking BRAF/MEK inhibition to 
increased IGF signaling, have also been reported by other groups 173,212.  
AKT plays a critical role in cancer development and regulates cell survival 
through direct phosphorylation of BAD, stimulation of ribosomal S6 kinase, inhibition of 
FOXO, and inhibition of glycogen synthase 3-kinase 272. To determine the mechanism 
of PLX4720-induced apoptosis in the PTEN+ melanoma cell lines, LC-MRM analysis 
was used to quantify the relative expression of members of the Bcl-2 protein family 274. 
For the majority of apoptotic related proteins examined, PLX4720 treatment was 
associated with similar dynamics in both the PTEN+ and PTEN$ cell lines. These 
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findings agree with previous studies and show that BRAF inhibition leads to an increase 
in the expression in the proapoptotic protein BIM 90,91,275. However, in contrast to 
previous investigations, our studies utilized highly selective and sensitive LC-MRM 
analysis, which allowed us to identify significant PTEN-dependent differences in the 
level of PLX4720-induced BIM expression. BIM is a proapoptotic BH3-only member of 
the Bcl-2 protein family that exists in 3 major splice forms; extra long (BIM-EL), long 
(BIM-L) and short (BIM-S) 276,277. It exerts its cytotoxic activity by binding to and 
antagonizing the antiapoptotic proteins Bcl-2, Bcl-w, Bcl-XL, and Mcl-1 276,277. 
Expression of BIM is regulated both transcriptionally and post-transcriptionally by a 
number of signaling pathways, including BRAF/MEK/ERK, JNK, p38 MAPK, and 
PI3K/AKT 90,276,278,279.  
In melanoma, the BRAF V600E mutation regulates BIM expression through 
MEK/ERK pathway-mediated phosphorylation of the extra-long form of BIM (BIM-EL) at 
Serine 69, resulting in subsequent BIM degradation by the proteasome 90 280. Our study 
was the first to demonstrate that the level of BIM expression following BRAF inhibition is 
also determined by PTEN status and that the differing levels of BIM induction can 
determine the extent of apoptosis induction when BRAF is inhibited. Apoptosis control in 
melanoma cells is complex and increased AKT signaling is likely to regulate survival at 
multiple levels. The cell death inducing protein, BAD, is a well-recognized target of AKT. 
AKT inactivates BAD via phosphorylation at Ser99, thereby preventing BAD from 
binding to Bax and relieving the antagonism of Bax on Bcl-2 and Bcl-XL 91. A role for 
BAD inactivation in the escape of PTEN$ cells from PLX4720-induced apoptosis was 
suggested by the preferential inactivation of BAD when BRAF was inhibited. Further, 
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overexpression of BAD sensitized the same cell line to PLX4720-induced apoptosis. 
Another candidate proapoptotic factor upregulated in melanoma cells following 
BRAF/MEK/ERK inhibition is Bcl-2 modifying factor (BMF) 275,281. BMF, which is also 
regulated through the PI3K/AKT pathway, mediates its apoptotic effects by binding to 
Mcl-1. Although it is possible that BMF may also be differentially regulated in PTEN+/$ 
cells, we, like other groups, were unable to confirm the selectivity of commercially 
available BMF antibodies 275 282.  
In addition to regulating cytoplasmic PIP3 levels through its lipid phosphatase-
dependent function, PTEN also localizes to the nucleus where it exerts its tumor 
suppressor function through lipid phosphatase-independent effects upon the regulation 
of chromosomal integrity, p53 acetylation and the expression of cyclin D1 283. As the 
lipid phosphatase-dependent and -independent functions of PTEN are likely to be very 
different, we re-expressed either wild-type PTEN or a PTEN mutant with impaired lipid 
phosphatase function (G129E) in melanoma cells that were PTEN$ 284. These studies 
confirmed the requirement for the lipid phosphatase function of PTEN in the 
suppression of BIM expression, with PLX4720 treatment inducing only a weak 
upregulation of BIM protein when PTEN G129E was expressed. The importance of the 
lipid phosphatase function in the suppression of BIM expression was supported by 
experiments showing that combined BRAF/PI3K inhibition and siRNA knockdown of 
AKT3 both enhanced the level of BIM expression and increased the level of apoptosis in 
the PTEN$ cells. In other systems, AKT downregulates BIM expression by 
phosphorylating and inactivating the transcription factor FOXO3a 262,264. In agreement 
with these reports, we confirmed that PLX4720 treatment led to increased nuclear 
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accumulation of FOXO3a in the PTEN+ cells only and demonstrated that siRNA 
knockdown of FOXO3a abrogated the increase in BIM expression.  
In summary, we have identified an important role for PTEN loss in the intrinsic 
resistance of BRAF V600E mutated melanoma cells to the BRAF inhibitor PLX4720. 
These studies further suggest that increased BIM expression may be a useful biomarker 
in predicting clinical response to BRAF inhibition and demonstrates that LC-MRM is a 
powerful tool for monitoring BIM expression that could be translated to patient 
assessment. This work also provides a rationale for combining MAPK and PI3K/AKT 
pathway inhibitors or MAPK inhibitors with BCL-2 family member inhibitors (for example 
the combination of dabrafenib + trametinib with navitoclax, Table 1.4) for the 
management of melanomas that are BRAFV600E/PTEN$.  
Methods and Materials 
Cell culture and MTT assay 
Melanoma cell lines were a gift from Dr. Meenhard Herlyn (The Wistar Institute, 
Philadelphia, PA) and were grown as described in Chapter 2. MTT assays were 
performed as described in Chapter 2. The identity of the Wistar Institute cell lines was 
confirmed using the Coriell Institute (Camden, NJ) cell identity mapping kit. The M233 
cell line was derived as described in 136 and its identity confirmed by Biosynthesis Inc 
(Lewisville, Tx) by STR validation analysis. 
Generation WM793TR-PTEN cell lines 
Wild-type and G129E PTEN (phosphatase deficient) human cDNAs were a gift from Dr. 
Bill Sellers (Dana-Farber Cancer Institute) 284. WM793TR-PTEN-wt, WM793TR-PTEN-
G129E and WM793 cells overexpressing wild-type BAD were a kind gift from Dr Andrew 
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Aplin (Kimmel Cancer Center, Philadelphia, PA). Inducible expression of PTEN was 
obtained by treatment of cultures with doxycycline at a final concentration of 100ng/ml. 
The WM793 cells stably expressing wild-type BAD were generated as described in 275. 
Western blotting 
Proteins were blotted for as described in Chapter 2. The antibodies to phospho-AKT 
(Ser473 and T308), total AKT, phospho-BAD (S75 and S99), Bcl-2, BIM, BRAF, 
FOXO3a, phospho-PDK1, total PDK1, PTEN, phospho-S6 and total S6 were from Cell 
Signaling Technology (Beverly, MA). 
Flow cytometry 
Cells were treated with 3 or 10µM PLX4720 for 24 or 48 hr or treated with PLX4720 (3 
or 10µM) in the absence or presence of GDC-0941 (3 µM, Selleck Chemical Co.) and 
harvested after 48 hr. Annexin-V/TMRM staining was performed as described in 
Chapter 2. 
RNA interference 
Cells were grown overnight in RPMI complete media. The following day, complete 
media was replaced with Opti-MEM (Invitrogen) and one of the following siRNA 
sequences in complex with Lipofectamine 2000 (Invitrogen): 50nM BRAF (Dharmacon), 
20nM PTEN, 25nM BIM (Cell Signaling Technology). Scrambled siRNA’s at each 
concentration were also added as non-targeting controls. A final concentration of 5% 
FBS in complete RPMI was added the next day. Cells were transfected for a total of 48-
72 hr prior to treatment with PLX4720 (3-10µM). 
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Quantitative real-time PCR 
Total RNA was isolated using Qiagen’s RNeasy mini kit. The following TaqMan® Gene 
Expression Assays primer/probes were used: Hs00197982_m1 (BIM), P/N 4319413E 
(18S) and Hs99999905_m1 (GAPDH). The 18S + GAPDH data were used for 
normalizing BIM. After a 2-min incubation at 50°C, AmpliTaq Gold was activated by a 
10-min incubation at 95°C, followed by 40 PCR cycles consisting of 15 s of denaturation 
at 95°C and hybridization of probe and primers for 1 min at 60°C. All standards and 
samples were tested in triplicate wells and data were analyzed using SDS software 
version 2.3. 
Immunofluorescence staining 
Cells were plated onto coverslips and treated with PLX4720 for 48hrs before being fixed 
and permeabilized as previously described 168 and imaged with a Leica confocal 
microscope at 40X magnification. 
3D spheroid assays 
Collagen implanted spheroids were prepared using the liquid overlay method as 
described in Chapter 2 and were treated with 3µM of PLX4720, 10µM LY294002 or both 
drugs in combination for 72hr before being analyzed by fluorescence microscopy as 
described in 258. In other studies, spheroids were treated for 72hrs, washed 3X in fresh 
media and allowed to recover for 120hrs before analysis. 
Liquid chromatography, multiple reaction monitoring mass spectrometry (LC-
MRM) analysis 
Whole cell proteins extracts were separated by SDS-PAGE, visualized with Coomassie 
Brilliant Blue G-250 (Bio-Rad, Hercules, CA) and selected bands were excised. 
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Following digestion, the internal standard peptides were added in 2% acetonitrile. LC-
MRM analysis was performed as described in 274 with three replicate analyses for each 
peptide. Quantification was achieved by using the sum of the peak areas for all detected 
transitions using Xcalibur QuanBrowser (Thermo, San Jose, CA). Relative protein 
expression is determined using the ratio of peak area of the native peptide to 
corresponding internal standard (Table 3.2). 
Table 3.2. Labeled Internal Standards for LC-MRM Quantification of Apoptosis-Related Proteins. Each 
protein is listed with its gel region and the target peptide sequence for quantitative monitoring as well as 
the stable isotope label or amino acid replacement used to synthesize the internal standard. After SDS-
PAGE separation and proteolytic digestion, each peptide standard is spiked at the amount listed. 
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Immunohistochemical staining 
A melanoma tissue array was generated from de-identified formalin-fixed paraffin-
embedded tissue samples from the Moffitt Pathology archives under a protocol 
approved by the Institutional Review Board of the University of South Florida. Slides 
were stained using the Ventana Discovery XT automated system (Ventana Medical 
Systems, Tucson, AZ) as per manufacturer’s protocol. The PTEN antibody (1:200, 
#E4250, Spring Bioscience, Pleasanton, CA) was incubated for 32 min and the pAKT 
antibody (1:20, #4051, Cell Signaling, Danvers, MA) was incubated for 16 min. Slides 
were analyzed by two independent observers and consensus scored on a scale from (0 
to +3). 
Statistical analysis 
Data show the mean of at least three independent experiments ± the S.E. mean, unless 
stated otherwise. GraphPad Prism 5 statistical software was used to perform the 
Student’s T-test where *indicates P% 0.05. 
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Chapter 4 
The heat shock protein-90 inhibitor XL888 overcomes BRAF inhibitor resistance 
mediated through diverse mechanisms. 
Note to Reader 
Portions of this chapter have been previously published in Clin Cancer Res. 2012 May 
1;18(9):2502-14 197 and have been reproduced with permission from the American 
Association for Cancer Research Publishing. Author contributions: Paraiso KH 
(designed/performed experiments, interpreted data, writing, figures); Haarberg HE, 
Rebecca VW (performed experiments); Wood E, Xiang Y, Koomen JM (designed and 
performed proteomic experiments); John JK, Sarnaik AA (patient specimens), Chen AY 
(statistics); Ribas A, Lo RS (cell lines); Weber JS, Sondak VK (data interpretation, 
wording); Smalley KS (study concept, designed experiments, interpreted data, writing, 
figures).  
Introduction 
In the previous chapters we discussed growing evidence that BRAF inhibitor 
resistance is complex, multifactorial, and results from intrinsic and acquired 
mechanisms. To date, the loss/inactivation of PTEN function, deletion of the 
retinoblastoma protein (RB), expression of the mitogen-activated protein kinase (MAPK) 
family member COT (MAP3K8) and amplification of cyclin D1 have each been shown to 
mediate de novo resistance by either diminishing the apoptotic response or allowing for 
cell-cycle entry when oncogenic BRAF is inhibited 150,153,211,285. Acquired resistance is 
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mediated through constitutive signaling by receptor tyrosine kinases (RTK; e.g. IGF1R 
and PDGFR-!), mutations in NRAS or MEK1, alterations in NF1, AKT1 and AKT3, 
increased expression of COT and as the result of BRAF amplifications or truncations 
134,206,209-215. The apparent diversity of BRAF inhibitor resistance mechanisms, and the 
likelihood that others exist, is expected to complicate the design of future clinical trials 
(Tables 1.2 and 1.4). These observations have lead us to hypothesize that BRAF 
inhibitor resistance may be best managed through broadly targeted strategies that 
inhibit multiple pathways at once. 
 The HSP90 family of chaperones maintains the malignant potential of cancer 
cells by regulating the conformation, stability, and function of many RTKs and kinases 
required for oncogenic transformation 200,286. Many proteins required for melanoma 
initiation and progression, including mutated BRAF, CRAF, IGF1R, cyclin D1, CDK4, 
and AKT are known to be clients of HSP90 287,288. The role of HSP90 in the stabilization 
of so many cancer-related proteins has made it an attractive target for therapeutic 
intervention. Currently, more than 13 small molecule inhibitors of HSP90 are at various 
stages of preclinical and clinical development (Table 1.5) 200. 
 Although HSP90 inhibitors have shown only limited single-agent activity, more 
promising clinical efficacy has been shown when HSP90 inhibitors are combined with 
other agents. There is now good evidence that HSP90 inhibitors can overcome 
trastuzumab resistance in breast cancer and potentiate the effects of bortezomib in 
treatment-refractory myeloma 289-291. In this study, we show that all of the signaling 
proteins implicated thus far in the escape from BRAF inhibitor therapy are clients of 
HSP90, and that the pharmacologic inhibition of HSP90 abrogates both acquired and 
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intrinsic vemurafenib resistance by restoring the apoptotic response. These studies 
support the use of HSP90 inhibitors in overcoming BRAF inhibitor resistance. 
Translational Relevance 
The impressive clinical response of melanoma patients to the BRAF inhibitor 
vemurafenib is limited by the onset of resistance. Resistance can be intrinsic or 
acquired and is mediated through an array of mechanisms including acquired mutations 
in NRAS and MEK1, truncated BRAF, overexpression of COT, CRAF, PDGFR-!, cyclin 
D1, and IGF1R. This apparent diversity of resistance mechanisms, coupled with the 
phenotypic and cell signaling plasticity of melanoma cells, represents a considerable 
clinical challenge for which no management strategies currently exist. Here, we show 
that all of the signaling proteins implicated thus far in the escape from vemurafenib 
therapy are clients of HSP90. Inhibition of HSP90 using XL888 overcomes both 
acquired and intrinsic vemurafenib resistance by restoring the apoptotic response, 
which suggests that the combination of vemurafenib and an HSP90 inhibitor may be a 
strategy to delay and/or overcome BRAF inhibitor resistance.  
Results 
Inhibition of HSP90 overcomes resistance to vemurafenib resistance mediated 
through diverse mechanisms 
We first assembled a panel of BRAF V600E mutant melanoma cell lines with 
different mechanisms of intrinsic resistance and acquired vemurafenib resistance (Table 
4.1). Treatment of matched BRAF inhibitor–naive and BRAF inhibitor–resistant 
melanoma cell lines with vemurafenib showed a statistically significant difference in the 
extent of growth inhibition (P = 0.02; t = $4.38; Fig. 4.1 and Fig 4.2) when resistance 
! 88 
was mediated through increased PDGFR! expression (M229R) and an acquired NRAS 
mutation (M249R), as well as 2 lines with uncharacterized mechanisms of resistance 
(WM164R and 1205LuR) (Fig. 4.2A). Cell lines with amplification of cyclin D1 (WM39) 
and overexpression of COT (RPMI 7951) showed signs of intrinsic resistance to 
vemurafenib (IC50 > 3 µmol/L). By contrast, treatment with the HSP90 inhibitor XL888 
led to dose-dependent decreases in the growth of all the cell lines with no significant 
difference in IC50 values observed between the naive and resistance pairs of cell lines (t 
= 0.25, P = 0.82; Fig. 4.2A). The growth inhibitory effects of XL888 were associated with 
induction of either a G1-phase cell-cycle arrest (WM164, M229, M229R, M249, M249R, 
1205Lu, and WM39) or a G2-M phase cell-cycle arrest (WM164R, 1205LuR, and RPMI 
7951; Fig. 4.2B). Treatment of all of the vemurafenib-resistant melanoma cell lines with 
XL888 (300 nmol) induced high levels (>66%) of apoptosis as shown by Annexin V 
binding, caspase-3 cleavage, and loss of mitochondrial membrane potential (TMRM) in 
every cell line tested (Fig. 4.2C and Fig. 4.3 ). The cytotoxic effects of XL888 were 
durable with no signs of colony formation observed in any of the cell lines (up to 4 
weeks: Fig. 4.2D and Fig. 4.4).  
Table 4.1: List of cell lines used in this study with mechanisms of resistance outlined.  
 
References:  
1. Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, et al. Melanomas acquire resistance to B-
RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature. 2010;468:973-7.  
2. Smalley KS, Lioni M, Palma MD, Xiao M, Desai B, Egyhazi S, et al. Increased cyclin D1 
expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas. Mol 
Cancer Ther. 2008;7:2876-83.  
! 89 
3. Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, et al. COT drives 
resistance to RAF inhibition through MAP kinase pathway reactivation. Nature. 2010.  
!
 
 
Fig. 4.1. Analysis of GI50 values in the naïve and resistant cell line panel shows a statistical significance 
difference between the two groups (P=0.02).  
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Fig. 4.2. The HSP90 inhibitor XL888 blocks the growth and survival of melanoma cell lines with diverse mechanisms of vemurafenib 
resistance. A, growth assay of vemurafenib-naive and vemurafenib-resistant melanoma cell lines and melanoma cell lines with 
intrinsic resistance. Left, cells treated with of vemurafenib (1 nmol/L–10 µmol/L: 72 hours) before being subject to the MTT assay. 
Right, cell growth assay of the cell line panel from (A) to the HSP90 inhibitor (1 nmol/L–10 µmol/L: 72 hours). B, cell-cycle effects of 
XL888 (300 nmol/L: 24 hours) on vemurafenib-sensitive and vemurafenib-naive cell lines. Cells were fixed, stained with propidium 
iodide, and distributions analyzed by flow cytometry. C, XL888 induces apoptosis in every model of acquired vemurafenib resistance 
tested. Cells were treated for either 72 or 144 hours with XL888 (300 nmol/L). Apoptosis measured by Annexin V (flow cytometry). 
D, top: colony formation assay showing the long-term effectiveness of XL888. Cell lines were treated with 300 nmol/L XL888 for 4 
weeks before being fixed and stained with crystal violet. Bottom: quantification (absorbance) of colony formation. 
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Fig. 4.3. XL888 induces apoptosis in every model of vemurafenib resistance tested. Figure shows loss of 
mitochondrial membrane potential (TMRM) following 72 and 144 hr of XL888 treatment (300 nM). Blot 
shows cleavage of caspase-3 following XL888 treatment (300 nM, 48 hrs).  
 
 
Fig. 4.4.  High power view of the control plates from the colony formation assay shown in Figure 4.2D. 
 
Inhibition of HSP90 degrades all of the proteins identified as being critical for 
vemurafenib resistance 
We next asked whether XL888 treatment induced the degradation of all the 
signaling mediators implicated in acquired and intrinsic resistance (Fig 4.5 summarizes 
melanoma-relevant HSP90 clients).  
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Fig. 4.5. HSP90 client proteins known to be important in melanoma.  
 
XL888 treatment (300 nmol/L, 48 hours) led to the degradation of IGF1R, 
PDGFR!, ARAF, CRAF, and cyclin D1 and the inhibition of AKT, ERK, and S6 signaling 
in all of the cell lines with acquired BRAF inhibitor resistance (Fig. 4.6A). These effects 
were found to be time dependent with some sensitive proteins, such as pAKT being 
downregulated at 8 hours or earlier (Fig. 4.6A). In the intrinsically vemurafenib-resistant 
melanoma cell lines RPMI7951 and WM39, XL888 treatment was found to degrade both 
COT and cyclin D1, respectively (Fig. 4.6A).  
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Fig. 4.6. XL888 degrades proteins involved in BRAF inhibitor resistance leading to apoptosis induction. A, Left: XL888 degrades 
IGF1R, PDGFR!, ARAF, CRAF, and cyclin D1 and inhibits pAKT, pERK, and pS6 signaling in 4 cell lines with acquired BRAF 
inhibitor resistance. XL888 degrades the expression of COT and cyclin D1 in cell lines with intrinsic resistance to vemurafenib. 
Right: time dependency of the XL888-mediated effects on pAKT, pERK, pS6, COT, and BIM. RPMI7951 cells were treated with 
XL888 for 0 to 48 hours. B, XL888 (1 µmol/L, 144 hours) blocks growth and survival of vemurafenib-resistant melanoma cell lines 
grown as 3D collagen-implanted spheroids. Staining shows cell viability, green corresponds to live cells and red to dead cells, 4x. C, 
XL888 + vemurafenib enhances apoptosis in RPMI7951, WM793 and 1205 Lu. Cells treated with vemurafenib (3 µmol/L), XL888 
(300 nmol/L), or both for 48 hours. Apoptosis was measured by Annexin V staining and flow cytometry. D, XL888 + vemurafenib 
reduces the survival of intrinsically resistant melanoma cell lines grown as 3D collagen-implanted spheroids. RPMI7951 and WM793 
were treated with XL888 (1 µmol/L), vemurafenib (3 µmol/L), or both of the 2 for 48 hours. Viability measured as above. 
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Because the microenvironment modulates the response of melanoma cells to targeted 
therapies 275, we next grew the panel of vemurafenib-resistant cell lines as collagen 
implanted 3-dimensional (3D) spheroids and noted that XL888 was effective at inducing 
cell death (Fig. 4.6B). In line with the observation that COT mediates resistance to 
vemurafenib 211, the combination of XL888 with vemurafenib significantly enhanced the 
level of apoptosis/cytotoxicity in 3D culture in RPMI7951 cells, compared with XL888 
alone (Fig. 4.6C and D). A similar enhancement was noted when the vemurafenib ± 
XL888 combination was applied to 2 melanoma cell lines in which the primary 
resistance was mediated through PTEN loss (WM793 and 1205Lu; Fig. 4.6C and D).  
Development of a quantitative pharmacodynamic assay of HSP90 inhibition 
The clinical development of HSP90 inhibitors has been hampered by the lack of 
a good pharmacodynamic assay for quantifying target inhibition within the tumor 200. As 
inhibition of HSP90 typically leads to the increased expression of other HSP family 
members, which can be used as a surrogate for HSP90 inhibition, we developed a 
highly sensitive quantitative LC-MRM assay for the quantification of 11 HSP family 
members (ref. 200; Fig. 4.7A). Treatment of cell lines that were naive, intrinsically 
resistant, and with acquired vemurafenib resistance with XL888 (300 nmol/L) led to 
robust time-dependent increases in the expression of HSP70 isoform 1 (HSP71; Fig. 
4.7B). Western blot experiments confirmed the XL888-dependent increases in HSP70 
expression in every cell line evaluated (Fig. 4.7C). The potential clinical relevance of the 
LC-MRM assay was shown by the successful quantification of HSP70 and other 
chaperone proteins from fine needle aspirates (!2,000 cells) taken from 2 melanoma 
specimens (Fig. 4.7D).  
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Fig. 4.7. Development of a quantitative pharmacodynamic assay for HSP90 inhibition. A, workflow of the 
LC-MRM experiment to measure HSP chaperone levels. After reversed-phase HPLC separation, 
peptides are selected by their mass-to-charge ratio and dissociated by collisions with background gas 
before the fragment ions are mass selected to enable specific detection and quantification of individual 
peptides in complex mixtures. B, heatmap showing XL888-induced (0–48 hours, 300 nmol/L) HSP70 
expression in all of the melanoma cell lines irrespective of vemurafenib resistance mechanism. C, 
Western blot confirmation of HSP70 upregulation following XL888 treatment (300 nmol/L, 48 hours). D, 
quantification of absolute (fmol/µg) expression of the HSP chaperone protein expression in fine needle 
aspirates from 2 melanoma specimens. 
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XL888 treatment causes the regression of vemurafenib-resistant xenografts in 
vivo associated with increased intratumoral HSP70 expression  
The relevance of HSP90 inhibition as a strategy to overcome BRAF inhibitor 
resistance in vivo was shown by the ability of XL888 (100 mg/kg, orally, 3 times a week) 
to significantly induce the regression of, or growth inhibition of established M229R and 
1205LuR xenografts in SCID mice (Fig. 4.8A and Fig. 4.9)  
 
Fig. 4.8. XL888 induces the regression of established M229R xenografts and is associated with increased intratumoral HSP70 
expression. A, XL888 leads to regression of M229R melanoma xenografts. M229R cells were grown until a palpable tumor had 
formed before being treated with XL888 thrice per week (100 mg/kg) by oral gavage. Data shows growth curves normalized to 
starting volumes; bar graph shows mean tumor volumes after 15 days of XL888 treatment. XL888 treatment led to significant levels 
of tumor regression (P = 0.003). B, heatmap showing the increase in HSP70 isoform 1 (HSP71) expression in XL888-treated (15 
days, 100 mg per kg) xenograft samples compared with vehicle controls. C, XL888 treatment (10 days) led to the induction of 
apoptosis in established M229R xenografts as measured by increased TUNEL staining (green) and was associated with the 
induction of BIM expression and the suppression of Mcl-1 expression. 
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It was noted that the XL888 was well tolerated by the mice, with no significant 
alterations in body weigh observed over the study period (Fig. 4.10A). XL888 was also 
noted to be tumor specific in in vitro studies, with minimal growth inhibitory effects 
observed upon 2 primary human skin fibroblast cell lines (Fig. 4.10B and C). LC-MRM–
mediated analysis of xenograft samples following 15 days of XL888 treatment showed a 
robust (8.6-fold) increase in intratumoral HSP70 expression compared with controls 
(Fig. 4.8B). XL888 treatment was noted to be proapoptotic in vivo and led to increased 
TUNEL staining in M229R xenografts associated with increased expression of BIM and 
decreased expression of Mcl-1 (Fig. 4C.8).  
 
 
 
 
Fig. 4.9.  XL888 significantly inhibits the growth established 1205LuR xenografts relative to vehicle 
control (* P=0.0036, ** P>0.05). 1205LuR cells were grown until a palpable tumor had formed before 
being treated with XL888 (100 mg/kg) three times per week by oral gavage. Data shows increases in 
tumor volume normalized to staring volumes and mean tumor volume at the end of the end of the 
experiment.  
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Fig. 4.10. XL888 treatment has minimal effects upon mouse weights and the growth and survival of two 
normal human skin fibroblast cell lines. A: Mean mouse weights of the vehicle and XL888 treated animal 
groups following day 15 of treatment. B: Minimal apoptosis is induced in two primary human skin 
fibroblast cell lines (FF2504, FF2407) after XL888 treatment (72 hrs, 300 nM). Apoptosis was measured 
by Annexin-V staining and flow cytometry. C: MTT assay for XL888 upon two human skin fibroblast cell 
lines. 
 
 
 
! 99 
HSP90 inhibition restores nuclear localization of FOXO3a, upregulates BIM 
expression, and inhibits Mcl-1 expression in vemurafenib-resistant cell lines  
To determine the mechanism of XL888-induced apoptosis in the vemurafenib-
resistant melanoma cell lines, we first focused upon BIM. Whereas vemurafenib 
treatment increased expression of BIM in melanoma cell lines that were drug naive 150, 
the resistant cell lines suppressed their expression of BIM even in the continuous 
presence of vemurafenib (Fig. 4.11A). XL888 treatment reversed this and increased 
BIM expression, irrespective of resistance mechanism (Fig. 4.11A). It was noted that 
XL888 treatment increased the expression of BIM-EL, BIM-L, and BIM-S expression in 
the M229R, 1205LuR, RPMI7951, and WM39 cell lines, induced expression of BIM-L 
and BIM-S in the WM164R cell line, and BIM-EL in the M249R cell line (Fig. 4.11A). 
These effects were mediated in part through increased BIM protein stability as noted by 
decreased BIM phosphorylation at Ser69 in all of the cell lines tested apart from M249R 
(Fig. 4.11A). We next asked whether HSP90 inhibition also affected BIM expression at 
the mRNA level. In vemurafenib-naive cells, inhibition of BRAF leads to the nuclear 
accumulation of the transcription factor FOXO3a and increased BIM expression 150. In 
contrast, cell lines with acquired resistance to vemurafenib excluded FOXO3a from the 
nucleus and suppressed BIM protein and mRNA expression even in the continuous 
presence of vemurafenib (Fig. 4.11A and Fig. 4.12). XL888 treatment reversed these 
effects and led to the nuclear accumulation of FOXO3a and an increase in BIM mRNA 
and protein expression (Fig. 4.11A and Fig. 4.12). An increase in nuclear size following 
XL888 treatment was also noted. The importance of BIM expression in the XL888-
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mediated cell death response was shown by the significant inhibition of apoptosis 
observed when BIM expression was knocked down by siRNA (Fig. 4.11B).  
 
Fig. 4.11. HSP90 inhibition increased BIM, decreases Mcl-1, and restores apoptosis in vemurafenib-resistant melanoma cell lines. 
A, Left: Western blot showing that XL888 (48 hours, 300 nmol/L) decreases BIM phosphorylation (Ser69) and increases BIM 
expression. Right: qRT-PCR experiment showing that treatment with XL888 (300 nmol/L, 48 hours) increases the expression of BIM 
at the mRNA level. B, siRNA knockdown of BIM significantly decreases XL888 (300 nmol/L, 48 hours) mediated apoptosis in 2 
vemurafenib-resistant melanoma cell lines (M229R and 1205LuR). C, left, Western blot of Mcl-1 expression in vemurafenib-resistant 
melanoma cell lines treated with XL888 (300 nmol/L) for 48 hours. Right: qRT-PCR showing that XL888 (300 nmol/L, 48 hours) 
treatment downregulates Mcl-1 expression at the mRNA level. D, induction of Mcl-1 reduces the magnitude of XL888-induced 
apoptosis. Western blot shows the induction of Mcl-1 following doxycycline treatment. Induction of Mcl-1 (DOX+XL) significantly 
reduces the level of XL888-induced apoptosis compared with XL888 (XL: 300 nmol/L, 72 hours) alone. *, P < 0.05.  
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Fig. 4.12. Immunofluorescence staining showing that XL888 (300 nM) enhances the nuclear 
accumulation of FOXO3a and increases BIM expression in M229R and 1205LuR cell lines. 
 
Mcl-1 is prosurvival BH3 family protein member that antagonizes the activity of 
BIM 92. Treatment of melanoma cell lines in which vemurafenib resistance was 
mediated through PDGFR!, COT overexpression, and 2 melanoma cell lines with 
unknown resistance mechanisms with XL888 (300 nmol/L, 48 hours) led to a marked 
decrease in the expression of Mcl-1 (Fig. 4.11C). qRT-PCR experiments showed that 
XL888 treatment also blocked Mcl-1 expression at the mRNA level (Fig. 4.11C). The 
importance of Mcl-1 expression for the survival of vemurafenib-resistant melanoma cell 
lines was confirmed by the significant induction of apoptosis observed following siRNA 
knockdown of Mcl-1 expression (Fig. 4.13). Further evidence for the role of Mcl-1 
expression in the drug resistance phenotype came from overexpression studies in 
which induction of Mcl-1 expression following doxycycline treatment led to a significant 
reduction in the magnitude of XL888-induced apoptotic response (Fig. 4.11D). 
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Fig. 4.13. siRNA knockdown of Mcl-1 induces apoptosis in vemurafenib resistant melanoma cell lines. 
1205LuR and M229R cells were treated with either non-targeting (NT) or Mcl-1 siRNA (Mcl-1 si) for 96 
hrs. Protein was resolved and probed for Mcl-1 and GAPDH expression by Western blot. Levels of 
apoptosis were quantified by Annexin-V staining and flow cytometry. 
 
HSP90 inhibition is more effective at inducing BIM expression and apoptosis than 
combined MEK+PI3K inhibition 
The simultaneous targeting of mitogen-activated protein/extracellular signal–regulated 
kinase (MEK/ERK) and phosphoinositide 3-kinase (PI3K)/AKT signaling is being 
explored as a strategy for overcoming vemurafenib resistance. We next asked whether 
HSP90 inhibition was more effective than the MEK+PI3K inhibitor combination at 
restoring apoptosis in vemurafenib-resistant melanoma cells. Although both XL888 and 
the PI3K inhibitor GDC-0941 were highly efficient at increasing nuclear accumulation of 
FOXO3a (Fig. 4.14A), XL888 treatment led to a greater induction of BIM expression at 
both the protein and mRNA levels and significantly restored the apoptotic response (Fig. 
4.14B and C). Similarly, XL888 treatment was also more effective than the MEK or PI3K 
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inhibitor, alone or in combination, at downregulating the expression of Mcl-1 at both the 
mRNA and protein levels (Fig. 4.14B and C). This was in marked contrast to the 
responses observed in the parental M229 and 1205Lu cell lines, in which the MEK ± 
PI3K inhibitor combination was equally effective as XL888 at inducing BIM expression 
(Fig. 4.15). Although there is evidence that the BH3 protein family member BMF plays a 
role in the apoptotic response to BRAF inhibition 275 XL888 treatment only weakly 
induced BMF mRNA expression (Fig. 4.16). In contrast, treatment of 2 vemurafenib-
resistant cell lines with either the MEK inhibitor (M229R) or the MEK+PI3K inhibitor 
(1205LuR) led to a robust induction of BMF expression but induced less apoptosis than 
following XL888 treatment (Fig. 4.14D and Fig. 4.16). As the phosphorylation of BIM by 
MEK/ERK leads to its proteasomal degradation and the 26S proteasome is an HSP90 
client protein, we next determined the contribution of proteasome inhibition to the 
cytotoxic effects of XL888. Although XL888 treatment was observed to partly degrade 
the 26S proteasome, HSP90 inhibition had a considerably weaker effect upon 
proteasomal activity than either the MEK+PI3K inhibitor combination or the proteasome 
inhibitor (MG-132; Fig. 4.17). In agreement with the marked effects of HSP90 inhibition 
on BIM and Mcl-1 expression compared with the MEK, PI3K, and MEK+PI3K inhibitor 
combination, XL888 was observed to induce significantly higher levels of apoptosis than 
each of the other drug combinations in cell lines in which resistance was mediated 
through amplification of COT, PDGFR! overexpression and in 2 other models where the 
resistance mechanism is as yet unknown (Fig. 4.14D). The level of apoptosis induced 
by the MEK+PI3K inhibitor combination was equivalent to that of the HSP90 inhibitor 
when resistance was mediated through NRAS mutation or cyclin D1 amplification (Fig. 
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4.14D). 
 
Fig 4.14. HSP90 inhibition is more effective at restoring the apoptotic response than combined MEK+PI3K inhibition. A, 
immunofluorescence staining of 1205LuR and M229R cells for BIM and FOXO3a after treatment with vehicle, XL888 (300 nmol/L), 
AZD6244 (3 µmol/L), GDC-0941 (3 µmol/L), or both AZD6244 + GDC-0941 (each at 3 µmol/L). B, XL888 is more effective than 
MEK+PI3K inhibitors at increasing BIM and decreasing Mcl-1 mRNA expression in 1205LuR and M229R cell lines. BIM and Mcl-
1qRT-PCR of cells treated as above. C, XL888 is more effective than MEK+PI3K inhibitors at increasing BIM and decreasing Mcl-1 
protein expression in 1205LuR and M229R cell lines. BIM and Mcl-1Western blot of cells treated as above. D, XL888 is more 
effective at inducing apoptosis of melanoma cell lines in which resistance is mediated through COT and PDGFR! expression and in 
2 models in which the resistance mechanism is unknown. Measurement of apoptosis for cells treated as above.  
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Fig. 4.15. The combination of the MEK + PI3K inhibitor is more effective at inducing BIM expression in the vemurafenib naïve 
compared to vemurafenib resistant melanoma cell lines. M229 and M229R and 1205Lu and 1205LuR cell lines treated with vehicle, 
XL888 (300 nM), AZD6244 (3 µM), GDC-0941 (3 µM) or both (3 µM each) for 48 hrs and Western blotting was performed for BIM. 
 
 
Fig. 4.16. XL888 (HSPi) is less effective than either an inhibitor of MEK (M229R) or the MEK + PI3K inhibitor (M+P) at inducing 
BMF mRNA in vemurafenib resistant melanoma cell lines. Cell cultures were treated with either vehicle (CT), HSPi (XL888, 300nM), 
MEKi (AZD6244, 3µM), PI3Ki (GDC-0941,3µM) or the MEK + PI3K inhibitor combination for 48 hrs, before being analyzed by q-RT-
PCR. 
 
 
Fig. 4.17. Although XL888 degrades the 26S proteasome, it is less effective than the MEK + PI3K inhibitor combination at inhibiting 
chymotrypsin like proteasome activity. A: Western blot showing the degradation of 26S proteasome following XL888 treatment (300 
nM, 48 hrs). Numbers indicate fold decrease in proteasome activity. B: Quantification of cellular chymotrypsin-like proteasome 
activity following treatment with either vehicle (CT), XL888 (XL, 300nM), AZD6244 (AZD, 3µM), GDC-0941 (GDC, 3µM), the MEK + 
PI3K inhibitor combination (A+G) or the proteasome inhibitor MG-132 (1 and 3 µM). 
M229R 1205LuR 
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Discussion 
This study addressed whether targeting multiple signaling pathways through the 
inhibition of HSP90 is sufficient to overcome intrinsic and acquired resistance to the 
BRAF inhibitor vemurafenib (PLX4032). XL888 is a novel, orally available HSP90 
inhibitor with high selectivity for HSP90& and HSP90! (IC50 = 22, 44 nmol/L, 
respectively) and little activity against a panel of 29 other diverse kinases (IC50 all 
>3,600 nmol/L; ref. *+*. XL888 induced growth arrest and apoptosis in melanoma cell 
lines where vemurafenib resistance was mediated through NRAS mutations, PDGFR! 
overexpression, COT overexpression, and cyclin D1 amplification. It was also 
proapoptotic in 2 melanoma cell lines with acquired vemurafenib resistance mediated 
through as yet unknown means. In all of the vemurafenib-sensitive cell lines, XL888 
induced a G1-phase cell-cycle arrest and reduced the percentage of cells in S-phase. In 
some of the resistance models, XL888 treatment instead induced cell-cycle arrest in 
G2–M, suggesting an altered signaling dependency following the acquisition of drug 
resistance. In all cases, the responses to XL888 were highly durable with no resistant 
colonies emerging after 4 weeks of continual drug treatment. The prolonged growth 
inhibition associated with XL888 was in marked contrast to that observed following 
vemurafenib (or PLX4720) treatment in which resistant colonies emerged in every case 
133,206,293. We next confirmed that XL888 decreased the expression of all the client 
proteins implicated so far in acquired and intrinsic vemurafenib resistance (IGF1R, 
cyclin D1, PDGFR-!, AKT, COT, ARAF, and CRAF)!134,206,209-215. In each case, not only 
did XL888 reduce the levels of the RTK/kinases implicated in BRAF inhibitor resistance, 
it also blocked the signaling activity of the pathways (MEK, AKT, and mTOR/S6) 
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involved in therapeutic escape 133,135,212,220. Although IGF1R, COT, AKT, ARAF, MEK, 
and CRAF have previously been reported to be HSP90 clients and subject to 
proteasome-mediated degradation following HSP inhibition, this is the first report to 
potentially identify PDGFR-! as a client of HSP90 (a current list of HSP90 clients is 
maintained at http://www.picard.ch/downloads/Hsp90interactors.pdf).  
The potential use of HSP90 inhibitors to overcome vemurafenib resistance was 
illustrated by the ability of XL888 to inhibit multiple, nonoverlapping resistance pathways 
in the same cell line model, for example, the inhibition of PDGFR!, IGF1R, and COT in 
the COT-amplified cell line and PDGFR!, IGF1R, and COT in the PDGFR!-
overexpressing cell line. The fact that melanomas express multiple RTKs and can 
flexibly switch between multiple signaling pathways suggests that individual melanoma 
cells may have a number of escape mechanisms at their disposal, underscoring the 
need to concurrently target multiple oncogenic pathways. There is already evidence 
from other cancers that HSP90 inhibitors can overcome multiple drug resistance 
mechanisms. In preclinical studies of breast cancer, inhibitors of HSP90 abrogate 
diverse trastuzumab resistance mechanisms, including those mediated by PI3K 
mutations, truncation mutants of p95-HER2, and the upregulation of membrane-
associated mucin-4 294-296. In NSCLC, inhibition of HSP90 prevents drug resistance 
associated with the oncogenic switch from EGFR to c-MET 296. HSP90 inhibitors have 
also been proven effective at managing drug resistance in the clinic, with activity being 
reported against trastuzumab-resistant HER2+ breast cancer and bortezomib-resistant 
multiple myeloma 290,291,297,298.  
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The measurement of HSP90 inhibition in vivo has proven to be challenging. 
Though HSP90 inhibition is well correlated with the increased expression of the co-
chaperone, HSP70 (which can be quantified in peripheral blood mononuclear cells), 
HSP70 levels do not correlate well with either intratumoral HSP90 inhibition or clinical 
activity 200. The high abundance of heat shock chaperone proteins makes them 
amenable to direct quantification by mass spectrometry with minimal processing 299. As 
patients with advanced melanoma typically present with accessible cutaneous lesions 
that can be biopsied or undergo fine needle aspiration, we developed a novel 
quantitative pharmacodynamic mass spectrometry–based assay for the quantification of 
HSP90 and its co-chaperones. In agreement with previously published studies on 
HSP90 inhibitors, XL888 treatment lead to upregulation of HSP70 isoform 1 expression 
in every vemurafenib-sensitive and resistant cell line tested 291,297,299. Although there is 
evidence that increased HSP70 expression limits apoptosis in leukemic cells, the 
therapeutic relevance of this observation in melanoma is still unclear 300. The in vivo use 
of the LC-MRM technique was shown by the robust increases in HSP70 expression 
observed in xenografts following XL888 treatment and the ability to quantify levels of 
HSP90 and its key cochaperones in small needle biopsies (fine needle aspirates) taken 
from fresh melanoma specimens. These results demonstrate that LC-MRM–based 
pharmacodynamic assays can be utilized to measure expression levels of intratumoral 
proteins and therefore is a technique that could be adopted for the direct quantification 
and monitoring of HSP90 client proteins during the course of therapy.  
Inhibition of BRAF, either by siRNA knockdown or small molecule inhibitors of 
BRAF or MEK, induces apoptosis in BRAF V600E mutant melanoma cells through the 
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proapoptotic proteins BIM, BMF, and BAD 90,91,275,281. BIM is a BH3 family protein 
member that plays a pivotal role in the induction of cell death by binding to and 
antagonizing the prosurvival proteins Bcl-2, Bcl-w, Bcl-XL, and Mcl-1 276,277. 
Vemurafenib resistance (both intrinsic and acquired) is characterized by a diminished 
apoptotic response and impaired BIM expression in the continuous presence of drug.  
The observation that BIM is regulated both transcriptionally and post-
transcriptionally through many pathways including ERK, AKT, JNK, and p38 MAPK, led 
us to hypothesize that XL888 (through the simultaneous targeting of multiple signaling 
pathways) may overcome vemurafenib resistance by upregulating BIM expression at 
both the mRNA and protein levels 301,302. Regulation of BIM mRNA is mediated by the 
transcription factor FOXO3a. AKT phosphorylates FOXO3a at T32, S253, and S315, 
leading to FOXO3a’s nuclear exclusion and localization to the cytoplasm 150,264. BIM 
levels are also controlled posttranslationally through phosphorylation at a number of 
sites (including S69) by MEK/ERK signaling, with the phosphorylation of BIM leading to 
its polyubiquitination and proteasomal degradation 90.  
Our previous studies showed that vemurafenib increased nuclear FOXO3a 
localization and BIM expression in drug-naive cells leading to increased apoptosis 150. 
Here we noted that vemurafenib resistance was associated with suppression of nuclear 
FOXO3a and BIM expression in the continued presence of drug and was reversed upon 
addition of XL888. Interestingly, XL888 treatment was more effective at restoring the 
expression of BIM at the mRNA and protein levels and inducing apoptosis than dual 
inhibition of MEK and PI3K, perhaps suggesting the involvement of other (as yet 
unidentified) pathways that are also HSP90 clients. Although expression of BIM is 
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regulated both through 26S ubiquitin-dependent and 20S polyubiquitin–independent 
proteasomal mechanisms and the 26S proteasome is a known HSP90 client, we were 
unable to show a role for downregulation of the 26S proteasome in the recovery of BIM 
expression following HSP90 inhibition 303,304. A number of recent studies have 
suggested a role for increased BMF (Bcl-2 modifying factor) expression in mediating the 
apoptotic response of melanoma cells treated with inhibitors of BRAF and MEK 275,281. 
Here, we observed that XL888 treatment was a relatively weak inducer of BMF 
expression in the vemurafenib-resistant melanoma cell lines compared with that seen 
following single-agent MEK or dual PI3K + MEK inhibition, suggesting that BMF is 
relatively dispensable in overcoming BRAF inhibitor resistance in our models.  
The decision between survival and apoptosis is regulated through the balance of 
pro- and antiapoptotic Bcl-2 family proteins. Survival of melanoma cells is controlled in 
part by the antiapoptotic protein, Mcl-1, whose stability is regulated by the 
BRAF/MEK/ERK pathway 92. A potential role for Mcl-1 in the tolerance of BRAF 
inhibition was suggested by the studies showing that acquired vemurafenib resistance 
led to the recovery of MAPK signaling, whereas resistant cells maintained their Mcl-1 
expression in the presence of vemurafenib, and that the forced overexpression of Mcl-1 
decreased the vemurafenib-induced apoptotic response 92,133. Inhibition of HSP90 led to 
the degradation of Mcl-1 protein and reduced Mcl-1 expression at the mRNA level. 
XL888 was also more effective at reducing Mcl-1 mRNA levels than inhibitors of MEK, 
PI3K, and the MEK+PI3K inhibitor combination. It therefore seems likely that the 
induction of BIM in together with Mcl-1 downregulation plays a key role in the induction 
of XL888-mediated apoptosis.  
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Preclinical and clinical strategies for managing vemurafenib resistance in 
melanoma have been centered upon combining vemurafenib with inhibitors of the MEK 
and PI3K/AKT/mTOR pathways 212,220. Although our study supports use of the 
MEK+PI3K inhibitor combination when resistance is mediated through NRAS mutations 
or cyclin D1 amplification, it appears suboptimal when resistance is mediated by 
increased COT expression, PDGFR! overexpression, and in 2 other cell lines models 
with undetermined resistance mechanisms. These findings suggest that other pathways 
(that also happen to be HSP90 clients) are required for therapeutic escape or that 
vertical inhibition of the same pathway at multiple points (e.g., ARAF/CRAF/MEK or 
IGF1R/AKT/S6) may be a more effective way of shutting down a signal transduction 
pathway.  
Another strategy for targeting MAPK dependent BRAF inhibitor resistance is 
simultaneous inhibition of BRAF and MEK. However, data from recent phase I/II clinical 
trial (NCT01072175) of 71 patients failing on vemurafenib, dabrafenib or experimental 
BRAF inhibitors indicated that vertical inhibition only minimally improved clinical 
outcomes (OR = 13-15%, PFS = 1.8-3.9 months) 305. Though it is possible that a triple 
combination of BRAF/MEK/ERK inhibitors could successfully block the MAPK pathway, 
ERK inhibitors have yet to be proven clinically efficacious. Further, due to the signaling 
plasticity of solid tumors such as melanoma, it is likely that complete inhibition of the 
MAPK pathway prior to adaptation would be required to eradicate the nidus of 
potentially treatment refractory cancer cells. 
In summary, in this study we showed for the very first time that all of the signaling 
proteins implicated thus far in intrinsic and acquired BRAF inhibitor resistance are 
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clients of HSP90 and that inhibition of HSP90 can restore sensitivity to vemurafenib-
mediated cell death through BIM upregulation Mcl-1 inhibition. Further, these 
observations have provided the rationale for targeting HSP90 and BRAF in BRAFV600E 
melanoma as a strategy to limit the therapeutic escape. A strategy that is currently in 
phase I clinical trial (NCT01657591 140). Thus far 15 patients have been enrolled 
(median age = 60 years, 73% male, majority stage IV). Four X888 dose escalations 
were evaluated in combination with a single dose of vemurafenib (960 mg bid 
vemurafenib + 30mg cohort 1, 45mg cohort 2, 90mg cohort 3, or 135mg cohort 4 XL888 twice 
weekly). Preliminary reports have been encouraging (OR = 85%) with 2 complete 
responders and a partially responding patient whose residual tumor was resected and 
shown to have no pathological evidence of viable melanoma cells. The most common 
side effects were typically associated with vemurafenib (anorexia, fatigue, arthralgia, 
and rash), with dose limiting toxicities occurring in only in cohort 4 (grade 3 diarrhea and 
pancreatitis). Of note, similar to BRAF + MEK combinations, secondary cutaneous 
events occurred less frequently in higher dose vemurafenib + XL888 cohorts (cohort 3 
and 4)140,306.  
Materials and Methods 
Cell culture and generation of BRAF inhibitor resistance 
The parental 1205Lu, WM39, and WM164 melanoma cells lines were a gift from Dr. 
Meenhard Herlyn (The Wistar Institute, Philadelphia, PA) and were genotyped as being 
BRAF V600E mutant in Smalley and colleagues 168. The M229, M229R, M249, and 
M249R were described in Nazarian and colleagues 206. The RPMI7951 melanoma cell 
line was purchased from American Type Culture Collection. The identities of all cell 
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lines were confirmed by Biosynthesis Inc., through short tandem repeat validation 
analysis. Naive and intrinsically resistant lines were cultured in 5% FBS, RPMI. For all 
studies, all acquired resistant cell lines were maintained in 5% media with the addition 
of vemurafenib at the following concentrations: 1 µmol/L for M229R and M249R, 2 
µmol/L for WM164R, and 3 µmol/L for 1205LuR.  
Growth inhibition 
Cells were plated at a density of 2.5 # 104 cells per mL and left to grow overnight before 
being treated with increasing concentrations of vemurafenib or XL888 as described in 
Smalley and colleagues 168. Data show the mean of at least 3 independent experiments 
± the SEM.  
Western blotting 
Proteins were extracted and blotted for as described in Smalley and colleagues 168. 
After analysis, Western blots were stripped once and reprobed for !-actin or 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) to show even protein loading. 
The antibodies to IGF1R, PDGFR!, ARAF, CRAF, phospho-AKT Ser473, total AKT, 
phospho-ERK (extracellular signal–regulated kinase), total ERK, cyclin D1, phospho-S6, 
total S6, phospho-BIM (Bcl-2 interacting mediator of cell death; Ser69), total BIM, 
HSP70, and MCL-1 were from Cell Signaling Technology. Anti-26S was purchased from 
Abcam whereas the antibody against COT was from Santa Cruz Biotechnology. For 
mouse xenograft studies, tumor samples were harvested and immediately placed into 
RNAlater solution (Invitrogen) before protein extraction.  
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Flow cytometry 
Cells were plated into 6-well tissue culture plates at 60% confluency and left to grow 
overnight before being treated with either 300 nmol/L XL888, 3 µmol/L AZD6244, 3 
µmol/L GDC-0941 (Selleck), or the combination of 3 µmol/L AZD6244 and 3 µmol/L 
GDC-0941 for 72 or 144 hours. In some studies, RPMI7951, WM793, and 1205Lu cells 
were treated with 300 nmol/L XL888 in the presence or absence of 3 µmol/L 
vemurafenib and harvested after 48 hours. Annexin V and TMRM staining was done as 
described in Paraiso and colleagues 133.  
Three-dimensional spheroid assays 
Melanoma spheroids were prepared using the liquid overlay method 174. Spheroids were 
either treated for 144 hours with vehicle or 1 µmol/L XL888 or for 48 hours with vehicle, 
1 µmol/L XL888, 3 µmol/L vemurafenib, or a combination of the 2 drugs before being 
washed and analyzed as described in Smalley and colleagues 174. 
RNA interference 
M229R and 1205LuR were plated at 1 # 105 and left to grow overnight in RPMI 
complete media. Complete media was replaced with Opti-MEM (Invitrogen) and Mcl-1 
or BIM (both 25 nmol/L; Cell Signaling Technologies) siRNAs in complex with 
Lipofectamine 2000 (Invitrogen) were added. In addition, scrambled siRNAs were 
added as nontargeting controls. A final concentration of 5% FBS in complete RPMI was 
added the next day. In the BIM studies, cells were transfected for a total of 48 hours 
before a 48-hour treatment with 300 nmol/L XL888. In the Mcl-1 studies, cells were 
treated for 96 hours.  
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Immunofluorescent staining 
M229R and 1205LuR cells were seeded at 50% confluency before being treated with 
300 nmol/L XL888, 3 µmol/L AZD6244, 3 µmol/L GDC-0941, or AZD6244 + GDC-0941 
in combination as previously described 150. Cells were stained with antibodies against 
BIM and FOXO3a followed by staining with secondary anti-rabbit AF488 and imaged 
with a Leica confocal microscope.  
Proteomics sample preparation 
Proteins were extracted as described for Western blotting and processed as described 
in Remily-Wood and colleagues 299.  
Liquid chromatography, multiple reactions monitoring mass spectrometry 
analysis 
Liquid chromatography, multiple reactions monitoring mass spectrometry (LC-MRM) 
was done as described in Remily-Wood and colleagues 299. Protein expression was 
determined using the ratio of peak area of the native peptide to corresponding internal 
standard; normalization of tissue results was done using GAPDH to control for cellularity 
(Table 4.2). Data were then normalized to the pretreatment (cell lines) or vehicle 
controls (tissue) and plotted to show the changes in expression after drug treatment.  
Table 4.2. Endogenous peptides, corresponding internal standards, and selected transitions for the quantification of heat shock 
proteins. Underlined amino acid residues are labeled with13C and 15N in the corresponding synthetic standards.  
 
! 116 
Human specimen procurement 
Patients scheduled to undergo surgical resection for metastatic melanoma were 
prospectively consented and accrued to an existing melanoma tissue procurement 
protocol approved by the Moffitt Cancer Center Scientific Review Committee and The 
University of South Florida Institutional Review Board. Following excision of the 
specimen in the operating room, fine needle tumor aspirates were taken using a 22-
gauge needle for proteomic analysis of the resulting tumor homogenate.  
MCL-1–inducible cell line 
WM793TR MCL-1 cells were a kind gift from Dr. Andrew Aplin (Kimmel Cancer Center, 
Philadelphia, PA; ref. +*). Mcl-1 expression was induced by the addition of 100 ng/mL 
doxycycline for 72 hours before treatment with 300 nmol/L XL888 for an additional 72 
hours.  
Quantitative real-time PCR 
Cells were treated for 48 hours with 300 nmol/L XL888, 3 µmol/L AZD6244, 3 µmol/L 
GDC-0941, or AZD6244 and GDC-0941 in combination before RNA isolation. Total 
RNA was isolated using Qiagen's RNeasy mini kit. The following TaqMan Gene 
Expression Assays primer/probes were used: Hs00197982_m1 (BIM), Hs01050896_m1 
(MCL-1), Hs00372937_m1 (BMF), P/N 4319413E (18S), and Hs99999905_m1 
(GAPDH). The 18S + GAPDH data were used for normalizing BIM. Quantitative reverse 
transcriptase PCR (qRT-PCR) reactions were carried out as previously described 150.  
Colony formation 
Cells (1 # 104 per mL) were grown overnight before being treated with vehicle (dimethyl 
sulfoxide) or XL888 (300 nmol/L) for 4 weeks as described in Paraiso and colleagues 
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150, and relative colony density was determined by solubilizing the crystal violet dye in 
10% acetic acid followed by measurement of absorbance at 450 nm.  
Xenograft experiments 
BALB severe combined immunodeficient (SCID) mice (The Jackson Laboratory) were 
subcutaneously injected with 2.5 # 106 cells per mouse and grown to approximately 100 
mm3 before dosing. Mice were treated with either 100 mg XL888/kg (n = 5) or an 
equivalent volume of vehicle (10 mmol/L HCl), 3# per week by oral gavage. Mouse 
weights and tumor volumes (L # W2/2) were measured 3# per week. Upon completion 
of the experiment, vehicle- and drug-treated tumor biopsies were processed for LC-
MRM analysis (as above). Detection of apoptosis by terminal deoxynucleotidyl 
transferase–mediated dUTP nick end labeling (TUNEL) staining (Millipore) was carried 
out according to the manufacturer's instructions.  
Statistical analysis 
Data show the mean of at least 3 independent experiments ± the SEM, unless stated 
otherwise. Statistically significant results were considered in which P % 0.05.  
Statistical analysis of GI50 values  
Triplicate experiments were performed for each cell line under each drug treatment. To 
estimate the IC50 values for each cell line for each treatment, a 4-parameter Hill 
equation was used to model the nonlinear sigmoid relationship between the drug 
concentration and % cell survival. Briefly, , where x is the 
drug concentration, y is the % survival, ' is the error term. The four parameters in the 
model to estimate are: 1) the control-level effect (E); 2) the background-level effect (B); 
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3) the median effect concentration (GI50); and 4) the strength of the inhibition (m). The 
constraint of non-negative minimum background effect (B) is imposed so the model is 
biologically meaningful. Levenberg-Marquardt algorithm for nonlinear 2 least squares 
was used to fit the model and estimate all four parameters for each cell line under each 
treatment. Estimated concentration at 50% cell survival, i.e., IC50, is estimated using 
the plugged-in parameters after model fitting. Note that when the control and 
background effects are 100% and 0%, respectively, the estimated GI50 and IC50 
values would be identical. To compare the estimated IC50 values between the 
resistance and naïve paired of cell lines, after log transformation, a paired t-test was 
performed for each drug.  
Measurement of proteasome activity  
M229R and 1205LuR cells were harvested and plated at 7,500 cells per well in a white-
walled 96 well plate. Cells were allowed to grow overnight prior to  treatment with either 
0.3µM XL888, 3µM AZD6244, 3µM GDC-0941 or the  combination of 3µM AZD6244 
and 3µM GD C-0941 (48hrs) or MG-132 (0.3, 1 or 3µM for 24hrs). Proteasome activity 
was assessed using the Proteasome-Glo Chymotrypsin-Like Cell Based Assay 
(Promega, Madison, WI) and was measured in relative luminescence units (RLU).  
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Chapter 5 
 
Inhibition of HSP90 by AT13387 Delays the Emergence of Resistance to BRAF 
Inhibitors and Overcomes Resistance to Dual BRAF and MEK Inhibition in 
Melanoma Models. 
Note to Reader 
Portions of this chapter have been previously published in Molecular Cancer 
Therapeutics. 2014 Dec;13(12):2793-804 198 and have been reproduced with 
permission from the American Association for Cancer Research Publishing. Author 
contributions: *Smyth T, *Paraiso KH (*contributed equally, designed/performed 
experiments, interpreted data, writing, figures); Hearn K, Rodriguez-Lopez AM, Munck 
JM, Haarberg HE, Thompson NT, Azab M (performed experiments); Sondak VK, Lyons 
JF (data interpretation, wording); #Smalley KS, #Wallis NG (#contributed equally, study 
concept, designed experiments, interpreted data, writing, figures). 
Introduction 
A number of different drug combinations have been investigated in an attempt to 
overcome or delay BRAF inhibitor resistance. Clinically the combined inhibition of BRAF 
and MEK with dabrafenib and trametinib appears to successfully increase progression-
free survival (PFS) 127, but ultimately, even with this combination, most patients relapse.  
Resistance mechanisms observed for the combination are similar to those seen for the 
monotherapy, and resistance to BRAF inhibition often confers cross-resistance to 
subsequent MEK inhibition 213,307-310. Other proposed combinations, including combining 
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BRAF inhibitors with phosphoinositide 3-kinase (PI3K), mTOR, c-MET or cyclin 
dependent kinase (CDK) 4 inhibitors 311-313, may address individual resistance 
mechanisms but are unlikely to target them all.  In addition, multiple mechanisms of 
resistance have been observed in tumors from individual patients 213,310,314, further 
underscoring the need for therapeutics with broad-spectrum activity. 
Mutant BRAFV600E protein is an HSP90 client, relying upon the chaperone 
machinery for its correct folding and stability 287,315. In addition to BRAFV600E, HSP90 
clients include key components of cellular signalling pathways involved in BRAF 
inhibitor resistance and as such, HSP90 inhibition has been proposed as a potential 
approach to concurrently target multiple BRAF inhibitor resistance mechanisms in 
melanoma 135,197,316. Unlike the first generation ansamycin class of HSP90 inhibitors, 
such as 17-N-allylamino-17-demethoxygeldanamycin (17-AAG), AT13387 is a second 
generation, fragment-derived inhibitor, which is active in a number of in vitro and in vivo 
tumor models 317.  Preclinically, AT13387 has been shown to be effective in kinase 
inhibitor-resistant diseases such as imatinib-resistant gastrointestinal stromal tumor 
(GIST) models 318.  Currently, AT13387 is in three Phase II clinical trials in combination 
with targeted agents (NCT01294202: GIST; NCT01712217: Anaplastic Lymphoma 
Kinase (ALK)-positive lung cancer and prostate cancer).   
Here, we demonstrated that AT13387 can overcome acquired resistance 
generated to BRAF inhibitors alone or to a BRAF/MEK inhibitor combination. In addition, 
combining AT13387 with a BRAF inhibitor in a sensitive in vivo model significantly 
delayed the emergence of BRAF inhibitor resistance.  These data further support the 
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clinical testing of a frontline combination of an HSP90 inhibitor with a BRAF inhibitor 
alone or as a triple combination of HSP90/BRAF/MEK inhibitors. 
Results 
AT13387 prevents the emergence of vemurafenib resistance in vitro  
AT13387 is a potent (Kd 0.71 nM) inhibitor of HSP90 (30;32) with broad spectrum 
activity in tumor models.  AT13387 potently inhibited the proliferation of a panel of 
melanoma cell lines, with different genetic backgrounds and sensitivity to the BRAF 
inhibitor, vemurafenib (Table. 5.1) and depleted relevant client proteins (Fig. 5.1).  Since 
HSP90 inhibitors, including AT13387, can overcome a variety of resistance 
mechanisms to BRAF inhibition once established, we investigated if HSP90 inhibition 
could also have a delaying effect on the emergence of this resistance in models initially 
sensitive to vemurafenib.   
Table. 5.1. Effects of AT13387 treatment on melanoma cell lines and xenograft models. Inhibition of 
proliferation was measured by Alamar blue detection and IC50 values generated as described in 
Materials and Methods. IC50 values shown are the mean of at least 3 independent experiments (SEM), 
except for SK-MEL-5 (vemurafenib) which shows the two independent IC50 determinations. 
 
A375 and SK-MEL-28 melanoma cell lines are both initially sensitive to 
vemurafenib treatment and their proliferation is also inhibited by AT13387 (Table. 5.1). 
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To investigate effects on the emergence of vemurafenib resistance, A375 and SK-MEL-
28 cells were exposed to 2 (M vemurafenib in vitro.  After two weeks of treatment, 
vemurafenib-resistant colonies had appeared (Fig. 5.2A).  However, significantly fewer 
colonies were generated when vemurafenib was combined with 18 nM AT13387 (Fig. 
5.2B),  suggesting  that  the  combination  delays  the  emergence  of  resistant   clones.   
!
Fig. 5.1. Melanoma cells were treated with the indicated concentrations of AT13387 or vemurafenib for 24 h. Proteins were resolved 
by SDS PAGE and then immunoblotted with the indicated antibodies. !!
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Fig. 5.2. AT13387 treatment delays the emergence of vemurafenib resistance in vitro. A375 (A) or SK-MEL-28 (B) cells treated with 
2 µmol/L vemurafenib and 18 nmol/L AT13387 alone or in combination. After 2 weeks, colonies were visualized by staining with 
0.1% crystal violet and quantitated. Graphs, average of three individual experiments for each cell line; *, **, ***, and **** indicate a 
significant difference from vemurafenib or AT13387 (P < 0.05, P < 0.01, P < 0.001, and P < 0.0001).  
AT13387 delays the emergence of vemurafenib resistance in vivo  
AT13387 inhibits the growth of both vemurafenib-sensitive and -resistant 
melanoma xenograft mouse models (Fig. 5.3 and Fig. 5.4A).  To further investigate the 
delay on emergence of resistance seen in vitro we carried out a comparable experiment 
in a SK-MEL-28 in vivo model (Fig. 5.4A and B).  AT13387 significantly inhibited the 
growth of SK-MEL-28 xenografts when dosed at 70 mg/kg ip once weekly.  As 
expected, oral administration of vemurafenib at 50 mg/kg twice a day caused significant 
regression of the SK-MEL-28 tumors over the initial period of dosing and combination of 
vemurafenib and AT13387 showed similar initial regression, with no significant 
difference observed between the two treatment groups (Fig. 5.4A).   
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Fig. 5.3. Mice bearing A2058 xenograft tumors received AT13387 at 70 mg/kg or its vehicle, 17.5% (w/v) 2-HPb-cyclodextrin, twice 
(Days 1, 4, 8 and 11) a week respectively. Vemurafenib at 50 mg/kg or its vehicle, 5% DMSO in 1% methylcellulose, was orally 
administered twice a day on Days 1-5 and 8-12, and once a day on Days 6, 7, 13 and 14. Mean tumor volumes were plotted with 
error bars representing standard error of the mean of N=8 (vehicles) or 7 (AT13387, vemurafenib and combination groups). Vehicle 
control ( ) AT13387 single-agent (!), vemurafenib single-agent (x), AT13387 and vemurafenib combination (o). * indicates 
statistically significant difference from the control group (P<0.05).  
 
However, over an extended dosing period (150 days) 2 tumors in the 
vemurafenib + vehicle group regrew (Tumor #8 and #7, PFS of 94 and 147 days, 
respectively), while no such regrowth was seen in the combination group over the same 
time period (Fig. 5.4B).  Combined with our in vitro data this further suggests that a 
combination of AT13387 and vemurafenib in a vemurafenib-sensitive model can delay 
the emergence of resistance that arises to vemurafenib treatment alone. The 
combination of AT13387 and vemurafenib was well tolerated with no significant 
increase in toxicity observed  (Fig. 5.5). 
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Fig. 5.4. AT13387 treatment delays the emergence of vemurafenib resistance in vivo. (A) Mice bearing SK-MEL-28 xenograft 
tumors received AT13387 at 70 mg/kg or its vehicle, 17.5% (w/v) 2-HP!-cyclodextrin, i.p. once a week. Vemurafenib at 50 mg/kg or 
its vehicle, 5% DMSO in 1% methylcellulose, was orally administered twice a day on days 1 to 5 and 8 to 12, and once a day on 
days 6, 7, 13, and 14. Mean tumor volumes were plotted with error bars representing SEM of n = 8 (vehicles and SK-MEL-28 
vemurafenib groups) or 7 (AT13387 and combination groups). Vehicle control (") AT13387 single-agent (!, blue), vemurafenib 
single-agent (!, red), AT13387, and vemurafenib combination (#, green). *, statistically significant difference from the control group 
(P < 0.05). (B) Vemurafenib monotherapy (!, red) and vemurafenib and AT13387 combination ( , green) groups of SK-MEL-28 
tumor-bearing mice continued to be dosed for 150 days as described above to allow resistance to develop to the therapies. (C) 
Levels of proteins were compared between one of the SK-MEL-28 vemurafenib-relapsed tumors (tumor #7) and a vemurafenib-
naive SK-MEL-28 tumor. Tumors were lysed, protein extracted, resolved by SDSPAGE, and immunoblotted with the indicated 
antibodies.  
  
Fig. 5.5. Effects of AT13387 and vemurafenib treatment on body weight of mice bearing SK-MEL-28 xenografts.  
 
AT13387 is active in models of acquired vemurafenib resistance 
Having demonstrated that AT13387 could delay the emergence of acquired 
vemurafenib resistance, we then continued to investigate the effect of AT13387 
treatment once resistance had been acquired in these models.  Two cell lines (A375R, 
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SK-MEL-28R) with acquired resistance to vemurafenib were generated using different 
methods.  Acquired resistance in the A375R cell line was produced by culturing A375 
cells in vitro with 2 (M vemurafenib for 3 weeks, while the SK-MEL-28R cell line was 
created from cells recovered from one of the SK-MEL-28 xenograft tumors, which 
became resistant to vemurafenib after the extensive dosing described above (Tumor 
#7).  The proliferation of these cell lines was no longer inhibited by vemurafenib in vitro 
(IC50 values > 10 (M, Fig. 5.7) but was still potently inhibited by AT13387 with IC50 
values in a similar range to those of the parental cell lines (22 nM vs. 19 nM for A375 
vs. A375R; 73 nM vs. 16 nM for SK-MEL-28 vs. SK-MEL-28R) (Table. 5.1, Fig. 5.6).  
Treatment with AT13387 still brought about the depletion of client proteins and inhibition 
of signalling as in the parental lines (Fig. 5.7A, Fig. 5.1).  Levels of PDGFR! and EGFR, 
which were again upregulated in the SK-MEL-28R cell line, were also depleted by 24 h 
treatment with 1 (M of AT13387 in vitro (Fig. 5.1).  Levels of cleaved PARP (Fig. 5.7A) 
and Annexin V (Fig. 5.7B) were increased on treatment of the SK-MEL-28R cell line 
with 0.1 or 1 (M AT13387 indicating apoptosis was being induced.  Cell death and 
inhibition of growth was also observed when collagen implanted 3D spheroids of the 
SK-MEL-28R cell line were treated with AT13387 (Fig. 5.7C). 
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Fig. 5.6. Effect of AT13387 on proliferation of resistant cell lines. The melanoma lines that had acquired resistance to vemurafenib 
alone (A375R and SK-MEL-28R) or to vemurafenib and selumetinib combination (SKMEL-28RR, WM164RR and 1205LuRR) were 
incubated in various concentrations of AT13387 (!) and viability determined using Alamar Blue. A375R and SK-MEL-28R were 
treated with AT13387 (!) or vemurafenib (!) alone. 1205LuRR, WM164RR and SK-MEL-28RR were incubated with various 
concentrations of AT13387 in presence of 1 µM each of vemurafenib and selumetinib. Each graph is representative of 2-5 
independent experiments performed in triplicate or quadruplicate. The table shows the mean IC50. 
 
Fig. 5.7. AT13387 treatment is still effective in in vitro models of acquired vemurafenib resistance. Cells with acquired vemurafenib 
resistance (A375R and SK-MEL-28R) were treated with varying concentrations of AT13387 or vemurafenib. Effects on cellular 
protein levels were measured by Western blotting with the indicated antibodies after 24 hours (A). SK-MEL-28R cells were treated 
with the indicated concentrations of AT13387 for 5 days in the presence of 1 µmol/L vemurafenib and apoptosis measured by 
Annexin V staining. Data, mean of three independent experiments each performed in duplicate (B). 3D spheroids were treated with 
the indicated concentrations of AT13387 for 6 days in the presence of 1 µmol/L vemurafenib. Red, dead cells; green, live cells; 
scale bar, 100 µm; bar graphs, average spheroid size as quantified by ImageJ analysis; *, significant difference in size compared 
with control (P < 0.05; C).  
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Finally, the in vivo activity of AT13387 was investigated in a SK-MEL-28R 
xenograft model.  Mice were subcutaneously injected with the vemurafenib-resistant 
SK-MEL-28R cells to form tumor xenografts and immediately treated with vemurafenib 
(50 mg/kg po bidx5/qdx2), to maintain resistance.  As expected, vemurafenib treatment 
did not inhibit tumorigenicity of these cells and xenograft tumors grew during dosing.  
When tumors reached a mean volume of approximately 100 mm3, AT13387 (70 mg/kg 
once weekly) was added to the vemurafenib treatment.  This significantly (P<0.01 from 
Day 3 onwards) inhibited the tumor growth (26 % T/C on Day 10), indicating these 
vemurafenib-resistant tumors retained sensitivity to AT13387 treatment (Fig. 5.8A), 
although growth was not completely suppressed as it was in the upfront combination.  
Single agent treatment with AT13387 also significantly (P<0.01 from Day 3 onwards, 
43% T/C on Day 10) inhibited tumor growth compared to vehicle control (Fig. 5.8B). 
 
Fig. 5.8. AT13387 treatment is effective in in vivo models of acquired vemurafenib resistance. SK-MEL-28R tumor 
xenografts were established in SCID mice and continuously treated with 50 mg/kg vemurafenib orally twice daily to 
maintain resistance. When the mean tumor volume reached approximately 110 mm3, once-weekly treatment with 
AT13387 ( , 70 mg/kg i.p.) or vehicle ( , cyclodextrin solution i.p.) was added (A) or vemurafenib treatment was 
stopped and tumors treated with vehicle ( , cyclodextrin solution i.p.) or AT13387 ( , 70 mg/kg i.p.) alone (B). *, **, 
***, and **** indicate a significant difference between the two treatments (P < 0.05, P < 0.01, P < 0.001, and P < 
0.0001, respectively).  
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AT13387 is active in cells with dual resistance to BRAF and MEK inhibitors 
Combined BRAF and MEK inhibition has been shown to extend PFS in the clinic 
but still ultimately leads to resistance in almost all cases.  We therefore investigated 
whether HSP90 inhibition could also overcome resistance to a dual BRAF and MEK 
inhibitor combination.  Three melanoma cell lines were generated with resistance to 
both BRAF and MEK inhibitors by prolonged (4-5 months, depending upon cell line) 
incubation with vemurafenib and selumetinib.  The resulting cell lines (SK-MEL-28RR, 
WM164RR, 1205LuRR) were found to be resistant to the vemurafenib and selumetinib 
combination as well as dabrafenib and trametinib (Fig. 5.9A and B).  All the resistant cell 
lines showed increased levels of phospho-ERK compared to the parental cell lines and, 
although there was a decrease in phospho-ERK in all of the resistant cell lines in the 
presence of vemurafenib and selumetinib, significant levels of signalling comparable to 
untreated parental cell lines were maintained  (Fig. 5.10A).  BRAF and MEK inhibitors 
also had little effect on the growth of collagen-implanted 3D spheroids of these cell lines 
(Fig. 5.11).  In contrast, treatment of these cell lines with AT13387 inhibited MAPK 
signalling as well as AKT signalling (Fig. 5.10B), induced apoptosis (Fig. 5.10C) and 
inhibited the growth and survival of the resistant cell lines in a 3D spheroid assay (Fig. 
5.10D). 
Similar to the vemurafenib resistant SK-MEL-28R cell line, western blot analysis 
of the 1205LuRR, SK-MEL-28RR and WM164RR cell lines demonstrated increased 
EGFR and/or PDGFRb expression in the dual resistant cell lines (Fig. 5.13).  We 
investigated whether other RTKs were upregulated in these cell lines using a phospho-
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RTK array (Fig. 5.14). As RTKs are known to signal largely through the phosphorylation 
of  tyrosine,  this  analysis  also  allowed us to measure relative changes in RTK activity. 
 
Fig. 5.9. Characterization of BRAF/MEK inhibitor-resistant cell lines.  Effect of BRAF and MEK inhibitors on proliferation of SK-MEL-
28 naïve vs. RR. SK-MEL-28 ( ) and SK-MEL-28RR cell line derived by prolonged incubation with vemurafenib and selumetinib ( ) 
were incubated in various combinations of dabrafenib and trametinib, or vemurafenib and selumetinib and viability determined using 
Alamar Blue. Each graph is representative of 3 independent experiments performed in quadruplicate.  
 
Fig. 5.10. Effect of BRAF and MEK inhibitors on SK-MEL-28RR. Both BRAF inhibitor and MEK inhibitor combination treatments 
caused little increase in Annexin V-positive or TMRM-negative cells when analyzed by FACS, indicating no increase in apoptosis.  
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Fig. 5.11. AT13387 overcomes acquired resistance to the BRAF and MEK inhibitor combination. Cell lines, parental (N) and those 
with acquired resistance to the BRAF inhibitor (vemurafenib) and the MEK inhibitor (selumetinib; RR) were treated with 1 µmol/L of 
each of vemurafenib and selumetinib for 2 hours. Proteins were resolved by SDSPAGE and immunoblotted with antibodies for ERK 
and phospho-ERK (A). Cell lines resistant to the BRAF and MEK inhibitor combination were treated with the indicated 
concentrations of AT13387. Proteins were resolved by SDSPAGE and immunoblotted with the indicated antibodies. Increasing 
concentrations of AT13387 blocked the expression of CRAF and inhibited phospho-ERK and phospho-AKT signaling (B). AT13387 
induced apoptosis in melanoma cell lines with resistance to the BRAF and MEK inhibitor combination. Cultures were treated with 
AT13387 (1 µmol/L, 5 days) before being stained with Annexin-V and analyzed by flow cytometry; ****, significant difference from 
control (P < 0.0001; C). The addition of AT13387 induces cell death in three cell line models of BRAF and MEK inhibitor resistance. 
Top, spheroids were grown in 1 µmol/L vemurafenib and 1 µmol/L selumetinib in the absence or presence of AT13887 for 6 days (1 
or 3 µmol/L); red, dead cells; green, live cells; scale bar, 100 µmol/L. Bottom, bar graphs show average spheroid area as quantified 
by ImageJ analysis at the indicated concentrations of AT13387 in the presence of 1 µmol/L vemurafenib and 1 µmol/L selumetinib; 
*, significant difference in size compared with control (P < 0.05; D). 
 
Fig. 5.12. Effect of BRAF and MEK inhibitors on 3D spheroid formation of resistant cell lines. 3D spheroid 
cultures of SK-MEL-28RR, WM164RR and 1205LuRR were treated with vemurafenib + selumetinib or 
dabrafenib + trametinib. These cultures show positive invasion and little cell death in the presence of 
these drugs. Red = dead cells, green = live cells.  
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Fig. 5.13. Upregulation of EGFR and PDGFR! in BRAF/MEK inhibitor resistant cell lines. Levels of EGFR 
and PDGFR! in naïve and resistant cell lines were assessed by western blotting. 
 
 
Fig. 5.14. HSP90 inhibition blocks RTK activation. WM164RR and 1205LuRR cell lines were treated for 
24 hours with 1 µmol/L AT13387 before probing for phosphorylation. RTK array dot blots showing global 
changes in RTK tyrosine phosphorylation between naive, resistant, and AT13387-treated resistant cells. 
Bar graphs show relative intensities of each RTK with a positive phospho-signal as quantified by 
densitometry.  
 
Comparison of the overall level of tyrosine phosphorylation of RTKs between the 
WM164RR and 1205LuRR cell lines and their respective parental lines revealed that 
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overall tyrosine phosphorylation appeared to increase following acquired BRAF plus 
MEK inhibitor resistance (Fig. 5.14) and that this increased level of phosphorylation was  
again decreased on treatment with AT13387 (1mM, 24hrs). In particular, the 
phosphorylated levels of PDGFRb  increased substantially in both resistant cell lines 
compared to very low levels in parental lines, and were depleted again after treatment 
with AT13387 (Fig. 5.14).   
Discussion 
Combinatorial BRAF plus MEK inhibitor regimens have proven successful at 
increasing overall responses and progression free survival when compared to targeted 
BRAF monotherapy 127,183,184. However, even with this combination, most patients 
eventually relapse with resistance mechanisms observed for the combination being 
similar to those seen for single agent BRAF or MEK inhibitor resistance 213,307-310. In 
previous studies, HSP90 inhibitors such as 17-AAG, PF-4470296, XL888 and 
ganetespib have been effective in a number of kinase-inhibitor resistant models 
including those with BRAF inhibitor resistance 197,319-322.  Here we demonstrated for the 
first time that the HSP90 inhibitor, AT13387, is also effective in overcoming acquired 
resistance to dual BRAF and MEK inhibition where treatment of dual agent resistant cell 
lines in both 2D and 3D culture with AT13387 lead to significant growth arrest and cell 
death. In long-term xenograft studies, the frontline combination of AT13387 plus 
vemurafenib was also found to be well tolerated and significantly delayed the resistance 
onset. These data suggest that HSP90 inhibitors, as a single agent or in combination, 
have potential use as both a front-line therapy for treatment naïve melanomas and as a 
second-line therapy for BRAF and BRAF plus MEK refractory disease 
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Current strategies for preventing and overcoming vemurafenib resistance are 
focused on concurrent BRAF and MEK or BRAF and PI3K/AKT/mTOR inhibition of 
signaling pathways. Though our previous studies support the use of such combinations 
when resistance is mediated through NRAS or cyclin D1 mutations, these studies also 
showed that inhibitor combinations that target the MAPK and PI3K/AKT were not as 
effective as single agent HSP90 inhibition when resistance is mediated through 
increased COT expression, PDGFR! overexpression or in two cell line models with 
unknown resistance mechanisms (both of which had significant levels of IGF1R and one 
of which had significant levels of PDGFR and IGF1R)  197. Mechanistically, RTK 
upregulation emerged as a potential resistance mechanism for both BRAF and BRAF 
plus MEK inhibitor resistant models with increased levels of both PDGFR! and EGFR 
being observed in relapsed vemurafenib treated xenograft tumors and significant 
increases in phospho-PDGFR! being detected in dual BRAFi/MEKi resistant cell lines. 
Importantly, AT13387 treatment lead to decreases in overall phospho-RTK levels in the 
dual resistant cell lines as well as total PDGFR! and EGFR protein levels in single 
agent resistant cell lines. Similar to the results seen with XL888, AT13387 also lead to 
marked decreases in the expression of key HSP90 client proteins which was associated 
with inhibition of ERK and AKT signaling.  
While early evaluations of HSP90 inhibitors (e.g. 17-AAG and IPI-504) showed 
some evidence of clinical activity in melanoma, investigations utilizing first-generation, 
ansamycin class inhibitors, were terminated due to limiting toxicities and low 
bioavailibity 323,324.  However, second-generation formulations of HSP90 inhibitors have 
much lessened toxicity profiles and significantly improved potency. As such this new 
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class of HSP90 inhibitors, which include AT13387, ganetespib and XL888, are being 
investigated for the treatment of melanoma as single agents or in combination with 
vemurafenib or dabrafenib plus trametinib (Table 1.3) with thus far promising 
preliminary therapeutic responses being seen for the combination of vemurafenib plus 
XL888 306.  
Materials and Methods 
Small molecule inhibitors  
AT13387 was synthesized at Astex Pharmaceuticals (Cambridge, UK) as described by 
Woodhead et al 325 and stored as a lyophilized powder.  Vemurafenib (PLX4032) was 
purchased from Sequoia Research Products Ltd (Pangbourne, UK) or Selleck 
Chemicals (Houston, TX, USA).  Selumetinib (AZD6244) was purchased from Selleck 
Chemicals.  Dabrafenib and trametinib were from Chemie Tek (Indianapolis, IN, USA).  
All other reagents were purchased from Sigma unless otherwise stated. 
Cell culture and reagents 
The human cell lines A375, SK-MEL-28, SK-MEL-2, SK-MEL-5 and WM266-4 were 
purchased from the American Type Culture Collection, Teddington, UK.  The A2058 
human cell line was purchased from the European Collection of Cell Cultures, Porton 
Down, UK.  The RPMI-7951 human cell line was purchased from Deutsche Sammlung 
von Mikroorganismen und Zellkulturen GmbH, Braunschwieg, Germany.  These cells 
lines were not passaged for more than 6 months since authentication by the cell banks 
(DNA fingerprinting and cytogenetic analysis or short-tandem repeat (STR) PCR).  The 
1205Lu and WM164 melanoma cell lines were a kind gift from Dr. Meenhard Herlyn 
(Wistar Institute, Philadelphia, PA) 133. Their identity was validated by STR analysis 
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(Biosynthesis, Lewisville, TX) at six monthly intervals.  All cells were grown in their 
recommended culture medium, supplemented with 10 % FBS and maintained at 37 °C 
in an atmosphere of 5 % CO2 unless otherwise stated.  All cell culture reagents were 
purchased from Invitrogen unless otherwise stated.  A375R cells were generated by 
culturing A375 cells in the presence of 2 µM vemurafenib for 3 weeks.  The resultant 
vemurafenib-resistant cell line was maintained in 2 µM vemurafenib.  SK-MEL-28R cells 
were derived as follows:  A SK-MEL-28 xenograft tumor that had relapsed on chronic 
vemurafenib treatment (50 mg/kg po bidx5/qdx2 for 150 days, see below) was excised 
out of the SCID mouse on Day 151 (Tumor #7).  The tumor was cut into small pieces 
and collagenase IV-digested for 45 min at 37 °C.  The digested tumor cell suspension 
was passed through a 100 (m filter, washed and cultured in Dulbecco’s Modified 
Eagle’s Medium (DMEM) containing 10% FBS, penicillin/streptomycin and 1 (M 
vemurafenib.  All assays were performed in antibiotic-free medium at passage numbers 
2 to 8.  Dual BRAF and MEK inhibitor resistant cell lines were established by chronically 
treating SK-MEL-28, WM164 and 1205Lu for 4-5 months with 1 µM each of vemurafenib 
and selumetinib.  Cell lines were maintained in 5% FBS in RPMI 1640 media with 1 µM 
vemurafenib and 1 µM selumetinib.   
Viability assays 
Viability studies were carried out using Alamar Blue (Invitrogen) as described previously 
199 with slight modifications.  Briefly, 5x103 cells were seeded in 200 µl of complete 
culture medium per well into flat-bottomed 96-well plates one day before the drug 
treatment.  Cells were incubated with compound in 0.1% (v/v) dimethyl sulfoxide 
(DMSO) for 3 or 6 days before viability was assessed by using Alamar blue.  IC50 values 
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were calculated using a sigmoidal dose response equation (Prism GraphPad software, 
La Jolla, CA, USA). 
Flow cytometry 
Melanoma cell lines were plated into 6-well tissue culture plates at 60% confluency and 
left to grow overnight.  Vemurafenib-resistant cells were treated with 1 mM vemurafenib 
alone or in combination with AT13387 while dual inhibitor-resistant lines were treated 
with 1 mM vemurafenib and 1 mM selumetinib alone or in combination with AT13387.  
After the indicated treatment time, cells were harvested and stained for Annexin V as 
described previously 197. 
Western Blotting 
Cells were seeded at 106 cells per well and incubated overnight at 37 oC followed by 
treatment with AT13387 or other compounds.  At the indicated time points, cells were 
harvested and lysed in ice-cold TG lysis buffer or RIPA buffer.  Xenograft tumor 
samples were prepared by homogenizing snap-frozen tumors in ice-cold TG lysis buffer 
using a Precellys 24 homogenizer and incubating on ice for at least 15 min.  After a 
freeze-thaw, all lysates were centrifuged at 14,000 rpm for 5 min at 4 °C to remove 
debris.  Protein concentrations were determined using BCA protein assay (Pierce) and 
normalised.  For western blot analysis, samples were resolved by SDS PAGE on 
NuPage® Novex Bis-Tris or Tris-Glycine gel systems, transferred to nitrocellulose or 
PVDF membranes and incubated with primary antibodies specific for: HSP70 (Enzo Life 
Sciences), BRAF, COT (Santa Cruz), BRAFV600E (Spring Biosciences), CRAF (BD 
Biosciences), phospho-AKT(S473), total AKT, phospho-ERK(T202/Y204), total ERK, 
phospho-S6 (S235/236) ,  total S6, cleaved PARP, PDGFR!, cKIT, IGF1R, EGFR (Cell 
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Signaling Technology), actin (Abcam), or GAPDH (Sigma) (Table S1).  Blots were then 
incubated with either infrared-dye-labeled secondary antibodies and fluorescence 
detected on the Odyssey infrared imaging system (LI-COR Bioscience) or incubated 
with horse-radish-peroxidase-conjugated secondary antibodies (Amersham) followed by 
detection with ECL (Perkin Elmer).   
 
Table 5.2. Further details of the suppliers of antibodies listed in Materials and Methods. 
 
 
Colony formation assays 
A375 and SK-MEL-28 cells were seeded in 6-well plates at a density of 500 cells per 
well. Both cell lines were maintained in culture by feeding with 2 ml fresh complete 
culture medium.  Cells were treated for two weeks with AT13387 (18 nM) and 
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vemurafenib (2 µM) as single agents or in combination; fresh compound was added 
every three days.  Colonies were fixed and stained with 0.1% crystal violet solution.  
Plates were scanned and colonies quantified using the GelCount software (Oxford 
Optronix).  
Three-dimensional spheroid assays 
Melanoma three-dimensional (3D) spheroids were prepared as described previously 199.  
Briefly, 50 mL of a 1.5% solution of agarose was added to each well of a 96-well tissue 
culture plate and allowed to solidify.  Into each well, 5#103 cells in 200 mL of media 
(containing the respective compound that the cells are resistant to) were overlayed on 
the agarose bed and allowed to grow over 5 days.  The resultant spheroids were 
implanted into rat tail collagen I and treated for 6 days with either 1 mM vemurafenib 
alone or in combination with AT13387 (single agent resistant cell lines) or 1 mM 
vemurafenib and 1 mM selumetinib alone or in combination with AT13387 (dual agent 
resistant cell lines).  Spheroids were then washed three times in media and stained with 
calcein-AM and ethidium bromide (Molecular Probes) for 1 hour at 37 °C, according to 
the manufacturer’s instructions.  Pictures of the invading spheroids were taken with a 5x 
objective using a Nikon 300 inverted fluorescence microscope.!!
Receptor Tyrosine Kinase (RTK) array  
Dual inhibitor resistant WM164RR and 1205LuRR cell lines were seeded at 50% 
confluency and grown overnight. Cells were then treated for 24 hours with 1 µM 
vemurafenib and 1 µM selumetinib (control) or 1 µM AT13387, 1 µM vemurafenib and 1 
µM selumetinib.  Vehicle (DMSO) treated naïve WM164 and 1205Lu cell lines were 
similarly plated and harvested. Global levels of RTK tyrosine phosphorylation were 
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determined using R&D Systems (Minneapolis, MN, USA) Proteome Profiler Human 
Phospho-RTK Array Kit.  Briefly, cells were lysed and proteins extracted with Lysis 
Buffer 17 supplemented with Cell Signaling Technology’s (Beverly, MA, USA) 
protease/phosphatase inhibitor cocktail.  RTK array membranes were then incubated 
with 700 µg of protein lysate.  All remaining steps were conducted per vendor 
instructions.  Densitometric values of all positive signals on the RTK array were 
measured with Adobe Photoshop CS3.  Corresponding levels of tyrosine 
phosphorylation were calculated by subtracting the average background values from the 
average values of duplicate RTK spots. 
Xenograft Studies 
The care and treatment of experimental animals were in accordance with the United 
Kingdom Coordinating Committee for Cancer Research guidelines 326 and with United 
Kingdom Animals (Scientific Procedures) Act 1986 327.  All animals were purchased 
from Harlan, UK.  SK-MEL-28 and SK-MEL-28R xenografts were prepared by 
subcutaneously injecting 5x106 cells suspended in serum-free DMEM mixed 1:1 with 
Matrigel (BD Biosciences, ~10 mg/ml protein concentration) into the flank of each male 
BALB/c SCID mouse.  A2058 xenografts were prepared similarly in BALB/c nude mice.  
Tumor burden was estimated from caliper measurements and by applying the formula 
for an ellipsoid.  Mice were randomised into different treatment groups when the mean 
of the tumors reached 100 mm3.  AT13387 was suspended in an aqueous solution of 
17.5% (w/v) (2-hydroxylpropyl)-!-cyclodextrin and administered intraperitoneally (ip) at 
70 mg/kg, once (SK-MEL-28 and SK-MEL-28R) or twice (A2058) a week.  Vemurafenib 
was suspended in 5% (v/v) DMSO and 95% (v/v) of an aqueous solution of 1% (w/v) 
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methylcellulose, and administered at 50 mg/kg twice daily on weekdays and once daily 
on weekends (bidx5/qdx2) by oral gavage (po).  All drugs were given at a dose volume 
of 10 ml/kg.  T/C was calculated as 100#mean treated tumor volume over mean control 
volume.  Tolerability was estimated by monitoring body weight loss and survival over 
the course of each study. 
Statistical analyses 
All statistical analyses were performed using GraphPad Prism version 6.01.  Effects of 
various drug treatments were compared using one-way ANOVA for comparing 3 or 
more groups, or unpaired t-test for 2 groups.  Differences were deemed statistically 
significant when P<0.05.!!
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Chapter 6 
Ligand independent EphA2 signaling drives the adoption of a targeted therapy-
mediated metastatic melanoma phenotype. 
Note to Reader 
Portions of this chapter have been previously published in Cancer Discovery. 2014 Dec 
26 224 and have been reproduced with permission from the American Association for 
Cancer Research Publishing. Author contributions: Paraiso KH (designed/performed 
experiments, interpreted data, writing, figures); Das Thakur M, Stuart D 
(designed/performed PDX experiments); Sloot S, Gibney GT (interpreted patient chart 
data); Fang B, Koomen JM (performed proteomic experiments); Pasquale EB (data 
interpretation, wording, plasmids); Villagra A (data interpretation HDAC experiments, 
inhibitors); Flaherty KT, Sondak VK (data interpretation, wording); Tsao H (plasmids) 
Fedorenko IV, John J (performed experiments); Meier FE (patient specimens); Messina 
JL, Rao U, Tawbi HA, Kirkwood JM (performed/interpreted pathology experiments); 
Smalley K (study concept, designed experiments, interpreted data, writing, figures). 
Introduction 
Though BRAF/MEK inhibition has improved progression-free survival compared 
to BRAF inhibitor alone, resistance is still prevalent 254. Currently, most of the clinically 
validated mechanisms of BRAF and BRAF/MEK inhibitor resistance are genetic and 
include acquired mutations that reactivate the MAPK pathway (BRAF splice mutants, 
NRAS mutations, MEK1/2 mutations) as well as genetic changes that increase 
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PI3K/AKT signaling (NF1, PTEN, PI3KCA and AKT1) 134,150,206,213,309. It has also been 
shown through RTK array-based platforms that increased receptor tyrosine kinase 
(RTK) signaling can also enable escape from BRAF and MEK inhibition 222,328. While 
gene- and phospho-array based approaches provide valuable information, they do not 
address dynamic global signaling changes that occur following acquired resistance.  
To address how global rewiring of melanoma signaling promotes resistance, we 
utilized mass spectrometry based phosphoproteomic and network analyses to identify 
signaling changes in tyrosine, threonine and serine that occur prior to and following 
acquired BRAF inhibitor resistance. This comprehensive bioinformatics approach 
uncovered a “resistance interactome” consisting of ~150 nodes that was marked by 
significant alterations and the emergence of signaling nodes such as ITGB1, EphA2, 
EphB4, FAK1, STAT3 and PXN. GeneGo pathway enrichment analysis revealed 
enhanced cytoskeletal rearrangement, adhesion, integrin signaling, cell migration and 
extracellular matrix remodeling.  Consistent with our bioinformatic predictions, 
melanoma cell lines with acquired vemurafenib resistance were considerably more 
invasive than their drug naïve counterparts.  
There is evidence from other cancer types that therapeutic intervention drives the 
adoption of phenotypes e.g. epithelial-to-mesenchymal transition (EMT), whereby 
epithelial cells can acquire the invasive characteristics of mesenchymal cells 329. For 
melanoma, the patterns of disease recurrence seen at progression are complex, with 
50% of individuals progressing at only new sites of metastasis, 44% at existing sites of 
metastasis and 6% at both new and existing sites 330. Though it is known that 
melanoma cells with intrinsic BRAF inhibitor resistance frequently show increased 
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invasive potential, the role of chronic BRAF inhibitor treatment in mediating the 
dissemination of melanoma cells has been little explored 331. Ephrins constitute the 
largest family of RTKs and play diverse roles in cell migration, development and 
maintenance of the stem cell niche 332,333. Under physiological conditions, EphA2 kinase 
binds to its membrane bound ligand EphrinA1, leading to the inhibition of AKT and 
reduced cell migration 332. In cancer, EphA2 is often overexpressed and, following 
phosphorylation by AKT at S897, can signal in a ligand-independent manner to drive 
tumorigenic behavior and increased cell migration 334,335.  
In the present study we utilized a label-free phosphoproteomic approach to 
quantify all of the phosphorylation events associated with long-term inhibition of BRAF 
signaling. These analyses revealed a previously unsuspected link between BRAF and 
BRAF/MEK inhibition and the adoption of an aggressive, invasive phenotype driven 
through ligand-independent EphA2 signaling. 
Results 
Phosphoproteomics identifies BRAF inhibitor resistance to be associated with an 
invasive signature 
We began by asking how chronic vemurafenib treatment rewired the signaling 
network of BRAF mutant melanoma at a systems level through the use of a mass 
spectrometry-based phosphoproteomic platform (Fig. 6.1). The goal of these studies 
was to uncover phenotypic adaptations to chronic BRAF inhibition. Our approach offers 
advantages over other proteomic methods such as reverse phase protein array (RPPA) 
in being comprehensive, unbiased and not limited by antibody availability. In brief, 
tyrosine phosphorylated peptides were retrieved by immunoprecipitation and the 
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threonine and serine phosphorylated peptides isolated by subjecting the resulting flow-
through to strong cation exchange (SCX) and immobilized metal affinity 
chromatography (IMAC). Liquid chromatography tandem mass spectrometry (LC-
MS/MS) (Fig. 6.1) was used to quantify all of the phospho-peptides from isogenic 
vemurafenib naïve and resistant 1205Lu melanoma cells. Levels of peptide 
phosphorylation were quantified using MaxQuant and the protein-protein interactions 
characterized using GeneGO. Cytoscape mapping of the global signaling changes 
showed an increase in both the number of nodes and the number of edges in 
vemurafenib resistant 1205Lu cells (Naïve: 544 nodes, 1208 edges. Resistant: 552 
nodes, 1288 edges) (Fig. 6.2).  
 
Fig. 6.1. Workflow of the phosphoproteomic experiment. 
LC-MS/MS 
Reduction/Alkylation & Proteolytic Digestion 
pY IP Ab Peptide Enrichment 
Peptide Fractionation (SCX) 
pS/pT IMAC Enrichment 
Phosphorylation ID Label Free Quantification  
MaxQuant SEQUEST, MASCOT 
Elution Flow Through 
naive resistant 
isogenic cell lines 
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Fig. 6.2. Comprehensive phosphoproteomic overviews of BRAF inhibitor naïve (L) and BRAF inhibitor 
resistant (R) melanoma. Proteins identified from the 1205Lu naïve and inhibitor resistant proteomes were 
analyzed using MetaCore (GeneGo) software. Direct protein-protein interactions emerging from this 
analysis were visualized with Cytoscape software. 
 
 
Chronic BRAF inhibition was associated with an enrichment of phospho-proteins 
involved in adhesion, cytoskeletal remodeling, FAK and integrin signaling (Fig. 6.3) as 
well as the emergence of a highly interconnected resistance interactome involving 
EphA2, EGFR, EphB4, FAK1, HDAC1, integrins (ITGA3, ITGA5, ITGAV, ITGB1, 
ITGB5), nucleolin, p130CAS, paxillin, SHC1, Tensin-3 and Zyxin (Fig. 6.4A and B). As 
this suggested the adoption of a migratory/invasive phenotype, we next characterized a 
panel of BRAF (designated “R” cell lines) and BRAF/MEK inhibitor resistant cell lines 
(designated “RR”), which were generated through chronic drug treatment for >6 months 
(Fig. 6.5).  
544 nodes 
1208 edges 
552 nodes 
1288 edges 
naïve 
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Fig. 6.3 Comprehensive phosphoproteomics identifies an invasive, motile signaling signature associated with BRAF inhibitor 
resistance. GeneGo enrichment analysis revealed several highly significant pathways (-log p-value >2) appearing within the 
resistance interactome.  
 
Fig. 6.4. A: Further enrichment analysis of the resistance network showed that several proteins were not only found be increased 
(log 10 relative peak intensity) following acquired resistance but also recurred across several of the resistance pathways. B: As 
these proteins would broadly contribute to resistance we conducted a connectivity analysis that revealed that the redundant nodes 
formed a highly connected sub-network. 
 
a b 
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Fig. 6.5. Characterization of BRAF/MEK inhibitor resistant melanoma cell lines. Resistance was 
confirmed through Alamar Blue experiments in which sub-confluent cultures were treated with increasing 
concentrations of dabrafenib (SK-MEL-28 and WM164: 0.001 - 3 µM, 1205Lu: 0.001 - 10µM), in the 
continual presence of trametinib (1 µM), increasing concentrations of trametinib (SK-MEL-28 and WM164: 
0.001 - 3 µM, 1205Lu: 0.001 - 10 µM), in the continuous presence of dabrafenib (1 µM), increasing 
concentrations of vemurafenib (SK-MEL - 28 and WM164: 0.001 - 3 µM, 1205Lu: 0.001 -10 µM) in the 
presence of selumetinib (1 µM) or increasing concentrations of selumetinib (SK-MEL-28 and WM164: 
0.001 - 3µM,1205Lu: 0.001 - 10 µM) in the continuous presence of vemurafenib (1 µM). *Figure shows a 
representative plot of WM164 naïve and resistant cell lines. 
 
 
It was noted that the resistant cell lines had increased motile behavior in both 
transendothelial migration assays (where melanoma cells were allowed to migrate 
through confluent endothelial cell monolayers), and 3D spheroid assays (in which 
melanoma cells migrated into the surrounding collagen matrix) (Fig. 6.6, Fig. 6.7, and 
not shown). One potential candidate identified from the screen was EphA2, a cell 
surface receptor tyrosine kinase implicated in development, stem cell niche 
maintenance and cancer progression 332. 
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Fig. 6.6. Acquired resistance to MAPK inhibition leads to increased invasion and migration. Left, human 
vascular endothelial cells (HUVECs) were plated onto transwell inserts and grown to confluency. DiI 
labeled (red fluorescence) naïve or resistant melanoma cells were then plated on top of the HUVEC layer 
and allowed to invade. Non-migratory cells were removed and the remaining cells were imaged by 
fluorescence microscopy.  
 
 
Fig. 6.7. Quantification of invasive of BRAF and BRAF/MEK inhibitor resistant cell lines Figure 6.6. 
 
Ligand-independent EphA2 signaling drives the adoption of an invasive 
phenotype 
Despite EphA2 being implicated in the suppression of cell adhesion and 
migration following stimulation with ephrin-A1, it can also function in a forward signaling, 
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ligand-independent manner following phosphorylation by AKT at S897 334 (See Model in 
Fig. 6.8). Validation of the phosphoproteomic screen through Western blotting showed 
increased EphA2, phospho-EphA2 (S897), phospho-FAK (Y397), phospho-Paxillin 
(Y118) and total Paxillin expression in BRAF inhibitor resistant cell lines (Fig 6.9A). 
Increased S897-EphA2 expression was also observed in other BRAF inhibitor resistant 
(R) cell lines as well as those with acquired BRAF/MEK inhibitor resistance (RR) (Fig, 
6.9B). An analysis of drug naïve 1205Lu and A375 melanoma cells (which expressed 
low-levels of EphA2 basally) did not reveal vemurafenib to increase EphA2 
phosphorylation at S897, with the addition of drug instead reducing phosphorylation at 
this site (Fig. 6.10). This, along with two previous studies showing that vemurafenib and 
its analogue PLX4720 did not alter EphA2 kinase activity in in vitro assays, suggested 
that the induction of ligand-independent EphA2 signaling was not a direct consequence 
of BRAF inhibitor treatment 147,336. In epithelial cancers, unrestricted forward EphA 
signaling is accompanied by decreased ephrin ligand expression 334. The loss of 
bidirectional Ephrin-Eph signaling in cell lines with acquired BRAF and BRAF/MEK 
inhibitor resistance was suggested by the reduction of ephrin-A1 ligand expression (Fig. 
6.9C) and the ability of exogenous ephrin-A1 ligand to suppress the invasion of 
vemurafenib resistant 1205LuR cells in a matrigel assay, in which cells migrated 
towards serum (Fig. 6.9D). In drug resistant melanoma cells, siRNA knockdown of 
EphA2 led to a significant (P<0.005) abrogation of invasiveness in a matrigel invasion 
assay in both the presence and absence of drug, but did not resensitize the cells to 
vemurafenib-mediated apoptosis (3 µM, 48 hrs) (Fig. 6.9E, Fig. 6.11, Fig, 6.12). It 
therefore appeared that EphA2 expression mediated the adoption of a drug-induced 
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phenotypic switch but not vemurafenib resistance per se. Conversely, the introduction of 
EphA2 into a melanoma cell line that lacked its expression increased cell invasion 
through matrigel (Fig. 6.9F). To rule out that the inhibition of invasion was due to cell 
death, we also performed Annexin V/DAPI staining and found no differences between 
non-targeting and EphA2 siRNA treated cohorts (data not shown). 
 
 
Fig. 6.8. Schema depicting ligand dependent and ligand independent ephrin signaling. EphA2 can 
proceed in a ligand independent way following phosphorylation at S897 by AKT leading to increased 
migration and invasion. 
 
Ligand-independent EphA2 signaling is AKT-dependent 
In all cases, S897 phosphorylation of EphA2 was mediated through PI3K/AKT, 
with Western blotting showing the resistance phenotype to be associated with increased 
phospho-AKT and phospho-GSK3! levels (Fig. 6.13A and Fig. 6.14) and the ability of a 
PI3K (GDC-0941, 3 µM) and an AKT inhibitor (MK-2206, 3 µM) to reverse receptor 
phosphorylation (Fig. 6.13B). Further studies showed PI3K inhibition (PI-103, 1 µM) to  
prevent  melanoma cell invasion in a 3D spheroid assay (Fig. 6.13C).  
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Fig. 6.9. BRAF and BRAF/MEK inhibition induces an invasive phenotype driven through ligand-independent ephrin-A2 signaling. A: 
Western Blot of increased total EphA2, phospho-EphA2 (S897), phospho-FAK (Y397), phospho-Paxillin (Y118) and paxillin 
expression in BRAF inhibitor resistant (R) vs. naïve (N) 1205Lu melanoma cells. B: Increased EphA2 and S897-EphA2 expression 
is observed in multiple models of BRAF (R) and BRAF/MEK (RR) inhibitor resistance. C: Ephrin-A1 ligand expression is decreased 
in cell lines with BRAF (R) and BRAF/MEK inhibitor (RR) resistance. D: Ephrin-A1 ligand prevents invasion of 1205LuR cells. Cells 
were treated with Ephrin-A1 ligand (1 µg /ml, 24 hrs) E: siRNA EphA2 reverses the invasive phenotype of BRAF (R) and BRAF/MEK 
(RR) resistant cell lines. (Upper) siRNA knockdown of EphA2 and representative images of reduced matrigel invasion. (Lower) 
Quantification of invasion following treatment with non-targeting control or siRNA against EphA2. F: EphA2 enhances invasion of 
SK-MEL-28 cells into collagen. SK-MEL- 28 cells were transfected with a plasmid containing EphA2 and selected for 14 days. After 
this time cells were plated on top of matrigel and allowed to invade. Image shows a Z-stack of phallodin-stained melanoma cells 
through matrigel invading towards serum. Bar graph shows the quantification of invasion relative to control. 
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Fig. 6.10. Acute vemurafenib treatment does not induce ligand independent EphA2 signaling. Treatment 
naïve A375 and 1205Lu cells lines were treated with BRAFi (3µM PLX4032/vemurafenib, 1hr) prior to 
probing for ligand-independent (S897) and ligand-dependent (Y772) EphA2 phosphorylations. 
 
 
Fig. 6.11. Knockdown of EphA2 expression does not resensitize melanoma cells to the pro-apoptotic 
effects of BRAF inhibition. Vemurafenib resistant 1205LuR cells were transfected with either 25nM non-
targeting siRNA (NTsi) or 25nM EphA2 siRNA for 24hrs in the absence of vemurafenib. After 24 hours, 
fresh serum supplemented media with 3µM vemurafenib (white bars) or DMSO (black bars) was added. 
Cells were then analyzed for Annexin V binding/DAPI uptake 72 hours after transfection. 
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Fig. 6.12. Knockdown of EphA2 reduces invasion in the absence and presence of vemurafenib. Vemurafenib resistant 1205LuR 
cells were transfected with 25nM non-targeting siRNA (NTsi) or 25nM EphA2 siRNA in the absence of vemurafenib. After 24 hours, 
fresh media with 3µM vemurafenib (black bars) or DMSO (white bars) was added. Cells were then treated with vemurafenib or 
DMSO for an additional 48 hours after transfection. The resistant 1205LuR were then allowed to invade and migrate across a 
matrigel barrier in the presence or absence of vemurafenib for 48 hours prior to confocal microscopy imaging. 
 
Treatment with the ephrin-A1 ligand restored EphA2 tyrosine phosphorylation 
(Y772), and kinase activity, inhibited AKT phosphorylation on S473, AKT-dependent 
EphA2 phosphorylation at S897 and FAK phosphorylation at Y397 (Fig. 6.13D, Fig. 
6.15, Fig. 6.16). The potential role of FAK signaling in the drug-mediated invasive 
phenotype was suggested by the ability of the FAK inhibitor PF-228 to inhibit invasion in 
a 3D spheroid assay (Fig. 6.16). Introduction of an EphA2 S897A mutant that is 
refractory to AKT mediated phosphorylation prevented its interaction with an AKT 
substrate (Fig. 6.13E) and reversed the invasion of BRAF inhibitor resistant cells 
through matrigel and their migration in a scratch assay (Fig. 6.13F).  
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Fig. 6.13. Ligand-independent phospho-EphA2 (S897) signaling is PI3K/AKT dependent. A: Western blot of pAKT, 
AKT, PTEN and GAPDH in melanoma cells that are drug naïve (N), BRAF inhibitor resistant (R) and BRAF/MEK 
inhibitor resistant (RR). B: The PI3K inhibitor GDC-0941 (3 µM, 24 hr) or the AKT 24 inhibitor MK-2206 (3 µM, 1 hr) 
decreases the phosphorylation of AKT (S473) and EphA2 (S897). C: PI3K inhibition reduces the invasion of BRAF 
inhibitor resistant melanoma cell lines. (Top panel) 1205LuR cells were plated on top of Matrigel and treated with 
either vehicle or PI-103 (1µM) for 24 hrs before being stained with phalloidin and imaged used confocal microscopy. 
(Bottom panel) 1205LuR cells were grown as 3D spheroids, implanted into collagen and treated with vehicle or 1µM 
PI-103 prior to staining with calcein AM. Invading cells were imaged with an inverted fluorescence microscope and 
levels of invasion were calculated with ImageJ software. D: Ephrin-A1 ligand reduces EphA2 (S897) phosphorylation 
levels in 1205LuR cells. Cells were treated with ephrin-A1 ligand (1 µg/mL, 24 hr) before being analyzed by Western 
Blot. E: Transfection of the EphA2 serine to alanine substitution at position 897 mutant plasmid (S897A) prevents 
S897 phosphorylation of EphA2. 1205LuR cells were transfected with either WT (control) or mutant S897A EphA2 
plasmid. Lysates from transfected cells were immunoprecipitated with antibodies against S897 and total EphA2 and 
immunoblotted with anti-phospho-serine/threonine AKT substrate antibody. Total, non-immunoprecipitated protein 
was also probed for EphA2 and GAPDH as loading controls. F: Mutant S897A expression reduces 1205LuR cell 
invasion and scratch wound closure. 1205LuR cells transfected with WT (control) or S897A mutant EphA2 plasmid 
were either allowed to invade through matrigel or plated into 6 well tissue culture plates and grown to confluency 
before being scratched with a p20 pipet tip after which the wound was allowed to close over 24 hours. 
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Fig. 6.14. PI3K and AKT inhibitors inhibit AKT phosphorylation and the AKT substrate GSK3!. Vemurafenib resistant 1205LuR cells 
were treated for 1 hr with 3µM vemurafenib alone (CT), 3µM GDC-0941 + 3µM vemurafenib (GDC) or 3µM MK-2206 + 3µM 
vemurafenib (MK) prior to Western Blotting. 
 
 
 
 
Fig. 6.15. EphrinA1 ligation leads to increased EphA2 tyrosine phosphorylation. 1205LuR cells were treated for 1 hr with 1µg/mL 
IgG-Fc or 1µg/mL ephrinA1-Fc and probed with anti-Y772-EphA2 antibody. 
 
 
 
Fig. 6.16. Ligation of EphA2 by ephrin A1 is associated with decreased signaling through FAK. (Left panel) Vemurafenib resistant 
1205LuR cells were treated for 24 hrs with 1ug/mL ephrinA1 ligand or Fc-IgG control prior to Western Blotting. (Right panel) 
1205LuR cells were treated for 5 days with 5µM FAK inhibitor (PF228) or an equivalent volume of DMSO control prior to inverted 
microscopy imaging and scoring of invasion. 
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Although increased phosphorylation by AKT explained the ligand-independent 
EphA2 signaling, it did not explain the increased EphA2 expression in BRAF inhibitor-
resistant melanoma cells. We therefore asked whether EphA2 expression in BRAF 
inhibitor resistant cell lines was dependent upon continuous drug selection pressure. 
Removal of BRAF or BRAF/MEK inhibition led to an initial decrease in the fitness of the 
resistant cells as seen by an increased doubling time, followed by the partial reversal of 
resistance (Fig. 6.17, Fig. 6.18), an effect associated with decreased phosphorylation of 
both AKT and EphA2 S897 (Fig. 6.19A). Phenotypically, these effects were paralleled 
by a marked reduction in the invasive capacity of the cells (Fig. 6.19B, C).  
 
 
 
 
Fig. 6.17. Removal of BRAF or BRAF/MEK inhibitors increases cell doubling time. Treatment naïve 
(1205Lu, WM164), chronically treated (1205LuR: 3µM vemurafenib, WM164RR: 1µM vemurafenib + 1µM 
selumetinib) and resistant cell lines given a 4 week drug holiday (1205LuR no drug, WM164RR no drug) 
were plated at a density of 25,000 cells per 2 mL of a 6 well tissue culture dish. Cells were counted on 
days 1, 3, 5 and 7 and doubling times calculated. 
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Fig. 6.18. Removal of drug leads to a reversal of the drug resistance phenotype. WM164RR cells were grown in drug free media for 
4 weeks before being treated with increasing concentrations of dabrafenib and trametinib ( 0.001-1 µM of each drug combined). 
Data shows the comparison of naïve WM164 cells, WM164RR maintained in the presence of BRAF/MEK inhibitor and WM164RR 
following 4 weeks of reversion. 
 
 
Fig. 6.19. Removal of drug reverses EphA2 signaling and the invasive phenotype of melanoma cells. A: Reversion of phospho-
EphA2, EphA2, pAKT and total AKT expression following removal of BRAF inhibitor (R) or BRAF/MEK (RR) inhibitors for 0-4 weeks. 
B: Removal of drug reverses the invasive phenotype of BRAF and BRAF/MEK inhibitor resistant cell lines through an endothelial 
monolayer. C: Quantification of data shown in B. 
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There is evidence that acquired BRAF inhibitor resistance leads to epigenetic changes 
that impair the apoptotic response, and that these effects can be reversed through 
HDAC inhibition 337,338. We next treated the resistant melanoma cultures with the pan-
HDAC inhibitor LBH-589 and observed decreases in EphA2 protein expression, its 
phosphorylation at S897 and an inhibition of AKT phosphorylation (Fig. 6.20A,B). In 
agreement with the role of phosphorylated EphA2 in melanoma cell migration, treatment 
with the HDAC inhibitor LBH-589 significantly reduced the invasion of melanoma cells in 
a 3D spheroid assay (Fig. 6.21).  
 
 
Fig. 6.20. HDAC inhibition reverses EphA2 phosphorylation, EphA2 expression and PI3K/AKT signaling. 
A: EphA2 phosphorylation is PI3K/AKT-dependent and epigenetically regulated. The HDAC inhibitor 
LBH589 (100nM, 24 hrs) decreases the phosphorylation of AKT and EphA2. B: LBH589 reduces EphA2 
and AKT phosphorylation across multiple resistant cell lines. 
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Fig. 6.21. The pan-HDAC inhibitor LBH589 reverses the invasive phenotype of A375R and 1205LuR 
cells. Spheroids of either A375R or 1205LuR were implanted into collagen and treated with either BRAF 
inhibitor (vemurafenib, 3 µM) or LBH589 (100nM) for 3 days before being imaged by confocal 
microscopy. Spheroids were stained with calcein-AM (green, live cells) or propidium iodide (red, dead 
cells). Magnification x5. 
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Ligand-independent EphA2 signaling is induced in vivo following BRAF inhibition 
and is associated with metastatic dissemination.  
The in vivo relevance of ligand-independent EphA2 signaling and its link to 
metastasis was explored in melanoma patient specimens. It was found that whereas 0% 
of primary (stage I/II) melanoma lesions (n=12) stained strongly (+2/3) for EphA2, 21% 
of metastatic lesions (stage III/IV) (n=19) showed strong staining (Fig. 6.22 A,B: Table 
6.1), with 57.9% of metastatic lesions showing some strong focal S897-EphA2 staining. 
We next established an in vivo resistance model where fragments of treatment naïve 
human melanoma specimens were implanted subcutaneously into nude mice (patient-
derived xenografts, PDX) 339. Vemurafenib dosing was commenced over 100-200 days, 
until resistance emerged (Fig. 6.23) 339.  
 
 
 
 
Table 6.1. Levels of EphA2 staining between primary (n=12) and metastatic melanoma lesions (n=19). 
Table shows breakdown of IHC staining by total EphA2 staining, phospho-EphA2 staining and focal 
phospho-EphA2 staining. 
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Fig. 6.22. Increased total and phosphorylated (S897) EphA2 in clinical specimens is associated with metastatic dissemination. A: 
Representative images of sequentially sectioned primary (S897-EphA2: +1-2, total EphA2: +2) and metastatic (S897-EphA2: +2, 
total EphA2: +3) IHC stained patient tumor specimens. B: Metastasis is associated with higher tumor-wide positive staining (+2/3) 
for pEphA2, increased focal S897-Epha2 staining and greater tumor-wide total EphA2 staining. Representative images of pEphA2 
staining of the advancing edge of 2 separate metastatic tumor specimens. Arrows indicate focal S897-EphA2 staining at the leading 
edge. C: Images from 3 matched pairs of primary and metastatic vemurafenib-treated patient derived melanoma mouse xenografts 
stained for total EphA2 showing greatly increased levels of total EphA2 expression in the matched metastatic vs. primary lesion. 
Images show paired samples from 3 independent mice. D: Vemurafenib treatment increases EphA2 expression in melanoma patient 
specimens. Representative images of staining for EphA2 and S897-EphA2 in matched melanoma lesions (from patient E) pre-
treatment and collected on vemurafenib therapy. See Table 6.2 for details. E: Vemurafenib resistance is associated with increased 
EphA2 expression in specimens derived from a patient with matched primary melanoma and metastatic lesions that emerged on 
therapy. Images show IHC staining for EphA2, S897 EphA2 and pAKT on a matched pair of primary (pre-vemurafenib treatment) 
and subcutaneous metastatic (post-vemurafenib treatment) lesions. 
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Fig. 6.23. Schematic for establishing resistance in patient derived xenografts. 
 
 
Local or distant metastases were frequently observed in vemurafenib resistant PDXs, 
but not in the vehicle treated animals (as these were sacrificed at much earlier time 
points) (Das Thakur et al., In preparation). Staining of matched pairs of subcutaneous 
and metastatic specimens from the same drug-treated animals at necropsy showed 
high levels of immunohistochemical staining for EphA2 in the metastatic lesions that 
were absent from the matched primary subcutaneous lesions (Fig. 6.22C). In common 
with other studies, a heterogeneous pattern of EphA2 staining was noted, with both 
membranous and cytoplasmic/nuclear staining observed 335. Analysis of specimens 
from a cohort of 6 melanoma patients receiving vemurafenib therapy (14-370 days) 
revealed increased EphA2 and S897-EphA2 expression in the majority of on-treatment 
and post-relapse samples that were lacking in the pretreatment lesions (5/6) (Table 6.2: 
Fig. 6.22D shows pre and post treatment specimens from patient E).  
 
Table 6.2. Relative EphA2 expression from matched pre and post-vemurafenib treatment biopsies. Table 
details time of sample procurement and results of IHC staining for phospho-EphA2 staining (S897). 
 
Xenografted mice 
treated b.i.d. with 
45mg/kg 
vemurafenib. 
Chronic treatment 
(100-200 days) 
leads to acquired 
resistance and 
metastasis. 
 
Patient tumor 
fragments implanted 
subQ into nude 
mice. 
Tumor resected from 
an untreated 
BRAFV600E 
melanoma patient 
tumor.   
Vemurafenib 
resistant, matched 
primary and 
metastatic lesions 
resected and stained 
by IHC for S897-
EphA2 and total 
EphA2. 
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Chronic treatment of A375 cells with vemurafenib (1 µM, 1-4 weeks) further 
supported the rapid induction of EphA2 and S897-EphA2 expression following BRAF 
inhibition, with increased EphA2 protein expression observed by 3 weeks and increased 
EphA2 and S897-EphA2 expression seen after 4 weeks of drug treatment (Fig. 6.24). It 
thus seemed that induction of EphA2 expression was a relatively rapid adaptation to 
BRAF inhibition, which may precede the development of acquired drug resistance.  
 
Fig. 6.24. Time-course of EphA2 and S897-EphA2 induction following chronic vemurafenib (PLX4032) 
treatment. Drug naïve A375 cells were treated with vemurafenib (1 µM) for 1-4 weeks and probed for the 
expression of EphA2 and S897-EphA2. Blots were stripped and reprobed for expression of GAPDH to 
confirm even protein loading. 
 
A potential link between acquired resistance and the role of BRAF inhibition in 
the emergence of new metastases was suggested by the observation patients failing 
vemurafenib therapy (n=28) had significantly higher incidence of tumor growth at new, 
distant disease sites (68%) rather than the regrowth of existing lesions, compared to 
patients receiving dacarbazine (n=20, 35%, Table 6.3).  
 
Table 6.3. Incidence of new metastases emerging in patients receiving either BRAF inhibitor 
(vemurafenib) or chemotherapy (dacarbazine). 
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These differences were seen despite the time on therapy being similar (147.5 days vs. 
101.5 days for vemurafenib and dacarbazine, respectively, p=0.1379) (Table 6.3). We 
next determined whether EphA2 expression increased in new metastatic lesions that 
arose on BRAF inhibitor therapy. The IHC staining of a pair of matched pre-treatment 
and therapy-derived metastases from a patient failing vemurafenib therapy showed high 
levels of EphA2, phospho-EphA2 and phospho-AKT expression in the treatment-derived 
metastatic lesions (Figure 4E), with much less EphA2 expression observed in the pre-
treatment primary lesion. 
Discussion 
Hostile microenvironments such as hypoxia, metabolic changes and nutrient 
deprivation favor the detachment of cancer cells and their migration to more favorable 
niches 340,341. We here demonstrate that chronic BRAF inhibition induces a migratory, 
invasive phenotype in melanoma cells. In epithelial tumors, therapeutic adaptation leads 
to an EMT, which is sometimes associated with increased tumor invasiveness and 
metastatic spread 329,342. Phosphoproteomic screening identified ligand-independent 
EphA2 signaling as a key driver of the metastatic phenotype in melanoma cells with 
acquired BRAF and BRAF/MEK inhibitor resistance. In agreement with this, increased 
S897 phosphorylated EphA2 was also identified in melanoma metastases from patients 
on treatment. Our findings mirror those in astrocytoma, where tumor aggressiveness 
was correlated with high expression of S897 phosphorylated EphA2 as well as 
phospho-AKT 334. In prostate cancer and glioma cell lines, ligand-independent EphA2 
signaling is known to promote invasion in an AKT-dependent manner and was reversed 
following treatment with Ephrin-A1 ligand 334.  
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Previous modeling studies have demonstrated BRAF inhibitor resistance to be 
dependent upon continuous drug administration, with treatment withdrawal leading to 
tumor regression 339. It was further observed that ligand-independent EphA2-mediated 
invasion also required constant BRAF and BRAF/MEK inhibitor-mediated selection 
pressure. The reversibility of the invasive phenotype upon drug removal suggested that 
ligand-independent EphA2 signaling could be abrogated through alternate dosing 
schedules. There is currently some debate as to whether intermittent BRAF/MEK 
inhibitor dosing can forestall resistance better than continuous dosing, with evidence 
being provided for each scenario 339,343. There is also clinical evidence that continuation 
of drug beyond the time of progression can prolong clinical benefit 339}343. Our data 
support the notion that continuous drug dosing can increase the fitness and metastatic 
potential of melanoma cells which suggests that the development of new metastases 
may be limited through intermittent drug dosing. Base on the current data, tyrosine 
kinase inhibitors directed against EphA2 are unlikely to reverse the migration driven 
through the EphA2/AKT axis. Instead, direct targeting of the EphA2 receptor with 
agonists should inhibit both ligand-independent EphA2 signaling and AKT signaling to 
limit metastatic dissemination.  
Previously, the HSP90 inhibitor, AT13387, was shown to be effective at inducing 
cell death in both BRAF and BRAF + MEK inhibitor resistant cell line models through 
simultaneous degradation or inhibition of several key client proteins that are necessary 
for survival and proliferation 198.  As whole exome sequencing did not reveal any genetic 
alterations that would account for drug insensitivity (data not shown), the mechanism of 
resistance for the BRAF (WM164R, 1205LuR) and BRAF + MEK (WM164RR, 
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1205LuRR) resistant cell lines is thought to be concurrent upregulation of multiple RTKs 
(e.g. PDGFRb, IGF1R, AXL and Tie-1). These findings have caused us to shift our 
focus from inhibitors that target one or two kinases to broad-spectrum inhibitors that 
target multiple hubs that exist within the BRAFV600E resistance interactome. To date, 
several proteins that are important for melanoma signaling, including EphA2, have been 
identified as HSP90 clients 189.  Based on our current findings, it is likely that an agonist 
of EphA2 would be the most effective at inhibiting deregulated EphA2 ligand-
independent signaling. In previous studies it was shown that combining an HSP90 
inhibitor with the EphA2 agonist, mAb208, lead to greater EphA2 degradation than for 
either agent alone 344. In addition, other groups have also found that HSP90 inhibitor-
mediated degradation of EphA2 protein increased the ability of cytotoxic CD8+ T-cells to 
recognize EphA2 expressing tumor cells and that combining an HSP90 inhibitor with an 
EphA2 peptide vaccine greatly increased immunotherapeutic efficacy 344,345. Taken 
together, our current findings underscore the importance of targeting multiple escape 
routes at once in order to achieve long lasting therapeutic benefit, where the addition of 
an EphA2 targeting arm would increase response duration by limiting the development 
of new disease in patients on BRAF and BRAF/MEK inhibitor therapies.   
Materials and Methods 
Cell culture and generation of BRAF inhibitor resistance 
Cells were cultured in 5% FBS, RPMI 1640 media. Parental 1205Lu, SK-MEL-28, and 
WM164 melanoma cells lines were a gift from Dr. Meenhard Herlyn (The Wistar 
Institute, Philadelphia, PA). Parental A375 cell line was purchased from American Type 
Culture Collection on April 18th 2012. Identities of all cell lines were confirmed by 
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Biosynthesis Inc., through short tandem repeat validation analysis at 6 monthly 
intervals. The date of last validation for these studies was December 20th 2013. Dual 
BRAF and MEK inhibitor resistant (RR) lines were established by chronically treating 
1205Lu, SK-MEL-28, and WM164 for >6 months with 1 µM each vemurafenib and 
selumetinib. Unless otherwise noted, single-agent vemurafenib (R) cell lines were 
maintained in 5% media with the addition of vemurafenib at the following 
concentrations: 1 µM for A375R, 2 µM for WM164R, and 3 µM for 1205LuR. Dual agent 
RR inhibitor resistant lines were maintained in 5% FBS, RPMI 1640 with 1 µM 
vemurafenib and 1 µM selumetinib. 
Proliferation assay 
Assays were performed as described in (18). Briefly, 4,000 cells were seeded into each 
well of a 96-well plate prior to drug treatment and allowed to attach overnight. Media 
containing inhibitor solubilized in DMSO, or an equivalent volume of DMSO alone was 
added and cells incubated for 3 days prior to the addition of Alamar blue reagent 
(Invitrogen, Carlsbad, CA). 
Inhibitors 
Vemurafenib (PLX4032), selumetinib (AZD6244), GDC-0941, LBH589, PI-103 and MK-
2206 were purchased from Selleck Chemicals (Houston, TX, USA). Dabrafenib and 
trametinib were from Chemie Tek (Indianapolis, IN, USA). 
Phosphoproteomic analysis 
Sample Processing 
Naïve and vemurafenib resistant 1205Lu cell lines were each grown in ten 15 cm tissue 
culture dishes. Cells were grown to ~70% confluency prior to washing each dish with 
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10ml of ice cold PBS + 1mM orthovanadate (Sigma Aldrich, St. Louis, MO). Cells were 
then lysed according to the manufacturer’s instructions for the Phospho-Tyrosine Mouse 
mAb (P-Tyr-100) (Cell Signaling, Beverley, MA). Lysed proteins were reduced and 
alkylated prior to proteolytic digestion and phosphorylated tyrosine containing peptides 
generated from tryptic digestion were enriched with antibody-based (P-Tyr-100) 
immunoprecipitation (Figure 6.1). Flow through from the immunoprecipitation was then 
further enriched for phosphorylated serines and threonines by strong cation exchange 
peptide fractionation (SCX) and immobilized metal affinity chromatography (IMAC). The 
enriched phospho tyrosine, serine and threonine fractions were then subjected to liquid 
chromatography tandem mass spectrometry (LC-MS/MS) and the resultant tandem 
mass spectra was searched against SEQUEST and MASCOT databases to identify 
phosphoproteins.  
Proteomic data analysis 
To calculate relative phospho-signal intensities, label-free protein quantification of the 
mass spectrometry data was analyzed using MaxQuant version 1.2.2.5 
(www.maxquant.org). Carbamidomethylation of cysteine was set as a fixed modification; 
oxidation of methionine, N-terminal protein acetylation, phosphorylation of serine, 
threonine and tyrosine were included as variable modifications. “First search ppm” for 
the peptide mass tolerance was set to 20 ppm, 10 ppm for final search and fragment ion 
tolerance was set to 0.6 Da. Protein and peptide false discovery rates were set to 0.1 
and 0.05, respectively, and minimum peptide length set to 6 amino acids. MS/MS data 
was searched against the Uni-Prot human database (Sprot_HUMAN_20111214.fasta). 
To filter out falsely identified peptide sequences, tandem mass-spec data were 
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combined with common contaminants and concatenated with the reversed versions 
(target decoy peptides) of all sequences using Andromeda search engine integrated 
into MaxQuant. Each cohort was run in duplicate and average intensities for each of the 
unique phosphopeptides identified was then calculated. In order to identify the 
significant phosphorylation changes that occurred following acquired vemurafenib 
resistance, the average intensities of the vemurafenib resistant cohort were divided by 
the average intensities of the naive cohort. The resulting ratio was log2 transformed and 
plotted to determine cut-off points (Fig. 6.25). Peptides that fell on the linear scale were 
removed as these were not significantly increased or decreased between the resistant 
and naive cohorts. Proteins with a positive log-scale value were highly phosphorylated 
in the resistant cell line while those with a negative log-scale value were not strongly 
phosphorylated in the resistant cell line. To perform pathway enrichment analyses, 
SwissProt protein labels corresponding to the phosphoproteins that were increased in 
the resistant cohort were then inputted into MetaCore’s GeneGo analysis software 
(thomsonreuters.com/metacore). Recurrent phospho-proteins found across the 
significantly enriched resistance pathways ((-log (p-value) < 2)) were identified. GeneGo 
software was further used to mine for direct protein-protein interaction within the 
recurrent phospho-proteins. The resulting subnetwork was then visualized with 
Cytoscape software (www.cytoscape.org) based on the connectivity metrics of degree, 
clustering coefficient, centrality and betweenness centrality. In order to model the 
individual signaling networks for the naïve and resistant cohorts, SwissProt protein 
labels corresponding to all naïve or resistant phospho-proteins were inputted into 
MetaCore’s GeneGo database and mined for direct protein-protein interactions. 
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Network connectivity metrics (degree, clustering coefficient, centrality and betweenness 
centrality) were again calculated with Cytoscape software and used to visualize the 
individual naïve and resistance interactomes. 
 
Fig. 6.25. Plot of log2 transformed data from the proteomic analysis used to define cutoff points for 
increased and decreased phosphorylation following acquired vemurafenib resistance. 
 
EphA2 and S897A mutant plasmid transfection 
The human EphA2 plasmid was generated as described in 225. The mutant S897A 
plasmid was a gift from Dr. Elena Pasquale. Naïve SK-MEL-28 cells were transfected 
with 4 µg of EphA2 or control plasmid while 1205LuR cells were transfected with 4 µg of 
S897A or WT EphA2 control plasmid with Lipofectamine (Invitrogen, Carlsbad, CA, 
USA) according to the manufacturer's instructions. Stable transfectants were harvested 
at 14 days and protein expression levels were confirmed by Western blotting. 
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Western blotting 
Proteins were extracted and blotted as described in 199. Antibodies against S897- 
EphA2, Y772-EphA2, EphA2, Y397-FAK, FAK, Y118-PXN, PXN, S9-GSK3, GSK3!, 
S473-AKT, AKT, phospho-S/T AKT substrate and PTEN were purchased from Cell 
Signaling Technology (Danvers, MA). Anti-ephrinA1 was from Santa Cruz 
Biotechnology (Santa Cruz, CA) while GAPDH was purchased from Sigma Aldrich. RNA 
interference Cells were transfected as described in 199 with 25nmol/L EphA2 and 
scrambled siRNA sequences (LifeTechnologies, Carlsbad, CA). Cells were transfected 
for 24 hours in the absence of inhibitor and an additional 48 hours in the presence of 
inhibitor prior to further experimentation. 
Quantitative real-time PCR 
Q-RT-PCR was performed as described in 199. TaqMan Gene Expression Assay 
Hs00171656_m1 primers/probe were used to quantify EphA2. The 18S (P/N4319413E) 
and GAPDH (Hs99999905_m1) used to normalize EphA2. All standards and samples 
were tested in triplicate and data were analyzed using SDS software version 2.3. 
3D spheroid assays 
Collagen implanted spheroids were prepared using the liquid overlay method as 
described in 199 and were treated with 100 nM LBH589 or 1µM PI-103 for 120 hours 
before being analyzed by fluorescence microscopy. Calculations of the areas of 
spheroid invasion into the collagen matrix were performed with ImageJ analysis 
software (Fig. 6.26). 
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Fig. 6.26. ImageJ calculations of spheroid areas of invasion. 
Transendothelial cell migration assay 
Migration assays were performed as described in 346. Human umbilical vein endothelial 
cells (HUVECs) were plated into transwell inserts and grown to confluence. DilI labeled 
naïve or resistant melanoma cell lines were plated on top of the HUVEC layer and 
allowed to invade for 1–4 hours. Non-migratory cells were removed prior to imaging with 
an inverted Nikon Eclipse TS100 microscope. Calculations of the percent spheroid 
invasion into the collagen matrix were performed with ImageJ analysis software (Fig. 
6.27). 
ImageJ 1.46r scoring of spheroid areas of invasion 
Areas of invasion were defined by converting the 8-bit spheroid images to masked images 
(ImageJ drop down menu>Process>Binary>Convert to Mask). Total areas of spheroid 
invasion (in relative square pixel units) were calculated by selecting the masked image and 
choosing Analyze and Measure from the ImageJ drop down menu.  
Area: 128436 Area: 371109 
Spheroid images were then split into red, green and blue channels (ImageJ drop down 
menu>Image>Color>Split Channels) .  The 8-bit, black and white images corresponding to 
the green fluorescence channel were then selected for further analyses. 
The relative percent reduction in invasion following drug treatment was calculated by 
subtracting the drug treated spheroid area from the untreated spheroid area and dividing 
by the untreated spheroid area. 
Images of calcein-AM stained spheroids (live cells, green fluorescence channel) were 
opened in ImageJ analysis software.  
Untreated Treated 
65.4% reduction 
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Fig. 6.27.Transendothelial invasion assay. 
Scratch wound assay 
S897A and control plasmid transfected 1205LuR melanoma were grown to confluency 
prior to scratching with a p20 pipette tip. Wounds were imaged at 0 and 24 hours and 
percentage wound closure was calculated using ImageJ software 1.46r. 
Matrigel invasion assay 
Cells were overlayed onto transwell inserts coated with Matrigel (BD) and allowed to 
invade for 24-48 hours (Fig. 6.28). For ephrin A1 ligand experiments, cells were 
pretreated for 72 hours with 1µg/mL ephrinA1-Fc or IgG-Fc (R&D Systems). Cells were 
fixed and stained with phalloidin-AF594 and noninvasive cells removed prior to 
fluorescence imaging with an inverted Nikon Eclipse TS100 microscope. To quantify 
levels of invasion, fixed and stained cells were imaged with a Zeiss confocal microscope 
(20x) at 0 µm with 0.5 µm image slices taken throughout the distance of invasion. 
Human umbilical vein embryonic cells (HUVEC) were seeded in the inner well of a 
Boyden chamber and grown to 100% confluency at which time the inner well EBM-2 
media (Lonza,!Walkersville, MD) was replaced with serum free RPMI 1640 media. 
DiI (1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine perchlorate) red 
fluorescently labeled melanoma cells were then resuspended in serum free RPMI 
1640 media and seeded on top of the HUVEC monolayer. 
RPMI 1640 media containing 5% FBS was then added to the outer well. The Boyden 
chamber was next placed in a 37oC, 5% CO2 incubator for 4 hours. 
After 4 hours, non-invading melanoma cells were removed from the inner well. The 
remaining invasive melanoma cells were fixed, stained and imaged with an inverted 
fluorescence microscope. 
Transendothelial invasion assay 
-serum 
-serum 
+serum 
-serum 
+serum 
-serum 
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Fig. 6.28. Matrigel invasion assay. 
Rates of new metastasis for vemurafenib and dabrafenib treated patients 
Patients managed at the Moffitt Cancer Center were selected from Moffitt medical 
records and archived melanoma specimens under the TCC/HRI, Moffitt pathology 
systems and written informed consent approved by the Institutional Review Board of the 
University of South Florida under the Declaration of Helsinki Protocols. For the 
vemurafenib and dabrafenib treated patients, the target population consisted of subjects 
with unresectable stage III or stage IV BRAF V600E mutant cutaneous melanoma 
treated with single-agent vemurafenib or dabrafenib as the first line of therapy. A similar 
patient cohort was also identified who received dacarbazine as their first line of therapy. 
Patients were selected for each treatment regimen who had similar numbers of 
restaging scans to eliminate sample bias. De-identified information pertaining to patient 
Matrigel was added to the inner well of a Boyden chamber and solidified by 
incubating for 30 minutes at 37oC . 
The inner well was inverted and melanoma cells were seeded on top in RPMI 1640 
media with FBS. To allow the melanoma cells to adhere to the matrigel, the inner 
wells were placed in a 37oC, 5% CO2 incubator for 30 minutes. 
After 30 minutes, the inner well was turned right side up and RMPI 1640 media 
containing FBS was added to the inner chamber while serum free RPMI 1640 media 
was added to the outer chamber. 
Cells were then incubated for 48-72 hours at 37oC, 5% CO2 prior to fixing, staining 
and confocal microscopy imaging. 
Matrigel invasion assay 
+serum 
-serum 
+serum 
-serum 
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demographics and clinical outcome during therapy was collected on subjects with 
exclusion of patients who completed less than 2 months of therapy or for whom follow-
up information was not available. 
Xenograft studies 
Xenograft implantation of tumor pieces from the subcutaneous tissue of a vemurafenib 
treatment naïve 44 year-old male with recurrent BRAF V600E mutant melanoma 
(HMEX2613) was performed as described in 339. Established HMEX2613 tumors were 
dosed continuously with 45mg/kg vemurafenib. After 100-200 days, tumors became 
resistant to vemurafenib with 30% of mice being euthanized due to clinical signs. Upon 
necropsy, widespread metastasis was found. IHC was carried out on sub-cutaneous 
resistant tumors and matched with corresponding metastatic lesions. 
Immunohistochemistry: Xenograft and patient samples 
Slides were stained using the Ventana Discovery XT automated system (Ventana 
Medical Systems, Tucson, AZ) per manufacturer's instructions with proprietary 
reagents. Slides were deparaffinized on the automated system with EZ Prep solution 
(Ventana). The retrieval method used was citrate buffer at pH 6.0. Rabbit antimouse 
polyclonal IgG primary antibody for EphA2 (Santa Cruz Biotechnology, Santa Cruz, CA, 
#sc-924) that reacts to human EphA2 was used at a 1:250 concentration in PSS 
antibody diluent (Ventana) and incubated for 12 min. Ventana Anti-mouse secondary 
antibody was used for 12 min and Ventana OmniMap kit used for detection. Slides were 
counterstained with Hematoxylin. De-identified formalin fixed paraffin-embedded tissue 
samples were obtained from the Moffitt Pathology, the University of Pittsburgh and the 
University of Tuebingen archives under a written informed consent protocol approved by 
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the Institutional Review Board of the University of South Florida under the Declaration of 
Helsinki Protocols and stained as above for the xenograft samples. Staining was 
visualized using the Ventana Chromomap Redkit. Slides were analyzed by two 
independent observers and consensus scored on a scale from (0 to +3). 
Statistical analysis 
Data show the mean of at least 3 independent experiments ± the SE mean, unless 
stated otherwise. GraphPad Prism 6 statistical software were used to perform the 2-
tailed Student's t -test and for contingency analyses of patient data (2-tailed Fisher’s 
exact test). For all statistical analyses, asterisks (*) indicates P % 0.05. 
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Chapter 7 
Summary  
Chapter 1 
The two major risk factors for developing melanoma are UV exposure and family 
history. Most diagnoses are made through histological criteria; however, there are 
subsets that are difficult to distinguish from benign melanocytic nevi. Melanomas 
frequently metastasize therefore proper diagnosis is critical. Among patients with stage 
IV disease, the anatomic site of metastases was the most significant predictor of 
survival with non-pulmonary visceral metastases and/or an elevated serum LDH having 
the worst one-year survival of 33% 20. The four main genetic subtypes of melanoma are 
BRAF, NRAS, c-KIT mutant and BRAF/NRAS WT. Melanomas rely heavily on MAPK 
signaling for survival and growth making this pathway an attractive candidate for 
targeted kinase therapy. Inhibitors of BRAF and BRAF combined with MEK have been 
FDA approved for the treatment of V600-BRAF mutant melanomas. Other compounds 
currently under development for BRAF melanoma include ERK, pan-RAF, and HSP90 
inhibitors. Drug resistance is a major problem in maintaining durable reponses with 
numerous and diverse melanoma host and microenvironmental factors playing a role. 
Chapter 2  
Vemurafenib and dabrafenib are clinical compounds that have been approved for 
the treatment of late stage, non-resectable and disseminated melanomas harboring a 
BRAFV600 mutation. Here we investigated the effects that PLX4720, an analogue of 
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vemurafenib, would have on BRAFV600E melanoma cell lines.  We observed that 
BRAF inhibition caused a significant reduction in proliferation corresponding to G1 
arrest, p27 stabilization, decreased RB phosphorylation and reduced cyclin D1 
expression. Although short treatment time-point (<1 hr) resulted in a significant 
reduction in ERK activity and the induction of apoptosis, longer time-points showed that 
phospho ERK levels were restored quite rapidly (<48 hrs) in the presence of drug with 
chronic treatment eventually leading to the emergence of PLX4720 resistant clones.  
The resistant clones were characterized by reactivation of the MAPK pathway 
independent of an acquisition of a MEK1 mutation leading us to postulate that the 
resistant clones would be sensitive to MEK inhibition. Indeed, treatment with the UO126 
MEK inhibitor resulted in decreased proliferation as measured by BrdU incorporation. 
Further, the combination of PLX4720 and UO126 prevented rebound ERK activation, 
resulted in marked levels of apoptosis and completely prevented the emergence of 
resistant clones.  This study provided strong pre-clinical support for the clinical trial 
evaluating the combination of BRAF and MEK inhibitors to delay or overcome MAPK 
mediated resistance. In January of 2014 the combination of Tanfinlar™ (dabrafenib) + 
Mekinist™ (trametinib) was FDA approved while the combination of Zelboraf™ 
(vemurafenib) plus cobimetinib is in late stage clinical evaluation (coBRIM) with 
promising results. 
Chapter 3 
In this study we separated BRAFV600E melanomas into 2 cohorts based on 
PTEN status. This stratification allowed us to observe that loss of PTEN confers intrinsic 
resistance to the BRAF inhibitor, vemurafenib. Utilizing LC-MRM (liquid chromatography 
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multiple reaction monitoring) base proteomic analysis, we quantified 17 members of the 
Bcl-2 protein family and found that upregulation of the pro-apoptotic BIM protein was 
important for the induction of apoptosis in PTEN expressing cell lines. Mechanistically, 
BRAF inhibition in the PTEN null cohort led to increased AKT activity corresponding to 
nuclear exclusion of FOXO3a and decreased BIM expression. Combining vemurafenib 
with an inhibitor of PI3K blocked the increase in AKT activity and increased nuclear 
FOXO3a accumulation.  This led to increased BIM expression and significant increases 
in apoptosis. The significance of PTEN status on therapeutic outcome was validated in 
a study showing that dabrafenib treated melanoma patients with PTEN loss had shorter 
progression free survival rates than those with WT PTEN 347. These findings highlight 
the importance of further molecular subgrouping of V600E melanomas and have 
provide preclinical support to combining BRAF with PI3K/AKT inhibitors and BRAF with 
Bcl-2 family inhibitors. 
Chapters 4 and 5 
A number of vemurafenib resistance mechanisms have been reported for 
melanoma including upregulated receptor tyrosine kinase signaling (HER3, IGF1R, 
PDGFRb, EGFR, and c-MET), secondary mutations (NRAS and MEK1), amplifications 
(COT, BRAF, cyclin D1), loss of tumor suppressor (PTEN, NF1) and truncated BRAF 
expression 134,176,210,223,226. Many of these mechanisms converge upon the MAPK 
pathway and therefore lead to reactivation of ERK signaling.  Due to increased 
PI3K/AKT/mTOR pathway transduction, AKT phosphorylation has also been observed 
in a smaller cohort of BRAFV600E melanomas 348.  The ability of resistant cells to 
circumvent MAPK inhibition by switching to alternate survival mechanisms suggests that 
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resistance can only be completely constrained through strategies that target the MAPK 
pathway along with other key and non-redundant pathways. In melanoma, HSP90 
stabilizes a multitude of client proteins known to be essential for growth, survival, 
differentiation and DNA damage response making it an attractive therapeutic target. 
Here we demonstrated that treatment of single and dual agent MAPK inhibitor resistant 
melanoma cells with the HSP90 inhibitors, XL888 and AT13387, led to the rapid 
degradation or inhibition of key HSP90 client proteins and resulted in marked inductions 
of apoptosis. Importantly, the combination of HSP90 and BRAF inhibitors was able to 
significantly forestall resistance in an in vivo model of BRAFV600E melanoma. These 
studies demonstrate that HSP90 inhibition is an effective therapeutic approach for 
managing the diverse array of resistance mechanisms and provided the ongoing clinical 
evaluation of combined BRAF and BRAF + MEK inhibition. 
Chapter 6 
In this study we used mass spectrometry-based phosphoproteomic screening to 
uncover key adaptive changes that lead to vemurafenib resistance. Based on significant 
global changes in phosphorylation events between naive and vemurafenib resistant cell 
lines (treated with 3mM vemurafenib >3 months), we have mapped the resistance 
interactome.  Our unbiased analysis revealed novel signaling hubs that have been 
reported to contribute to metastasis. Consistent with our bioinformatics prediction, 
melanoma cell lines with acquired vemurafenib resistance were considerably more 
invasive than their drug naïve counterparts and showed increased trans-endothelial cell 
migration. Importantly, we found that resistance to dual BRAF + MEK inhibition (treated 
with 1mM vemurafenib + 1mM selumetinib, >4 months) also led to increased migration 
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and invasion. This was a significant finding as mortalities associated with melanoma are 
due in large part to disseminated disease, with worst prognoses in patients with 
metastasis to distant sites such as the brain, liver and bone 349. Our analysis revealed 
ligand-independent EphA2 signaling as an adaptation to BRAF inhibitor therapy leading 
to the adoption of a metastatic phenotype. EphA2-mediated invasion was ligand-
independent and AKT-dependent and was reversible upon the removal of MAPK 
inhibition. In patient derived xenograft models, where resistance was established in 
vivo, BRAF inhibition lead to the development of EphA2 positive metastases. A 
retrospective analysis of melanoma patients on BRAF inhibitor therapy showed that 
68% of those failing therapy develop metastases at new disease sites, compared to 
38% of patients on dacarbazine. IHC staining of melanoma specimens taken from 
patients on BRAF inhibitor therapy as well as metastatic samples taken from patients 
failing therapy showed increased EphA2 staining.  Here we suggested that the 
sequential dosing of targeted kinase inhibitors in combination with an agonist of EphA2 
signaling could limit metastases associated with kinase inhibitor therapy. 
Future Perspectives 
At the onset of the studies described in this dissertation, our lab was keenly 
aware of the potential use of systems level platforms. Our experience with studying 
escape from targeted therapies suggested that kinase inhibition leads to rapid adaptive 
responses and rewiring of signaling networks, but while holistic approaches were 
greatly needed, the existing focus had been on individual genes or proteins. We also 
understood that studies that relied solely on genome-based data did not always 
translate into meaningful phenotypic changes. Therefore our goal was to utilize 
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sensitive and selective tandem mass spectrometry based proteomic analyses to 
understand the network of post-translational modifications that lead to drug resistance in 
melanoma.  Armed with an arsenal of kinase inhibitors, we embarked on a journey into 
the unknown world of computational biology. In an eager spirit of discovery we set up 
large batch experiments to be interrogated for global serine, threonine and tyrosine 
phosphorylation changes and our collaborators in the Moffitt Proteomics Core quickly 
rewarded us with a return of thousands of identified phospho-peptides. Unfortunately, 
the technology of high throughput proteomics superseded our ability to analyze such 
large datasets. It was only through multiple meetings with experts in the fields of 
proteomics, bioinformatics and biostatistics, and the integration of concepts that I 
learned from these meetings, that I was finally able to untangle the messy hairball that 
represents the BRAF resistance interactome.  
This integrated approach enabled me to evaluate the global changes that occur 
following the onset of acquired resistance and allowed us to make the important 
observation that BRAF inhibition can lead to increased metastatic potential of an 
already disseminated disease. Further, this phenotype change was not due to “hard 
wiring” of the genome but instead arose because of post-translational modifications that 
would not have been observed with genetic analysis alone. Improvements in high-
throughput mass spectrometry based proteomics have made them even more sensitive 
and this type of analysis can now accurately quantify tens of thousands of unique 
peptide modifications which can potentially lead to functional changes 350,351. It is 
expected that the continuation of such interdisciplinary collaborations, such as the ones 
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I described here, will allow us to broaden our understanding of treatment refractory 
melanoma and thereby enable us to improve upon therapeutic strategies.  
The work that is hoped will be achieved through such collaborations is 
summarized in Figure 7.1. In this model, additional DNA classifications of BRAFV600 
mutated melanomas would allow for the further stratification of patients who would be 
likely to respond to MAPK inhibitor therapy (i.e. genetically homogenous tumors) vs. 
those who would be non-responders (i.e. genetically heterogeneous tumors). In this 
scenario, patients whose melanomas harbor additional mutations that are known to 
cause intrinsic resistance (e.g. PTEN, NF1, AKT3, cyclin D1, MAPK38 mutations) would 
receive additional therapies (based upon the presence of a specific molecular target) in 
combination with inhibitors of BRAF. As targeted and immunotherapies doses would be 
limited by their combined toxicities, frontline combinations that inhibit as many targets at 
once while maintaining acceptable levels of side effects would be selected first. Studies 
from our group and others have provided evidence that intermittent 224,339 or sequential 
dosing (data not shown) would also be viable dosing options that might prevent kinase 
addiction and lower toxicities.  
Late stage melanomas often metastasize to distant sites that cannot be surgically 
resected making it difficult to follow the molecular course of disease progression. As 
such, the role of circulating tumor cells (CTCs), which are thought of as liquid tumor 
biopsies, is of growing interest in the field of melanoma. In this model, diagrammed in 
Figure 7.1, patients would be monitored at regular intervals during the course of 
treatment and biospecimens, such as CTCs, or residual tumor if available, would be 
collected for the detection of early modifications (e.g. protein phosphorylation 
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(proteomic platform), DNA methylation and histone acetylation/deacetylation) that would 
be predictive of adaptive phenotypic changes. In this early intervention scenario, the 
patient’s therapeutic regimen would be redesigned to optimally target emergent 
resistance targets. Additional genetic testing during the course of therapy would also 
enable the detection of treatment refractory tumor cells and allow for the earliest 
possible intervention. Though this is an idealized model involving biomarkers and 
technologies that do not exist at present, it is hoped that continued efforts to understand 
the intrinsic and acquired nature of resistance, such as the ones discussed here, will 
lead to discoveries that will allow us to achieve durable therapeutic outcomes for 
patients with disseminated melanoma. 
 
Fig. 7.1. Diagram of rationally designed therapeutic strategies. Based upon genetic subclassifications, 
BRAF patients would receive further rational combinations in addition to BRAF and/or MEK inhibitors. 
During the course of treatment, patients would be monitored for the protein, epigenetic and genetic 
changes predictive of relapse and their therapies redirected accordingly. 
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